Identification of effective drug targets in treating Glutaric

aciduria type 1 disease by Ediga, Raga Deepthi
	
	
	
	
	
	
	
	
	
Dissertation	
submitted	to	the	
Combined	Faculties	for	the	Natural	Sciences	and	for	Mathematics		
of	the	Ruperto‐Carola	University	of	Heidelberg,	Germany		
for	the	degree	of		
Doctor	of	Natural	Sciences	
	
	
	
Presented	by	
	
M.Sc.	(Animal	Biotechnology)	Raga	Deepthi	Ediga	
Born	in	Kurnool,	India	
	
Oral‐examination:	November	2018	
	
	
Identification	of	effective	drug	targets	in	treating	Glutaric	
aciduria	type	1	disease	
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referees:	 Prof.	Dr.	Marc	Freichel	
	Dr.	rer.	nat.	Sven	Wolfgang	Sauer	
	 	
	
	
This	thesis	is	dedicated	to	my	better	half	Dr.rer.nat.	Jagadeesh	
Gandla.	You	are	incredible….	
	
Table	of	Contents	
	
Summary	 																																																																																																																	1‐2	
	 	 	 	 	 	 	 	 	 	
Zussamenfassung																																																																																																							3‐4	
	
Abbrevations																																																																																																																5‐6	
	
1.	Introduction																																																																																																											7‐30	
	1.1			Lysine	
					1.1.1	Metabolism	of	Lysine	
												1.1.1.1	Anabolism	of	Lysine	
												1.1.1.2	Catabolism	of	Lysine	
					1.1.1.2.1	Saccharopine	pathway	of	lysine	degradation	
					1.1.1.2.2	Pipecolate	pathway	of	lysine	degradation	
					1.1.1.2.3	Convergence	of	pipecolic	acid	pathway	and	saccharopine	pathway	
	
	1.2	Inborn	errors	of	lysine	metabolism	
					1.2.1	Hyperlysinemia	
					1.2.2	2‐aminoadipic	2‐oxoadipic	aciduria	
					1.2.3	Zellweger	syndrome	
					1.2.4	Glutaric	aciduria	type	I	
												1.2.4.1	Biochemical	features	of	GA‐I	
												1.2.4.2	Clinical	features	of	GA‐I	
												1.2.4.3	Neuropathology	of	GA‐I	
												1.2.4.4	Gcdh	knockout	mouse	model	
												1.2.4.5	Treatment	strategies	followed	for	GA‐I	patients	
												1.2.4.6	Alternate	therapeutic	strategies	
																					1.2.4.6.1Target	1,	DHTKD1	
																					1.2.4.6.2	Target	2,	AADAT	
					
	1.3	Objectives	of	the	thesis																																																																								
	
2.	Materials	and	Methods																																																																																			31‐56	
	2.1	Materials	
					2.1.1	Chemicals	used	
					2.1.2	Consumables	used	
					2.1.3	List	of	Primers	
					2.1.4	List	of	antibodies	
					2.1.5	Inhibitors	used	
					2.1.6	Commercially	available	kits	used	
					2.1.7	General	Buffers	used	
					2.1.8	Instruments	used	
	
	2.2	Methods	
					2.2.1	Cloning	of	DHTKD1	into	pGEX4T1	vector	
											2.2.1.1	PCR	amplification	of	DHTKD1	
											2.2.1.2	Restriction	digestion	of	vector	and	insert	
											2.2.1.3	Ligation	of	vector	and	insert	
											2.2.1.4	Transformation	and	positive	clone	confirmation	
					2.2.2	DHTKD1	protein	expression	and	purification	using	Glutathione																																				
																sepharose	beads	
												2.2.2.1	Transformation,	starter	culture	preparation	and	protein	expression	
												2.2.2.2	Preparation	of	Glutathione	sepharose	beads	and	purification	of				
																											protein	(protocol	from	GE	healthcare,	modified)	
												2.2.2.3	Western	blotting	and	confirmation	of	purified	DHTKD1	protein	
					2.2.3	DHTKD1	enzyme	activity	assay	
					2.2.4	Determination	of	Km	and	Vmax	for	DHTKD1	
												2.2.4.1	DHTKD1	inhibitor	studies	
					2.2.5	Western	blotting	of	Dhtkd1	in	mouse	tissue	samples	
													2.2.5.1	Preparation	of	tissue	homogenates	
													2.2.5.2	Determining	the	concentration	of	protein	
													2.2.5.3	SDS‐PAGE,	immunoblotting	and	detection	by	enhanced		
																											chemiluminescence	
					2.2.6	Analysis	of	Glutaric	acid	(GA),	2‐oxoadipic	acid	(OA)	and	2‐aminoadipic		
																acid	(AA)	quantitatively	
					2.2.7	Measurement	of	Glutaryl	carnitine	levels	
					2.2.8	Culturing	of	fibroblasts,	HEK	293T	and	HeLa	cells	
					2.2.9	AADAT	siRNA	treatment	
					2.2.10	CRISPR/Cas9	method	for	the	generation	of	GCDH	and	AADAT		
																			Knockouts	
															2.2.10.1	Designing	gRNAs	
															2.2.10.2	Oligo	annealing	and	cloning	into	PX459	vector	
															2.2.10.3	Determining	the	cytotoxicity	of	puromycin	for	HEK	and	HeLa		
																																cells	
															2.2.10.4	Transfection	of	PX459‐gRNA	constructs	into	HEK	and	HeLa	cells	
															2.2.10.5	Confirmation	of	Knockout	cells	by	western	blotting	
															2.2.10.6	Generation	of	single	cell	clones	of	GCDH	Knockout	and	AADAT														
																																knockout	cells	
					2.2.11	Inhibitor	treatment	of	patient	fibroblasts	and	measurement	of	glutaric				
																		acid	(GA)	levels	using	GCMS	
					2.2.12	Establishing	enzyme	activity	assay	for	AADAT	in	patient	fibroblasts	
					2.2.13	Effect	of	PF‐04859989	inhibitor	on	HEK	and	HeLa	GCDH	Knockout	cells		
																			and	GA	detection	using	GCMS	
					2.2.14	Detection	of	DNA	damage	in	fibroblasts	
														2.2.14.1	Seeding	of	patient	and	control	cells	
														2.2.14.2	Immunofluorescence	staining	
														2.2.14.3	Image	analysis	
					2.2.15	Statistical	analysis	
	
3.	Results																																																																																																																					57‐87	
	3.1	Can	targeting	DHTKD1	rescue	the	clinical	and	biochemical	phenotype	of	GA‐									
							I?	
					3.1.1	Cloning,	expression	and	purification	of	DHTKD1protein	
					3.1.2	Determining	the	substrate	specificity	and	enzyme	kinetics	of	purified		
															DHTKD1	protein	
					3.1.3	Pharmacological	inhibition	of	DHTKD1	
					3.1.4	Murine	model	for	targeting	DHTKD1	
													3.1.4.1	Generation	of	Dhtkd1	Knockout	(Dhtkd1‐/‐/	Gcdh+/+)	mice	
													3.1.4.2	Behavioral	and	biochemical	characterization	of	Dhtkd1‐/‐/		
																										Gcdh+/+	mice	
													3.1.4.3	Knockout	of	Dhtkd1	was	not	able	to	rescue	the	clinical	and																								
																										biochemical	phenotype	seen	in	Gcdh‐deficient	mice	
																							3.1.4.3.1	Generation	and	characterization	of	double	Knockout		
																																							(Dhtkd1‐/‐/Gcdh‐/‐)	mice	
																																					3.1.4.3.1.1	The	clinical	phenotype	of	Dhtkd1‐/‐/Gcdh‐/‐	mice		
																																																									contradicts	our	current	hypothesis	
																																						3.1.4.3.1.2	The	biochemical	phenotypes	of	Dhtkd1‐/‐/Gcdh‐/‐		
																																																											and	Gcdh‐/‐	mice	do	not	differ	
																				
	3.2.	AADAT	as	an	alternative	target	for	treating	GA‐1	patients?	
					3.2.1	siRNA	mediated	knockdown	of	AADAT	
					3.2.2	Inhibition	of	AADAT	by	PF‐04859989	in	vitro	
					3.2.3	Effect	of	lysine	stress	induction	on	GA	levels	of	GA‐I	patient	and	control		
															Fibroblasts	
				3.2.4	Effect	of	AADAT	inhibitor	on	GA	levels	of	patient	and	control	fibroblasts	
	3.3	Generation	of	alternative	GA‐I	cell	culture	models	
					3.3.1	CRISPR/Cas9‐mediated	generation	of	knockout	cells	
					3.3.2	Analysis	of	GA	levels	in	GCDH	Knockout	and	control	cells	after	inhibitor		
															treatment	
	
4.	Discussion																																																																																																													88‐97	
	
	4.1	Inhibiting	of	DHTKD1	function	does	not	rescue	the	clinical	and	biochemical	
							phenotype	of	Gcdh‐/‐	mice	
	4.2	Development	of	an	alternative	therapeutic	strategy	
	4.3	Outlook	1.	Novel	mechanism	of	chronic	GA‐induced	toxicity	
	4.4	Outlook	2,	Role	of	DHTKD1	in	Diabetes	
	
5.	Conclusions																																																																																																																	98	
	
6.	References																																																																																																										99‐115	
	
7.	Original	publications																																																																																												116	
	
8.	Acknowledgements																																																																																																		117	
	1	
	
Summary	(English)	
	
Glutaric	 aciduria	 type	 I	 (GA‐I)	 is	 an	autosomal	 recessive	 cerebral	 organic	 aciduria,	
caused	by	a	defective	GCDH	enzyme.	This	protein	lies	in	the	common	final	catabolic	
pathway	 of	 L‐lysine,	 L‐hydroxy	 lysine	 and	 L‐tryptophan.	 Individuals	 possessing	
GCDH	 enzyme	 deficiency	 are	 biochemically	 characterized	 by	 the	 accumulation	 of	
neurotoxic	metabolites	glutaryl‐CoA,	GA,	3‐OH‐GA	as	well	as	non‐toxic	C5DC	in	their	
tissues	 and	 body	 fluids.	 If	 untreated,	 most	 of	 the	 individuals	 develop	 an	 acute	
encephalopathic	 crisis	 causing	 striatal	 damage	 during	 a	 finite	 period	 of	 brain	
growth,	resulting	 in	complex	movement	disorder	with	predominant	dystonia,	most	
commonly	 between	 3	months	 to	 3	 years	 of	 age.	 Individuals,	 diagnosed	 before	 the	
onset	of	irreversible	neurologic	symptoms	can	be	prevented	from	striatal	damage,	if	
they	 are	 treated	 with	 a	 special	 diet	 consisting	 of	 low	 L‐lysine	 content,	
supplementation	 with	 carnitine	 and	 essential	 amino	 acids	 as	 well	 as	 emergency	
treatment	 on	 demand.	 Even	 though	 the	 currently	 followed	metabolic	 treatment	 is	
predicted	 to	be	safe	and	effective,	a	significant	number	of	patients	still	 suffer	 from	
striatal	 damage	despite	 early	diagnosis	 and	 treatment.	 In	 addition,	 recent	 findings	
report	on	extra‐striatal,	extra	cerebral	and	non‐neurologic	abnormalities	despite	the	
current	regimen	followed.	This	highlights	the	prerequisite	for	the	discovery	of	novel,	
safe	and	more	efficient	long‐term	treatment	strategies.	In	this	thesis,	we	hypothesize	
that	 pharmacological	 inhibition	 of	 upstream	 enzymatic	 steps	 of	 the	 lysine	
degradation	 pathway,	 prior	 to	 GCDH,	 will	 prevent	 toxic	 metabolite	 accumulation	
and,	consequently,	induction	of	clinical	disease	phenotype	in	Glutaric	aciduria	Type	
I.	To	this	end,	Dehydrogenase	E1	and	transketolase	domain	containing	1	(DHTKD1)	
(approach1)	and	Aminoadipate	amino	transferase	(AADAT)	(alternate	approach	2)	
are	 targeted	 and	 our	 hypothesis	 is	 tested	 in	 genetically	 modified	 cell	 models,	
Glutaric	aciduria	type	I	patient	cell	lines,	and	knockout	mouse	models.	We	therefore,	
developed	 a	 Dhtkd1‐/‐/	 Gcdh‐/‐	 mouse	 model	 and	 studied	 its	 characteristics	
biochemically	 and	 clinically	 after	 giving	 high	 lysine	 (4.7%	 (w/w)	 or	 235mg	 of	 L‐
lysine	 in	 food)	 in	 diet.	 Our	 studies	 showed	 that	 DHTKD1	 knockout	was	 unable	 to	
rescue	 GA‐I	 phenotype	 in	Dhtkd1+/+/	Gcdh‐/‐	mice	 as	 seen	 by	 the	 accumulated	 GA	
levels	 on	 GCMS	 measurement.	 Since	 our	 in	 vivo	 data	 strongly	 suggested	 that	
DHTDK1	is	not	a	suitable	drug	target	in	GA‐I,	we	did	not	proceed	with	drug	testing.	
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Next,	 we	 evaluated	 the	 commercially	 available,	 patented	 AADAT	 inhibitor	
PF04859989	 in	 GCDH‐deficient	 cells.	 Indeed,	 the	 inhibitor	 treatment	 significantly	
reduced	 GA	 accumulation	 in	 these	 cells.	 Overall	 this	 thesis	 suggests	 that,	
pharmacological	inhibition	of	AADAT	is	a	novel	therapeutic	strategy	for	GA‐I.	.	
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Zusammenfassung	(Deutsch)	
	
Die	 Glutarsäure‐Azidurie	 Typ	 I	 (GA‐I)	 ist	 eine	 autosomal‐rezessive	 zerebrale	
Organoazidurie,	 die	 durch	 einen	 genetischen	 Defekt	 der	 Glutaryl‐CoA‐
Dehydrigenase	 (GCDH)verursacht	 wird.	 Dieses	 Protein	 liegt	 in	 dem	 gemeinsamen	
Abbauweg	 von	 L‐Lysin,	 L‐Hydroxylysin	 und	 L‐Tryptophan.	 Patienten,	 die	 einen	
GCDH‐Defekt	 aufweisen,	 sind	 biochemisch	 durch	 die	 Akkumulation	 der	
neurotoxischen	 Metaboliten	 Glutaryl‐CoA,	 GA,	 3‐OH‐GA	 sowie	 nicht	 toxische	
Glutarylcarnitin	 in	 Geweben	 und	 Körperflüssigkeiten	 charakterisiert.	 Wenn	 sie	
unbehandelt	sind,	entwickeln	die	meisten	Individuen	eine	akute	encephalopathische	
Krise,	 die	 während	 einem	 zeitlich	 begrenzten	 Abschnitt	 der	 kindlichen	
Gehirnentwicklung	 (zwischen	 3	 Monaten	 bis	 3	 Jahren)	 eine	 striatale	 Schädigung	
verursacht	 und	 zu	 einer	 komplexen	 Bewegungsstörung	 mit	 vorherrschender	
dystonie	 führt.	 Patienten,	 die	 vor	 dem	 auftreten	 irreversibler	 neurologischer	
symptome	 diagnostiziert	 wurden,	 können	 vor	 einer	 Schädigung	 des	 Striatums	
bewahrt	 werden,	 wenn	 sie	 mit	 einer	 Diät	 bestehend	 aus	 niedrigem	 L‐lysingehalt,	
Supplementierung	 mit	 Carnitin	 und	 essentiellen	 Aminosäuren	 sowie	
Notfallbehandlung	 während	 kataboler	 Krisen	 behandelt	 werden.	 Auch	 wenn	 die	
derzeit	 durchgeführte	 metabolische	 Behandlung	 als	 sicher	 und	 wirksam	 gilt,	
erleiden	 trotz	 einer	 rechtzeitigen	 Diagnose	 und	 Behandlung	 immer	 noch	 eine	
signifikante	Anzahl	von	Patienten	Schäden	des	Striatums.	Darüber	hinaus	berichten	
neuere	 Studien	 über	 extrastriatale,	 extra‐zerebrale	 und	 nicht‐neurologische	
Veränderungen	 trotz	 Einhaltung	 der	 Therapieleitlinien.	 Dies	 verdeutlicht	 die	
Notwendigkeit	 der	 Entwicklung	 neuer,	 sicherer	 und	 effizienterer	
Langzeitbehandlungsstrategien.	In	dieser	Arbeit	stellen	wir	die	Hypothese	auf,	dass	
die	 pharmakologische	 Inhibition	 eines	 enzymatischen	 Schritts,	 der	 dem	 defekten	
Protein	GCDH	vorangeschaltet	ist,	die	Produktion	toxischer	Metabolite	und	damit	die	
Induktion	des	klinischen	Phänotyps	der	GA‐I	verhindert.	Zu	diesem	Zweck	wurden	
die	 Proteine	 D	 Dehydrogenase	 E1	 And	 Transketolase	 Domain	 Containing	 1	
(DHTKD1)	 (Ansatz	 1)	 und	 Aminoadipat‐Aminotransferase	 (AADAT)	 (Ansatz	 2)	
ausgewähltund	 unsere	 Hypothese	 in	 genetisch	 modifizierten	 Zellmodellen,	 GA‐I‐	
Patientenzelllinien	 und	 knockout‐Mausmodellen	 getestet.	 Wir	 entwickelten	 daher	
ein	 Dhtkd1‐/‐/	 Gcdh‐/‐	 Mausmodell	 und	 untersuchten	 seine	 biochemischen	 und	
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klinischen	Eigenschaften	nach	Gabe	einer	Hochlysin‐Diät	(4,7%	(w	/	w)	oder	235	mg	
L‐lysin	in	der	nahrung).	Unsere	Studien	zeigten,	dass	DHTKD1‐Knockout	nicht	in	der	
lage	 war,	 den	 GA‐I‐phänotyp	 in	Dhtkd1+/+/	Gcdh‐/‐	 mäusen	 zu	 therapieren,	 da	 die	
Tiere	weiterhin	hoheGA‐Spiegel	und	einen	klinischen	Phänotyp	aufwiesen.	Von	einer	
Inhibitor‐Testung	für	DHTKD1	haben	wir	daher	abgesehen.	Eine	pharmakologische	
Inhibierung	 der	 AADAT	 unter	 Verwendung	 des	 patentierten	 und	 kommerziell	
erhältlichen	 Wirkstoffs	 PF04859989	 in	 GCDH‐defizienten	 Zelllinien	 keinen	 effekt,	
führte	hingegen	zu	einer	stark	verminderten	GA‐Produktion.		
	
Insgesamt	zeigen	diese	Arbeiten,	dass	die	AADAT	ein	neues	und	vielversprechendes	
drug	target	für	die	Behandlung	der	GA‐I	ist.	
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Abbreviations	
	
AA	 α‐Aminoadipate	
AAS	 α‐Aminoadipatesemialdehyde	
AASDH	 α‐Aminoadipatesemialdehyde‐	
																																																																																		Dehydrogenase	
AASS	 α‐Aminoadipatesemialdehyde‐			
																																																																																							Synthase	
ADP	 Adenosin	5’‐Diphosphate	
AADAT																																																																								α‐		Aminoadipateaminotransferase																																						 						
ATP	 Adenosin	5’‐Triphosphate	
d	 day	
BSA	 Bovine	Serum	Albumin	
C5DC	 Glutarylcarnitine	
C0	 free	L‐Carnitine	
CoA	 Coenzyme	A	
Da	 Dalton	
DAPI	 4’,6‐Diamidino‐2‐phenylindol	
DCPIP	 Dichlorophenolindophenol	
DMSO	 Dimethylsulfoxid	
EDTA	 Ethylendiamintetraaceticacid	
GA	 Glutaricacid	
GC/MS	 Gaschromatography/Massspektrom‐	
																																																																																					etry	
GCDH	 Glutaryl‐CoA‐Dehydrogenase	
h	 hours	
3‐OH‐GA	 3‐Hydroxyglutaricacid	
H2O	 distilled	water	
min	 Minute	
ml	 Milliliter	
µg	 Microgram	
µl	 Microliter	
LOR	 Lysine	oxido	reductase	
n	 number	
NaCl	 Sodium	chloride	
NAD	 Nicotinamide	Adenine	dinucleotide,					
																																																																																							oxidised	
											NADH	 	 Nicotinamide	Adenine	dinucleotide,									
																																																																																																		reduced	
									NADP	 	Nicotinamide	Adenine	dinucleotide				
																																																																																																phosphat,oxidised	
									NADPH	 	Nicotinamide	Adenine	dinucleotide			
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																																																																																																phosphate	reduced	
									NMDA																																																																										N‐Methyl‐D‐Aspartate	
									PBS	 Phoshate	Buffer	saline	
									P6C	 1‐Pipereidin‐6‐Carboxylate	
									OA	 Oxo	adipicacid	
								OGDHc	 	2‐Oxoglutaratedehydrogenase‐		
																																																																																													complex	
									RT	 Roomtemperature	
									s	 Seconds	
									SD	 	standard	deviation	=							
																																																																																																																					Standardabweichung	
								SDH	 Saccharopine‐Dehydrogenase	
								Tris	 Trishydroxymethyaminomethan	
								Triton‐X‐100																																																															t‐Oktoylphenoxypolyethoxyethanol	
								U/mg	 	Units	per	mg	[µmol	min	‐1],	specific			
																																																																																																		Activity	
									O/N	 over	night	
									WT	 Wildtype	
										vs.	 versus	
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1.1.	Lysine	
	
Lysine	 (α,	 ε	 ‐diaminocaproic	 acid),	 a	 positively	 charged	 amino	 acid	 is	
indispensable	 for	 growth	 and	maintenance	 in	mammals	 (Anthony	 A.	 Albanese	
Selma	E.	Snyderman	Marilyn	Lein	Emilie	M.	Smetak	Betty	Vestal,	1949;	 Jansen,	
1962;	Neuberger	&	Webster,	 1945;	 Thomas	B.	 Osborne	&	Wakeman,	 1914).	 It	
was	 for	 the	 first	 time	discovered	by	E.	Drechsel	 in	1889	 (G.	Wu,	2010).	 It	 falls	
under	the	category	of	essential	amino	acids	because	of	the	inability	of	mammals	
to	synthesize	 inherently	and	hence	 is	 to	be	necessarily	 taken	through	diet.	The	
average	dietary	 intake	 of	 lysine	 in	 order	 to	maintain	 the	nitrogen	balance	 and	
growth,	as	proposed	by	the	Food	and	Nutrition	Board	is	30	mg/kg/day	for	young	
adults	above	18	years	(Tomé	&	Bos,	2007).	Infants	above	0.5	years	of	age	need	
64	 mg/kg/day	 lysine	 and	 are	 at	 a	 higher	 range	 of	 lysine	 requirement	 when	
compared	 to	 adults	 (Tomé	&	Bos,	 2007).	The	 individuals	 falling	under	 the	 age	
groups	between	the	infants	and	adults	require	lysine	of	range	45‐34	mg/kg/day	
(Tomé	&	Bos,	2007).	Lysine	is	present	at	a	lower	concentration	in	plant‐derived	
foods	when	 compared	 to	 animal‐derived	 foods.	However,	 legumes	harbor	high	
amounts	 of	 lysine	 and	 cereals;	 usually,	 the	 staple	 source	of	 energy,	 harbor	 the	
least	(Young,	1994).	
	
The	chemically	reactive	ε‐ammonium	group	(NH3+)	containing	amino	acid	lysine	
(Tomé	&	Bos,	2007),	plays	a	significant	role	 in	providing	essential	nitrogen	 for	
the	synthesis	of	proteins	and	other	biological	molecules	(Friedman,	1996).	It	is	of	
paramount	 importance	 in	the	production	of	many	precursor	molecules	 like	 the	
neurotransmitters	 glutamate	 (Fabio	 Papes,	 Surpili,	 Langone,	 Trigo,	 &	 Arruda,	
2000),	carnitine;	a	key	player	in	the	metabolism	of	fatty	acids	(Vaz	&	Wanders,	
2002),	etc.	Modification	of	 lysine	residues	 in	different	proteins	via	methylation	
(Lanouette,	 Mongeon,	 Figeys,	 &	 Couture,	 2014),	 acetylation	 (Tapias,	 Wang,	 &	
Yang,	 2017),	 hydroxylation	 (Slyke	 &	 Sinext,	 1958),	 glutarylation	 (Tan	 et	 al.,	
2014)	or	sumoylation	(Zhang	et	al.,	2014)	is	a	very	important	process	happening	
after	 translation	 to	 build	 a	 functionally	 active	 protein.	Metabolism	 of	 lysine	 is	
complex	and	differs	from	other	amino	acids	in	that	it	cannot	reversibly	accept	α‐
amino	nitrogen	from	any	other	sources.	Weisman	and	co‐workers	using	isotope	
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exchange	 method	 have	 shown	 that	 the	 α‐hydroxy	 analog	 of	 lysine	 does	 not	
support	 the	 growth	 of	 rats	 on	 a	 lysine‐free	 diet,	 suggesting	 lysine	 as	 an	 inert	
indispensable	amino	acid	(Weissman	&	Schoenheimer,	1941).	
	
1.1.1.	Metabolism	of	Lysine	
	
1.1.1.1.	Anabolism	of	Lysine	
	
Lysine,	 amongst	 the	 other	 20	 Proteinogenic	 amino	 acids	 is	 unique,	 since,	
evolutionarily,	 its	 synthesis	 occurs	 de	novo	 via	 two	 well	 distinct,	 independent	
pathways:	1)	The	diaminopimelic	acid	(DAP)	pathway	(fig:	1)	which	begins	with	
L‐aspartate	and	includes	nine	enzymatic	steps	leading	to	L‐lysine	synthesis.	This	
Pathway	occurs	in	most	bacteria,	certain	lower	fungi	and	green	plants.	2)	The	α‐
aminoadipic	 acid	 (AAA)	 pathway	 (fig:	 1)	 is	 preceded	 by	 2‐oxoglutarate	 giving	
rise	 to	 L‐lysine,	 following	nine	 enzymatic	 steps.	This	pathway	occurs	 only	 in	 a	
few	 groups	 of	 organisms	 such	 as	 fungi,	 bacteria	 such	 as	Thermus	thermophilus	
and	Deinococcus	radiodurans	and	 the	 Archaea	 Pyrococcus,	 Thermoproteus,	 and	
Sulfolobus.	Certain	higher	fungi	and	euglenoids	were	typically	shown	to	possess	a	
distinct	variant	of	 the	AAA	pathway	 for	 lysine	synthesis	(Fondi,	Brilli,	Emiliani,	
Paffetti,	 &	 Fani,	 2007).	 Since	 mammals	 are	 deprived	 of	 lysine	 synthesis,	 they	
depend	on	lysine	producers	for	their	dietary	lysine	needs.	
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Figure	 1:	 Lysine	 biosynthesis	 via	 DAP	 and	 AAA	 pathway	 (Source:	 modified	 from	
Kobashi,	Makoto,	&	Tanokura,	1999)	
	
1.1.1.2. Lysine	Catabolism	
	
Breakdown	of	 lysine	is	 important	to	maintain	the	general	nitrogen	balance	and	
essential	 ketone	 body	 production	 (Hutzler	 &	 Dancis,	 1968,	 1975).	 Lysine	
catabolism	 is	 very	 diverse	 and	 distinct	 among	 different	 organisms	 and	 nine	
catabolic	fates	of	lysine	have	been	discovered	so	far	(Zabriskie	&	Jackson,	2000).	
In	mammals,	lysine	degradation	is	complex	and	is	shown	to	occur	mainly	via	two	
different	 pathways.	 The	 saccharopine	 pathway,	 which	 is	 the	 mitochondrial	
10	
	
means	 of	 lysine	 degradation,	 operates	 predominantly	 in	 the	 fetal	 brain	 and	
extra‐cerebral	 tissues,	 while	 the	 pipecolate	 pathway,	 which	 localizes	 in	 the	
peroxisomes	 and	 cytosol,	 occurs	 mostly	 in	 the	 adult	 brain	 (Hallen,	 Jamie,	 &	
Cooper,	 2013).	 In	 the	 saccharopine	 pathway,	 the	 ε‐ammonium	 group	 (NH3+),	
which	resides	in	the	side	chain	of	lysine	is	converted	to	an	aldehyde	group,	while	
in	the	pipecolate	pathway,	the	α‐amino	group	of	lysine	is	converted	to	the	α‐keto	
group	(Hallen	et	al.,	2013).	Both	pathways	converge	into	a	common	degradative	
pathway	finally	giving	rise	to	two	molecules	of	acetyl	CoA	and	CO2.	
	
1.1.1.2.1. Saccharopine	pathway	of	lysine	degradation	
	
Saccharopine	(ε‐N‐	[glutaryl‐2]‐L‐lysine)	pathway	or	the	mitochondrial	pathway	
of	 lysine	degradation	is	considered	to	be	the	major	route	for	the	breakdown	of	
lysine.	It	is	shown	to	occur	in	the	liver	and	kidney	of	mammals.	The	existence	of	
this	 pathway	 was	 first	 experimentally	 demonstrated	 by	 Higashino	 and	 co‐
workers	in	the	rat	liver	mitochondria,	where	the	formation	of	saccharopine	from	
L‐lysine	 was	 shown	 in	 the	 presence	 of	 α‐ketoglutarate	 (α‐KG)	 (Higashino,	
Fujioka,	Aoki,	&	Yamamura,	1967;	Higashino,	Tsukada,	&	Lieberman,	1965).	The	
enzyme	 catalyzing	 the	 conversion	 of	 L‐lysine	 to	 saccharopine	 in	 humans	 was	
subsequently	identified	by	Hutzler	and	Dancis	as	a	NADPH	dependent	lysine	α‐
KG	reductase	(LKR)	(Hutzler	&	Dancis,	1968).	However,	an	enzyme	with	a	higher	
specific	 activity	 that	 converts	 L‐lysine	 to	 saccharopine	 was	 later	 identified	 as	
saccharopine	dehydrogenase	(SDH),	using	 liver	 tissue	samples	 from	herbivores	
(pig	 ox,	 sheep),	 carnivores	 (rat,	 dog,	 cat)	 and	 omnivores	 (human).	 Such	
observations	 from	 Fellows	 and	 Lewis	 showed	 that	 herbivores	 have	 a	 higher	
specific	activity	of	SDH	when	compared	to	carnivores	and	omnivores	(Fellows	&	
Lewis,	 1973).	 Additionally,	 SDH	 activity	 was	 further	 confirmed	 by	 performing	
complementary	experiments	by	Fellow	and	Lewis.	They	observed	the	activity	of	
saccharopine	 oxidoreductase	 in	 Ox	 and	 human	 liver,	 that	 catalyses	 the	
hydrolysis	 of	 saccharopine	 to	 lysine	 and	 α‐ketoglutarate	 (Fellows	 &	 Lewis,	
1973).	 Carson	 and	 co‐workers	 identified	 patients	 with	 saccharopinuria,	 who	
were	characterized	with	abnormal	 levels	of	 saccharopine	 in	 their	physiological	
fluids	(CARSON,	SCALLY,	NEILL,	&	CARRÉ,	1968).	This	discovery	eventually	 led	
11	
	
to	the	identification	of	the	next	step	of	saccharopine	pathway	i.e;	the	conversion	
of	 saccharopine	 to	 α‐aminoadipate	 δ‐semialdehyde	 (AAS)	 and	 glutamate	
(Fellows	&	Lewis,	1973).	Interestingly,	both	LKR	and	SDH	activities	were	shown	
to	be	catalyzed	by	a	bi‐functional	enzyme	in	the	 liver	mitochondrial	extracts	of	
baboon	and	bovine,	which	was	named	as	aminoadipate	semialdehyde	synthase	
(AASS)	(P.	J.	Markovitz,	Chuang,	&	Cox,	1984;	Paul	J	Markovitz	&	Chuang,	1987).	
Other	eukaryotes,	including	C.	elegans	and	plants	(Epelbaum,	Mcdevitt,	&	Falco,	
1997),	also	seem	to	have	evolved	a	single‐gene	locus	for	these	two	activities.	But,	
in	 lower	 eukaryotes	 like	 in	 S.	 cerevisiae,	 LKR	 and	 SDH	 are	 encoded	 by	 two	
distinct	genes,	LYS1	and	LYS9	respectively	(Kobashi	et	al.,	1999)	.	Papes	and	co‐
workers	moved	a	 step	 further	and	 identified	 two	mRNA	variants	 in	 the	mouse	
liver	 and	 kidney	 samples	 by	 northern	 blot	 analysis,	 in	 which	 the	 longer	
transcript	 corresponds	 to	 a	 bi‐functional	 mitochondrial	 LKR/SDH	 and	 the	
shorter	encodes	a	mono‐functional	SDH	(F	Papes,	Kemper,	Cord‐Neto,	Langone,	
&	Arruda,	1999).	In	humans,	however,	LKR	and	SDH	are	shown	to	be	encoded	by	
a	single	gene	(Sacksteder	et	al.,	2000).	By	performing	LKR/SDH	enzyme	activity	
measurements,	 Rao	 et	 al	 experimentally	 demonstrated	 that	 saccharopine	
pathway	 is	 the	major	 contributor	 of	 L‐lysine	metabolism,	 in	 the	 liver	 of	 adult	
rats.	Findings	 from	Hutzler	and	Dancis	 showing	 low	LKR/SDH	activity	 in	adult	
rat	 brain,	 were	 further	 strengthened	 by	 Chang	 et	 al,	 who	 demonstrated	 that	
adult	 rat	 brain	 harbors	 pipecolate	 pathway	 as	 the	 major	 route	 for	 lysine	
degradation	 (Chang,	 1976,	 1978,	 Hutzler	 &	 Dancis,	 1968,	 1975;	 Rao	 &	 Chang,	
1992).	Further	confirmation	was	given	by	Sauer	et	al.	using	adult	mouse	brain	
samples,	 where	 they	 detected	 low	 LKR/SDH	 mRNA	 expression	 along	 with	 no	
detectable	enzyme	activity	 (Sauer	et	al.,	2011).	Although	adult	 rat	brain	shows	
low	 LKR/SDH	 activity,	 Rao	 and	 co‐workers	 experimentally	 showed	 that	 in	 the	
embryonic	 rat	 brain,	 LKR/SDH	 activity	 was	 high	 and	 gradually	 decreases	
through	development.	This	establishes	the	fact	that	saccharopine	pathway	is	the	
major	 lysine	degradation	pathway	 in	the	 fetal	brain	(Rao,	Pan,	&	Chang,	1992).	
The	saccharopine	pathway	converges	with	the	pipecolate	pathway	at	the	level	of	
aminoadipate	 semialdehyde	 (AAS),	 which	 is	 the	 product	 of	 oxidative	
deamination,	 catalyzed	 by	 AASS	 enzyme	 (fig	 2).	 AAS	 is	 in	 equilibrium	with	 its	
cyclic	 ketamine	 form	 Δ1‐piperidine‐6‐carboxylate	 (P6C)	 (Soda,	 Misono,	 &	
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Yamamoto,	1968).	Inter‐conversion	between	AAS	and	P6C	occurs	spontaneously	
without	any	enzyme	involved	and	the	equilibrium	favors	P6C.	
	
	
Figure	2:	Saccharopine	pathway,	Source:	(Hallen	et	al.,	2013)	
	
1.1.1.2.2. Pipecolate	pathway	of	lysine	degradation	
	
The	existence	of	an	alternate	route	for	lysine	degradation	has	been	an	interesting	
topic	of	high	speculation	and	a	challenging	experimental	question	for	over	many	
years.	For	the	first	time,	Rothstein	and	Miller	demonstrated	that	pipecolic	acid	is	
a	major	metabolite	 of	 lysine	 and	 it	 lies	 on	 the	 pathway	between	 lysine	 and	α‐
aminoadipic	 acid,	 by	using	 the	metabolite‐overloading	procedure	 in	 intact	 rats	
(Rothstein	&	Miller,	1954a).	Reports	showing	the	clinical	cases	of	hyperpipecolic	
acedemia	 indicate	the	essential	role	of	 lysine	degradation	via	the	pipecolic	acid	
forming	 pathway	 (Gatfield	 et	 al.,	 1968).	 Knowing	 that	 the	mammalian	 brain	 is	
inactive	 in	 terms	of	 degrading	 lysine	 via	 the	 saccharopine	pathway	 (Hutzler	&	
Dancis,	 1968,	 1975),	 in	 turn,	 highlights	 the	 speculations	 about	 the	 functional	
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existence	of	pipecolic	acid	pathway.	These	speculations	were	further	confirmed	
by	 Chang	 via	 intra‐cerebroventricular	 administration	 of	 14C	 labeled	 L‐	 and	 D–
lysine	enantiomers,	which	subsequently	metabolized	to	L‐pipecolic	acid	but	not	
saccharopine,	 thus	 emphasizing	 the	 concept	 of	 the	 separate	 existence	 of	
saccharopine	pathway	and	pipecolate	pathway	for	L‐lysine	metabolism	(Chang,	
1976,	 1978).	 Findings	 from	Woody	 and	 Pupene	 about	 the	 abnormal	 levels	 of	
pipecolate	 excretion	 in	 case	 of	 hyperlysinemia	 patients	 in	 comparison	 to	
unaffected	controls	also	indicate	the	existence	of	L‐pipecolate	pathway	of	lysine	
degradation	 (Woody	 &	 Pupene,	 1970).	 In	 the	 developing	 fetal	 brain,	 the	
saccharopine	 pathway	 is	 highly	 active	 and	 predominates.	 However,	 during	
development,	 the	 capacity	 of	 the	 pipecolate	 pathway	 increases,	 becoming	 the	
major	catabolic	pathway	for	lysine	degradation	in	adult	brain	(Rao	et	al.	1992).	
This	 relationship	 suggests	 a	 specific	 neuronal	 developmental	 role	 for	 the	
pipecolate	pathway	and	 its	 intermediate	metabolites.	The	existence	of	 regional	
differences	 in	 the	concentrations	of	L‐pipecolate	 in	 the	dog	brain	and	causal	of	
cerebral	 dysfunction	 due	 to	 hyperpipecolic	 acidaemia	 in	 infants	 specifies	 the	
significant	 role	 of	 L‐pipecolate	 neurobiologically	 (Y.	 Kasé,	 Kataoka,	 Miyata,	 &	
Okano,	1973;	Yoshitoshi	Kasé	et	al.,	1980).		
	
Many	speculations	about	the	conversion	of	D‐lysine	and	L‐lysine	to	pipecolate	in	
brain	came	into	existence.	According	to	Grove	and	Henderson,	in	rats,	D‐lysine	is	
converted	 to	 L‐pipecolate	 by	 D‐amino	 acid	 oxidase	 (DAAO),	 a	 peroxisomal	
enzyme	 (Grove	 &	 Henderson,	 1968).	 D‐lysine	 is	 oxidatively	 deaminated	 to	 ‐
keto‐‐amino	 caproate	 (KAC)	 in	 the	 first	 step,	 which	 instantly	 cyclizes	 to	
ketamine	P2C,	 that	 in	 turn	 is	reduced	to	L‐pipecolate	by	 the	action	of	cytosolic	
P2C	 reductase	 (Meister,	 1962;	 Scannone,	 Wellner,	 &	 Novogrodsky,	 1964).	
However,	when	it	comes	to	L‐lysine	conversion	to	KAC	and	then	to	L‐pipecolate,	
it	was	shown	to	be	via	 the	 loss	of	‐amino	group	of	 lysine	from	the	metabolite	
overloading	experiments	in	the	rat	(Rothstein	&	Miller,	1954b).	However,	little	is	
known	 about	 the	 enzymes	 involved	 in	 this	 conversion	 (L‐lysine	 to	 KAC/P2C).	
Many	 theories	 about	 the	 involvement	 of	 an	 L‐amino	 acid	 oxidase	 (LAAO)	
(Murthy	&	Janardanasarma,	1999)	or	an	aminotransferase	(Fabio	Papes,	Surpili,	
Langone,	Trigo,	&	Arruda,	 2001)	or	 an	 acetyltransferase	 (Neuberger	&	 Sanger,	
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1943)	in	the	conversion	of	L‐pipecolate	to	KAC/P2C	came	into	picture.	However,	
KATIII/GTL,	which	is	present	in	cytosolic	fractions	of	mammalian	brain,	appears	
to	 be	 the	 most	 likely	 option	 for	 the	 source	 of	 KAC	 in	 brain,	 even	 though	 its	
efficacy	in	transaminating	lysine	at	physiological	pH	values	is	still	not	clear	(Han,	
Robinson,	Cai,	Tagle,	&	Li,	2009).	Further	studies	and	confirmation	are	markedly	
essential	 to	 unravel	 the	 mechanism	 behind	 the	 conversion	 of	 L‐lysine	 to	
KAC/P2C.	 The	 second	 step	 of	 the	 pipecolate	 pathway	 is	 also	 cytosolic	 and	
involves	the	reduction	of	P2C	via	‐crystallin	(CRYM)/	Ketimine	reductase	(KR)	
to	 L‐pipecolate.	 Interestingly,	 CRYM/KR	 is	 shown	 to	 be	 strongly	 regulated	 by	
Thyroid	hormone	T3	(Beslin,	Vie,	Blondeau,	&	Francon,	1995;	Mori	et	al.,	2002).	
The	 third	 step	 of	 the	 pipecolate	 pathway,	 however,	 occurs	 in	 the	 peroxisomes	
(Hallen	 et	 al.,	 2013).	 Studies	 about	 the	patients	with	Zellweger	 syndrome	who	
have	 increased	plasma	pipecolate	 levels	suggests	 that	oxidation	of	L‐pipecolate	
occurs	 in	 liver	 peroxisomes	 and	 indeed	 these	 patients	 are	 defective	 in	 L‐
pipecolate	 oxidation	 (Wanders	 et	 al.,	 1988;	 Wanders,	 Romeyn,	 Schutgens,	 &	
Tager,	1989).	Zellweger	syndrome	is	an	autosomal	recessive	disorder,	where	the	
affected	 individuals	 are	 characterized	 by	 a	 defect	 in	 the	 formation	 of	
peroxisomes	(Versmold	et	al.,	1997)	leading	to	the	improper	development	of	the	
brain	and	mental	retardation.	Studies	 from	Wanders	and	co‐workers	about	 the	
oxidation	of	L‐pipecolate	in	human	liver	peroxisomes	were	further	confirmed	by	
Rao	and	Chang	(Rao	&	Chang,	1990;	Rao,	Tsai,	Pan,	&	Chang,	1993).	They,	in	turn,	
identified	the	product	formed	from	L‐pipecolate	oxidation	as	the	cyclic	ketimine	
Δ1‐piperidine‐6‐carboxylate	 (P6C),	which	 is	 in	 close	 equilibrium	with	 its	 open‐
chain	 aldehyde	 form	 ‐	 aminoadipate	 ‐semialdehyde	 (AAS)	 (Rao	 &	 Chang,	
1990).	It	is	also	reported	that	in	humans,	Δ1‐piperidine‐6‐carboxylate	(P6C)	can,	
in	 turn,	 generate	 L‐pipecolic	 acid	 by	 the	 action	 of	 enzyme	 pyrroline‐5‐	
carboxylate	 reductase	 (PYCR1)	 (Struys,	 Jansen,	 &	 Salomons,	 2014).	 However,	
few	studies	also	identified	the	enzyme	involved	in	the	oxidation	of	L‐pipecolate	
to	 P6C/AAS	 as	 L‐pipecolate	 oxidase	 (L‐pox),	 whose	 subcellular	 localization	
differs	 amongst	 several	 mammalian	 species	 (Mihalik,	 S.J.,	 Rhead,	 1991;	 S	 J	
Mihalik	 &	 Rhead,	 1989;	 Rao	 et	 al.,	 1993).	 The	 pipecolate	 pathway,	 thus,	 is	
considered	 to	 be	 operative	 predominantly	 in	 the	 cytosol,	 with	 a	 peroxisomal	
component	involved.	
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Figure	3:	Pipecolate	pathway,	Source:	(Hallen	et	al.,	2013).	
	
1.1.1.2.3.	 Convergence	 of	 pipecolic	 acid	 pathway	 and	
saccharopine	pathway	
	
The	 pipecolate	 pathway	 and	 the	 saccharopine	 pathway	 both	 converge	 at	 the	
step,	where	2‐aminoadipate	semialdehyde	(AAS)	 is	oxidized	 to	‐aminoadipate	
(AA)	 via	 aminoadipate	 semialdehyde	 dehydrogenase	 enzyme	 (AASDH),	 which	
resides	 in	 cytosolic	 compartment	 (Chang	 et	 al.,	 1990;	Okuno	 et	 al.,	 1993).	 The	
next	step	in	the	lysine	degradation	is	transamination	of	AA	to	2‐oxoadipate	(OA).	
The	 enzymes	 that	 catalyze	 the	 reversible	 transamination	 between	 AA	 and	 2‐
oxoglutarate	(OG)	 to	 form	OA	and	glutamate	were	 identified	 in	yeast	and	were	
named	as	glutamate‐‐ketoadipate	transaminase	I	and	II	(GKAT	I	and	GKAT	II)	
(Matsuda	&	Ogur,	1969).	Mammalian	aminoadipate	aminotransferase	 (AADAT)	
that	has	the	capacity	to	catalyze	the	transamination	between	AA	and	OG	was	first	
discovered	in	rat	liver	mitochondria	(Nakatani,	Fujioka,	&	Higashino,	1970)	and	
was	 shown	 to	possess	 activity	 in	both	 cytosolic	 and	mitochondrial	 fractions	of	
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rat	 liver	and	kidney	(Tobes	&	Mason,	1975,	1977).	Aminotransferases	exhibit	a	
broad	 range	 of	 specificity	 and	 so	 does	 AADAT.	 Namely,	 kynurenine	
aminotransferase	 II	 (KAT	 II),	 an	 enzyme	 that	 catalyzes	 the	 transamination	
between	 L‐kynurenine	 (Kyn)	 and	 OG	 was	 discovered	 (Mason,	 1954;	 Miller,	
Tsuchida,	&	Adelberg,	1953)	which	was	 subsequently	 shown	 to	be	 identical	 to	
AADAT	 in	 the	 rat	 by	 Tobes	 and	 Mason	 (Tobes	 &	 Mason,	 1975,	 1977).	 It	 is	
noteworthy	to	know	that	OA	formed	here	is	a	common	metabolic	intermediate	in	
both	L‐lysine	 and	L‐tryptophan	degradation	pathways	 (Wass	 et	 al.,	 2011).	The	
OA	 formed	 is	 oxidatively	 decarboxylated	 to	 glutaryl‐CoA	by	dehydrogenase	E1	
and	transketolase	domain	containing	1	(DHTKD1),	which	is	the	E1	like	subunit	of	
oxoglutarate	dehydrogenase	complex	enzyme	(OGDHc),	 (V.	Bunik	&	Degtyarev,	
2008).	 Glutaryl	 CoA	 is	 then	 dehydrogenated	 to	 form	 glutaconyl	 CoA,	 which	 in	
turn	 is	 decarboxylated	 to	 form	 Crotonyl	 CoA	 and	 CO2.	 Both	 the	 steps	 are	
catalyzed	 by	 glutaryl	 CoA	 dehydrogenase	 enzyme	 (Gomes,	 Fendrich,	 &	 Abeles,	
1981).	 Crotonyl	CoA	 is	 further	degraded	 to	2	molecules	 of	 acetyl	 CoA	and	CO2	
(Benevenga	&	Blemings,	2007;	Varadkar	&	Surtees,	2004).		
	
1.2. Inborn	errors	of	lysine	metabolism	
	
Till	now,	a	variety	of	 inborn	errors	of	 lysine	metabolism	have	been	delineated.	
Though	 these	 disorders	 are	 considered	 rare,	 collectively	 they	 account	 for	 a	
substantial	 portion	 of	 childhood	 deformities	 and	 mortality	 rate	 (Dasgupta,	
Wahed,	Dasgupta,	&	Wahed,	2014).	Most	of	these	inborn	errors	are	inherited	as	
autosomal	 recessive	 traits.	 Up	 to	 date,	 several	 disorders	 linked	 to	 lysine	
metabolism	are	known,	i.e.,	hyperlysinemia,	saccharopinuria,	2‐aminoadipic	and	
2‐oxoadipic	 aciduria,	 Pyridoxine‐dependent	 epilepsy	 or	 antiquitin	 deficiency,	
Zellweger	 syndrome,	 glutaric	 aciduria	 type‐I	 (Divry,	 Vianey‐Liaud,	 &	 Mathieu,	
1991).		
	
1.2.1.	Hyperlysinemia	
Hyperlysinemia	I	(MIM	#	238700)	was	first	described	in	1964	when	two	siblings	
were	shown	to	have	reduced	capacity	to	degrade	lysine,	after	radioactive	lysine	
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administration	 (WOODY,	1964).	 Fibroblasts	 from	 the	 affected	 individuals	were	
detected	 to	 have	 a	 defect	 in	 the	 first	 enzymatic	 step	 of	 major	 route	 of	 lysine	
degradation,	 catalyzed	 by	 AASS	 (Dancis,	 Hutzler,	 Woody,	 &	 Cox,	 1976).	
Hyperlysinemia	 type	 I	 patients	 have	 defects	 in	 both	 LKR	 and	 SDH	 activities	 of	
AASS	 resulting	 in	 hyperlysinemia,	 hyperlysinuria	 and	 a	 relatively	 mild	
saccharopinuria.	Patients	with	hyperlysinemia	I	are	characterized	by	abnormally	
high	 levels	 of	 lysine	 in	 the	 body	 fluids	 (Dancis	 et	 al.,	 1976)	 resulting	 in	
accumulation	 of	 homoarginine,	 N‐ε‐acetyl‐L‐lysine,	 N‐α‐acetyl‐L‐lysine	 and	
pipecolic	 acid	 as	 a	 result	 of	 usage	 or	 activation	 of	 alternate	 detoxifying	
biochemical	 pathways	 (vd	 Heiden	 et	 al.,	 1978;	 Woody	 &	 Pupene,	 1970).	
Hyperlysinemia	I/	Saccharopinuria	is	generalized	as	a	benign	metabolic	variant	
and	hence	 is	not	associated	with	any	 increase	 in	mortality	(Dancis	et	al.,	1983;	
Gelderen	&	Teijema,	1973;	Georg	F	Hoffmann,	2006;	Houten	et	al.,	2013;	Tondo	
et	al.,	2013).	
In	hyperlysinemia	II	or	saccharopinuria	(MIM	#	268700)	as	described	by	Carson	
(1968),	a	defect	 in	SDH	activity	of	AASS	 is	observed	with	 residual	LKR	activity	
resulting	in	increased	excretion	of	saccharopine	(CARSON	et	al.,	1968).	Patients	
with	 saccharopinuria	 show	 elevated	 levels	 of	 saccharopine,	 citrulline,	 lysine	
(Houten	et	al.,	2013).	Hyperlysinemia	II/	Saccharopinuria	follows	an	autosomal	
recessive	inheritance	and	appears	to	be	a	non‐disease.	About	50%	of	the	patients	
described	were	discovered	accidentally	and	reported	to	be	healthy	(Dancis	et	al.,	
1983).	 Clinical	 characteristics	 of	 some	 of	 the	 patients	 include	 psychomotor	
retardation,	 microcephaly,	 developmental	 delay,	 spastic	 diplegia,	 epilepsy,	
ataxia,	nonspecific	seizures	and	short	stature	(Houten	et	al.,	2013;	Tondo	et	al.,	
2013),	yet	a	causal	link	between	deficient	AASS	activity	and	clinical	phenotypes	
is	lacking.	Till	now,	only	a	few	studies	explain	about	the	therapeutic	approach	to	
be	 followed	and	one	treatment	option	includes	 long‐term	dietary	regimen	with	
lysine	restriction,	which	is	of	no	benefit	(Tondo	et	al.,	2013).	Since	the	patients	
do	 not	 suffer	 from	 any	 metabolic	 crisis,	 specific	 interventions	 during	
intercurrent	illnesses	are	not	needed.		
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1.2.2.	2‐aminoadipic	2‐oxoadipic	aciduria		
	
2‐aminoadipic	 and	 2‐oxoadipic	 aciduria	 (MIM	 #	 204750)	 is	 an	 autosomal	
recessive	 inborn	 error.	 Affected	 individuals	 are	 characterized	 by	 the	
accumulation	 of	 2‐aminoadipic	 acid	 and	 2‐oxoadipic	 acid	 in	 their	 body	 fluids	
(Duran,	Beemer,	Wadman,	Wendel,	&	Janssen,	1984).	Till	now,	not	more	than	30	
individuals	are	reported	with	this	disorder,	out	of	which	half	are	asymptomatic	
and	the	other	half	presented	with	mild	neurological	phenotype	 like	 intellectual	
disability,	 ataxia,	 epilepsy,	 muscular	 hypotonia	 and	 developmental	 delay	
(Biagosch	 et	 al.,	 2017;	 Duran	 et	 al.,	 1984;	 Przyrembel	 et	 al.,	 1975).	 Since	 this	
disease	conditions	are	not	 lethal,	dietary	 lysine	 restrictions	and	administration	
of	Vitamin	B1	and	B6	were	followed	but	has	proven	no	long‐term	effects	(Casey,	
Zaleski,	Philp,	Mendelson,	&	MacKenzie,	1978;	Duran	et	al.,	1984).	By	performing	
whole	 exome	 sequencing	 of	 two	 patients	 with	 2‐aminoadipic	 and	 2‐oxoadipic	
aciduria,	Danhauser	and	colleagues	have	identified	mutations	in	Dehydrogenase	
E1	and	transketolase	domain	containing	1	(DHTKD1)	(EC	1.2.4.2)	gene	to	cause	
2‐aminoadipic	and	2‐oxoadipicaciduria	(Danhauser	et	al.,	2012a).	Findings	from	
Hagen	et	al.	 further	delineates	additional	mutations	in	DHTKD1,	confirming	the	
studies	of	Danhauser	and	co‐workers	(Hagen	et	al.,	2015).		
	
1.2.3. Zellweger	syndrome	
	
Cerebrohepatorenal	 syndrome	 or	 Zellweger	 syndrome	 (MIM	 #	 214100)	 is	 an	
autosomal	recessive	severe	congenital	disorder	characterized	by	a	defect	in	the	
development	 of	 functional	 peroxisomes	 (Stephanie	 J.	 Mihalik	 et	 al.,	 1989).	
Patients	with	 Zellweger	 syndrome	 are	 associated	with	 an	 impairment	 in	 brain	
development,	 neuronal	 positioning,	 neuronal	 migration	 and	 several	 other	
characteristics	like	loss	of	myelin	in	the	central	nervous	system,	loss	of	hearing,	
vision,	etc.	(Versmold	et	al.,	1997).	Matsumato	et	al.,	have	observed	a	reduction	
in	neuronal	viability	and	also	an	 increase	 in	neuronal	apoptosis	 in	 the	affected	
patients	 (Matsumoto	 et	 al.,	 2003).	 Patients	 with	 Zellweger	 syndrome	 do	 not	
survive	more	than	one	year	after	birth.	Biochemically,	patients	are	characterized	
among	other	 abnormal	metabolite	patterns	by	elevated	 levels	of	pipecolic	 acid	
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excretion	 in	 body	 fluids,	 indicating	 a	 defect	 in	 a	 pathway	 related	 to	 pipecolate	
breakdown	 (Danks,	 Tippett,	 Adams,	 &	 Campbell,	 1975;	 Trijbels,	 Monnens,	
Bakkeren,	Van	Raay‐Selten,	&	Corstiaensen,	1980).		
Studies	 from	 different	 groups	 on	 Zellweger	 syndrome	 were	 supportive	 in	
understanding	the	role	of	peroxisomes	in	the	oxidation	of	L‐pipecolate,	which	is	
an	alternate	route	of	lysine	degradation.		
	
1.2.4.	Glutaric	aciduria	type	I	
	
Glutaric	 aciduria/acidemia	 type	 I	 (GA‐I;	MIM	#	 231670)	was	 for	 the	 first	 time	
discovered	 by	 Goodman	 and	 co‐workers	 in	 the	 year	 1975	 (Goodman,	Markey,	
Moe,	Miles,	&	Teng,	1975b).	Affected	individuals	were	reported	to	have	defective	
oxidation	 of	 glutaryl‐CoA	 in	 their	 peripheral	 leukocytes.	 By	 giving	 oral	 lysine	
administration	 to	 the	 affected	 patients,	 they	 demonstrated	 glutaric	 acid	
accumulation	and	interestingly	they	also	identified	that	by	lowering	the	intake	of	
protein,	 glutaric	 acid	 accumulation	 was	 decreased.	 Subsequent	 findings	 from	
different	 groups	 described	 this	 neurodegenerative	 disorder	 as	 an	 autosomal	
recessive	 inherited	deficiency	of	glutaryl‐CoA	dehydrogenase	 (GCDH)	 (Borsook	
H,	Deasy	CL,	Haagen‐Smit	A	J,	Keighley	G,	1948;	Gholsoi,	Sanders,	&	Henderson,	
1959;	Goodman	&	Kohlhoff,	1975;	Goodman	et	al.,	1975b).	GCDH	(EC	1.3.8.6)	is	a	
flavin	 adenine	 dinucleotide	 (FAD)	 dependent	 mitochondrial	 enzyme	 that	
catalyzes	the	oxidative	decarboxylation	of	glutaryl‐CoA	to	crotonyl‐CoA	and	CO2	
in	the	common	downstream	catabolic	pathway	of	L‐lysine,	L‐hydroxy	lysine	and	
L‐tryptophan.	 It	 is	 encoded	 by	 the	 GCDH	 gene,	 in	 humans,	 it	 is	 located	 on	
chromosome	 19p13.2	with	 7kb	 in	 length	 spanning	 11	 exons	 (C.	 R.	 Greenberg,	
Duncan,	 .Gregory,	Singal,	&	Goodman,	1994).	Till	now,	the	prevalence	of	GA‐I	is	
approximated	 to	 be	 about	 1:110,000	 newborns	 (Heringer	 et	 al.,	 2010),	 it	 is	
significantly	 widespread	 in	 certain	 genetically	 isolated	 ethnic	 groups	 like	 the	
Pennsylvania	 Amish,	 Canadian	 Ojibway‐Cree	 aboriginals	 of	 Manitoba,	 Lumbee	
heritage	of	eastern	North	Carolina	and	the	Irish	travellers	(Basinger	et	al.,	2006;	
B.	L.	Greenberg	&	Glick,	2012;	C.	R.	Greenberg	et	al.,	2002a;	Naughten	et	al.,	2004;	
Strauss,	Puffenberger,	Robinson,	&	Morton,	2003;	van	der	Watt	et	al.,	2010).	So	
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far,	close	to	200	disease‐causing	mutations	are	identified	in	the	GCDH	gene	with	
missense	mutations	being	the	most	common	type	(Aishah	et	al.,	2016).		
	
1.2.4.1.	Biochemical	features	of	GA‐I	
	
Individuals	possessing	a	defective	GCDH	enzyme	are	biochemically	characterized	
by	 the	 accumulation	 of	 neurotoxic	 glutaryl‐CoA,	 glutaric	 acid	 (GA),	 3‐
hydroxyglutaric	acid	(3‐OH‐GA),	low	levels	of	glutaconic	acid	as	well	as	non‐toxic	
glutaryl	 carnitine	 (C5DC)	 in	 their	 tissues	 and	 body	 fluids	 (Goodman,	 Markey,	
Moe,	 Miles,	 &	 Teng,	 1975a;	 Hoffmann	 et	 al.,	 1991;	 Georg	 F.	 Hoffmann	 et	 al.,	
1996),	which	are	detectable	by	organic	acid	(GA,	3‐OH	GA,	glutaconic	acid)	and	
acyl	 carnitine	 analysis	 (C5DC)	 (Chace,	 Kalas,	 &	 Naylor,	 2003;	 Schulze	 et	 al.,	
2003).	Reports	 from	different	groups	suggest	 that	a	significant	number	of	GA‐I	
patients	 have	 differential	 (either	 very	 low	 or	 normal	 or	 even	 highly	 elevated)	
levels	 of	 GA	 excretion	 (Bergman	 et	 al.,	 1989;	 Campistol,	 Ribes,	 Alvarez,	
Christensen,	 &	 Millington,	 1992;	 Superti‐Furga,	 1997).	 Among	 the	 disease‐
causing	 mutations	 identified	 in	 GA‐I	 patients,	 R402W	 is	 the	 most	 frequent	
mutation	reported	and	patients	with	this	mutation	were	shown	to	excrete	high	
amounts	of	glutaric	acid	(GA)	and	3‐hydroxyglutaric	acid	(3‐OH‐GA)	(Busquets,	
Merinero,	&	Christensen,	2000;	Christensen,	Ribes,	Merinero,	&	Zschocke,	2004a;	
Schwartz,	 Christensen,	 Niels,	 &	 Brandt,	 1998;	 Zschocke,	 Quak,	 Guldberg,	 &	
Hoffmann,	 2000).	 Two	 bio‐chemically	 demarcated	 groups	were	 defined,	 based	
on	 the	 GA	 levels	 detected	 in	 urine	 and	 serum	 samples	 using	 gas	
chromatography‐mass	 spectrometry	 (GC/MS).	The	 individuals	having	complete	
loss	of	GCDH	activity	and	as	a	result	excrete	high	amounts	of	GA	(GA	in	urine	>	
100	 mmol/mol	 creatinine)	 are	 categorized	 into	 the	 group	 of	 high	 excretors;	
whereas	 the	 individuals	 who	 possess	 residual	 enzyme	 activity	 (up	 to	 30%	 in	
fibroblasts	 or	 leucocytes;	 (Christensen,	 Ribes,	 Merinero,	 &	 Zschocke,	 2004b))	
and	 as	 a	 result	 excrete	 no	 to	 low	 levels	 of	 GA	 (GA	 in	 urine	 <	 100	mmol/mol	
creatinine)	are	categorized	into	the	group	of	low	excretors	(Baric	et	al.,	1999a).	
Interestingly,	 a	 correlation	 exists	 between	 the	 genotype	 and	 the	 biochemical	
phenotype,	 but	 the	 severity	 of	 the	 clinical	 phenotype	 is	 not	 predicted	 by	 the	
biochemical	 phenotype,	 i.e.	 low	 excretors	 and	 high	 excretors	 can	 exhibit	 the	
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same	 severity	 in	 the	 clinical	 phenotype	 and	 low	 excretors	 are	 not	 to	 be	
considered	to	have	a	mild	clinical	phenotype.	(Baric	et	al.,	1999b;	Busquets	et	al.,	
2000;	 Christensen	 et	 al.,	 2004b;	 S.	 Kölker,	 Sauer,	 Surtees,	 &	 Leonard,	 2006;	
Stefan	Kölker,	Sauer,	Okun,	Hoffmann,	&	Koeller,	2006;	Mühlhausen	et	al.,	2003).	
However,	 high	 excretors	 were	 recently	 proposed	 to	 be	 at	 risk	 to	 have	 severe	
clinical	phenotype	progressing	with	age	(Harting	et	al.,	2015)	and	all	 late‐onset	
GA‐I	 (definition	 see	 chapter	 1.2.4.2)	 patients	were	 shown	 to	 be	 high	 excretors	
(Boy,	Heringer,	et	al.,	2017).	
	
1.2.4.2.	Clinical	features	of	GA‐I	
	
Clinically,	although	some	GA‐I	patients	are	asymptomatic	(Monavari	&	Naughten,	
2000;	Strauss,	Lazovic,	Wintermark,	&	Morton,	2007),	macrocephaly,	usually	the	
early	 symptom	of	 the	disease,	 can	be	 seen	 immediately	 after	birth	or	 after	 the	
30th	 week	 of	 pregnancy.	 Neurological	 malformations	 begin	 in	 utero,	 and	 in	
exceptional	 cases	 might	 lead	 to	 severe	 abnormalities	 like	 optic	 hypoplasia,	
agenesis	of	 corpus	 callosum,	 lisencephaly	 (G	F	Hoffmann	&	Zschocke,	1999).	 If	
untreated,	approximately	around	90%	of	the	affected	individuals	develop	clinical	
symptoms	during	a	finite	period	of	brain	growth,	i.e.	during	the	first	six	years	of	
life	 (most	 commonly	 between	 3	 months‐3	 years	 of	 age),	 as	 a	 result	 of	 acute	
encephalopathic	 crisis	 that	 is	 induced	 by	 incidents	 like	 gastroenteritis,	 fever,	
routine	 vaccinations	 or	 surgical	 interventions	 resulting	 in	 irreversible	 striatal	
damage	 and	 eventually,	 a	 complex	 movement	 disorder	 with	 predominant	
dystonia.	These	patients	fall	into	the	early	onset	category	(Hoffmann	et	al.,	1991;	
S.	Kölker	et	al.,	2006;	Stefan	Kölker	et	al.,	2007,	2011).	With	increasing	age,	the	
infants	 progressively	 suffer	 from	 intellectual	 deterioration,	 feeding	 problems,	
hyperpyrexia,	regression	of	midbrain	structures	during	the	course	of	additional	
encephalopathic	 crises	 which	 are	 mostly	 linked	 with	 catabolic	 events	 further	
increasing	 the	 degree	 of	 morbidity	 and	 mortality	 (G	 F	 Hoffmann	 &	 Zschocke,	
1999;	 Stefan	Kölker,	Garbade,	 et	 al.,	 2006;	Kyllerman	et	 al.,	 2004).	Most	 of	 the	
above‐stated	symptoms	are	reduced	and	of	 less	prognostic	value	if	the	affected	
infants	are	diagnosed	early	and	treated	successfully	(Heringer	et	al.,	2016;	Georg	
F.	Hoffmann	et	al.,	1996).		
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Two	 clinical	 subsets	 of	 GA‐I	 patients	 (10‐20%)	 were	 diagnosed,	 in	 which	 the	
neurological	 disease	 state	 was	 demonstrated	 even	 in	 the	 absence	 of	 an	
encephalopathic	crisis	and	were	categorized	under	insidious‐	onset	(Busquets	et	
al.,	 2000;	 Georg	 F.	 Hoffmann	 et	 al.,	 1996;	 Strauss	 et	 al.,	 2007)	 and	 late‐onset	
groups	(Külkens	et	al.,	2005).		
	
The	insidious	onset	group	of	GA‐I	patients	differs	from	the	acute	onset	or	early	
onset	group	in	that	they	develop	dystonia	even	in	the	absence	of	an	acute	event	
(Boy,	 Garbade,	 et	 al.,	 2018).	 Few	patients	were	 also	 shown	 to	 develop	distinct	
perinatal	 striatal	 lesions,	 followed	 by	 latency	 over	 several	 months	 before	 the	
actual	signs	of	permanent	disability	become	clinically	apparent	(Boy,	Garbade,	et	
al.,	 2018;	 Strauss	 et	 al.,	 2007;	 Strauss	 &	 Morton,	 2003).	 Observations	 from	
Heringer	 and	 co‐workers	 suggested	 that	 insidious	 onset	 symptoms	 are	
particularly	 developed	 in	 the	 neonatally	 diagnosed	 individuals	 deviating	 from	
the	 metabolic	 dietary	 management,	 in	 particular,	 from	 lysine	 restricted	 diet	
(Heringer	 et	 al.,	 2010).	 This	 was	 in	 turn	 confirmed	 by	 the	 observations	 from	
Strauss	et	al.	who	observed	the	disappearance	of	insidious	onset	of	dystonia	in	a	
genetic	 cohort	 following	 improved	 dietary	 treatment	 (Strauss	 et	 al.,	 2011).	
Overall,	 insidious	onset	GA‐I	patients	differ	from	the	early	or	acute	onset	group	
in	terms	of	the	 lesser	extent	of	striatal	 lesions	followed	by	 less	severe	dystonia	
and	are	categorized	by	symptomless	latency	phase	regardless	of	the	previously	
prevailing	 dorsolateral	 lesions	 of	 the	 putamen	 (Boy,	 Garbade,	 et	 al.,	 2018).	
Apparent	changes	in	white	matter	with	increasing	age	is	also	a	common	feature	
observed	in	this	group	of	GA‐I	patients	(Harting	et	al.,	2009).	
	
The	clinical	sub‐set	of	GA‐I	patients	who	are	diagnosed	after	the	age	of	six	years	
come	under	 the	 late‐onset	 or	 adult‐onset	 group.	 Their	 clinical	manifestation	 is	
shown	 to	 be	 non‐specific	 with	 more	 severe	 neurologic	 symptoms	 in	 older	
patients	 compared	 to	 younger	 patients	 who	 are	 either	 asymptomatic	 or	
commonly	presented	with	a	headache,	vertigo,	etc	(Boy,	Heringer,	et	al.,	2017).	
Interestingly,	 all	 the	 reported	 late	onset	patients	 so	 far	were	shown	 to	be	high	
excretors	 and	 were	 devoid	 of	 striatal	 necrosis	 (Tuncel	 et	 al.,	 2018).	 The	 late	
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onset	 patients	 do	 not	 show	 any	 particular	 differences	 in	 genotypes	 and	
biochemical	 phenotypes	 to	 that	 of	 the	 early	 onset	 group	 (childhood‐onset),	
however,	 severe	 leukencephalopathy	 (Bähr,	 Mader,	 Zschocke,	 Dichgans,	 &	
Schulz,	2002),	changes	 in	white	matter	(spongiform	myelinopathy)	(Külkens	et	
al.,	2005),	frontotemporal	hyperplasia,	sub‐ependymal	mass	lesions	(Herskovitz,	
Goldsher,	Sela,	&	Mandel,	2013a;	Korman	et	al.,	2007;	Pierson	et	al.,	2015)	are	
the	striking	neuroradiologic	hallmarks	observed	in	these	patients.	According	to	
Boy	 et	 al.,	 the	 extra‐striatal	 abnormalities	 observed	 in	 late‐onset	GA‐I	 patients	
are	a	result	of	the	chronic	neurotoxicity	caused	due	to	the	cerebral	accumulation	
of	 toxic	metabolites	over	several	years.	Thus,	 in	 the	case	of	 late‐onset	group	of	
GA‐I	patients	who	are	high	excretors,	the	biochemical	phenotype	is	responsible	
for	determining	the	clinical	outcome	(Boy,	Heringer,	et	al.,	2017).	
	
All	 clinical	 subsets	 of	 GA‐I	 patients	 were	 shown	 to	 be	 prone	 to	 extra‐striatal	
abnormalities	despite	neonatal	 treatment	(as	 in	case	of	acute	onset)	or	despite	
lack	of	susceptibility	to	striatal	damage	(as	in	case	of	late‐onset	group)	(Tuncel	et	
al.,	 2018).	 Few	 GA‐I	 patients	 were	 reported	 to	 have	 extra	 cerebral	 and	 non‐
neurologic	 abnormalities	 (Boy,	 Heringer,	 et	 al.,	 2017)	 like	 peripheral	
polyneuropathy	 (Herskovitz,	 Goldsher,	 Sela,	 &	 Mandel,	 2013b),	 chronic	 renal	
disease	(du	Moulin	et	al.,	2017)	showing	that	the	GA‐I	disease	is	not	restricted	to	
brain	alone.		
	
1.2.4.3.	Neuropathology	of	GA‐I	
	
The	toxic	metabolites,	GA,	3‐OH	GA	and	glutaryl‐CoA,	have	been	shown	to	be	of	
high	significance	in	the	pathophysiology	of	the	disease	(Sauer	et	al.,	2011).	The	
basis	behind	the	metabolite	mediated	neuropathogenesis	in	GA‐I	is	attributed	to	
different	synergistic	pathomechanisms,	based	on	the	results	of	many	in	vitro	and	
in	vivo	 studies.	They	 include	primarily,	 the	excitotoxicity	mediated	cell	damage	
and	 oxidative	 stress	 involving	 nitric	 oxide	 production	 stimulated	 by	 cytokines	
(Stefan	 Kölker,	 Koeller,	 Okun,	 &	 Hoffmann,	 2004),	 impairment	 of	 the	 energy	
metabolism	due	 to	 inhibition	of	oxoglutarate	dehydrogenase	complex	 (OGDHc)	
and	 the	 dicarboxylic	 acid	 shuttle	 between	 the	 astrocytes	 and	 neurons	 by	 the	
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accumulating	 GA,	 3‐OH	 GA	 and	 glutaryl	 CoA	 (Sauer	 et	 al.,	 2005;	 Sauer,	 Okun,	
Fricker,	Mahringer,	et	al.,	2006),	and	the	disturbance	of	cerebral	hemodynamics	
leading	 to	 expansion	 in	 the	 cerebrospinal	 fluid	 volume	 (Strauss,	 Donnelly,	 &	
Wintermark,	2010).	Interestingly,	reports	from	several	groups	via	in	vitro,	in	vivo	
and	postmortem	findings	identified	that	the	blood‐brain	barrier	(BBB)	is	a	major	
player	in	the	neuropathogenesis	of	GA‐I	(S.	Kölker	et	al.,	2006;	Sauer	et	al.,	2010;	
Sauer,	 Okun,	 Fricker,	 Mahringer,	 M??ller,	 et	 al.,	 2006).	 The	 toxicity	 inducing	
metabolites	 GA,	 3‐OH	 GA	 and	 glutaryl‐CoA	 are	 synthesized	 within	 the	 brain	
compartment	and	subsequently	 trapped	due	 to	 limited	permeability	across	 the	
BBB,	 further	 enhancing	 the	 toxic	 effects	 of	 accumulating	 metabolites	 (Jafari,	
Braissant,	Bonafé,	&	Ballhausen,	2011;	S.	Kölker	et	al.,	2008,	2006).		
	
1.2.4.4.	Gcdh	knockout	mouse	model	
	
In	 order	 to	 understand	 the	 pathophysiological	 mechanisms	 which	 drive	 the	
neuropathology	 of	 glutaric	 aciduria	 type	 I,	 a	 clinically	 relevant	 Gcdh	 knockout	
(Gcdh‐/‐)	mouse	model	was	generated	via	 targeted	deletion	of	 the	Gcdh	gene	 in	
mouse	 embryonic	 stem	 cells	 by	 Koeller	 and	 co‐workers	 (Koeller	 et	 al.,	 2002).	
The	murine	Gcdh	gene	shares	a	high	degree	of	homology	to	that	of	humans	and	is	
located	on	chromosome	8	with	11	exons,	 spanning	a	 region	of	7kb	of	 the	 total	
genomic	DNA	(Koeller	et	al.,	1995).	The	knockout	mice	are	characterized	by	the	
loss	of	GCDH	activity	 in	all	 the	 tissues	and	organs.	Biochemically,	 the	knockout	
mouse	model	replicated	the	GA‐I	patients,	as	seen	via	the	accumulation	of	toxic	
metabolites	 in	 tissues	 urine	 and	blood	 (Sauer,	Okun,	 Fricker,	Mahringer,	 et	 al.,	
2006)	and	also	showed	vulnerability	to	striatal	damage	during	the	early	neonatal	
period,	 when	 exposed	 to	 striatal	 toxins	 (Bjugstad,	 Crnic,	 Goodman,	 &	 Freed,	
2006).	 However,	 the	 KO	mouse	 showed	 a	 substantial	 difference	 clinically	 and	
histopathologically	 to	 GA‐I	 patients,	 i.e.,	 the	 absence	 of	 acute	 encephalopathic	
crises	induced	by	catabolism	or	inflammatory	cytokines	as	well	as	the	absence	of	
gliosis	 and	 neuronal	 loss	 in	 the	 striatum	 (Koeller	 et	 al.,	 2002).	 Interestingly,	
studies	 from	 Zinnanti	 et	 al.,	 showed	 that	 Gcdh‐/‐	mice	 exposed	 to	 high	 dietary	
lysine	 develop	 severe	 neurological	 phenotype	 induced	 by	 increased	 cerebral	
accumulation	 of	 toxic	metabolites	 (Zinnanti	 et	 al.,	 2006).	 Gcdh‐/‐	 mice	 showed	
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age‐dependent	 susceptibility	 to	 increased	 lysine	 and	 GA	 accumulation	 in	 the	
developing	 brain,	 which	 was	 similar	 to	 the	 human	 GA‐I	 disease.	 This	 work	
provided	 a	 basis	 for	 utilizing	 the	 Gcdh‐/‐	 mouse	 model	 as	 a	 valuable	 tool	 in	
understanding	 the	 GA‐I	 pathophysiology	 during	 critical	 stages	 of	 brain	
development	 and	 eventually	 advancing	 towards	 the	 development	 of	 novel	
treatment	strategies	(Zinnanti	&	Lazovic,	2010).	
	
1.2.4.5.	Treatment	strategies	followed	for	GA‐I	patients	
	
The	treatment	strategies	followed	for	GA‐I	patients	primarily	focus	on	reducing	
the	accumulation	of	neurotoxic	metabolites	GA,	3OH‐GA	and	glutaryl‐CoA.	This	
can	be	achieved	by	following	age‐dependent	dietary	lysine	restriction	along	with	
ensuring	 the	 supplementation	 of	 essential	 amino	 acids	 in	 combination	 with	
carnitine	 (S.	 Kölker	 et	 al.,	 2007).	 The	 outcome	 of	 GA‐I	 patients	 was	 best	 and	
patients	 remained	 asymptomatic	 when	 they	 were	 diagnosed	 neonatally	 and	
received	 all	 the	 three	 interventions	 and	 an	 emergency	 treatment	 during	
catabolism‐inducing	episodes.	However,	 the	outcome	was	poor	and	 the	dietary	
treatment	 was	 not	 helpful	 when	 diagnosed	 after	 the	 manifestation	 of	 the	
neurological	 disease	 (Boy,	 Mühlhausen,	 et	 al.,	 2017).	 Apart	 from	 dietary	
treatment,	GA‐I	patients	were	also	treated	with	different	pharmacological	agents,	
but	 there	 was	 no	 evidence	 to	 confirm	 the	 beneficial	 role	 of	 neuroprotective	
agents	like	N‐acetyl	cysteine,	phenobarbitone,	creatine	monohydrate,	glutamate	
receptor	 antagonists	 (C.	 R.	 Greenberg	 et	 al.,	 2002b;	 Kyllerman	 et	 al.,	 2004;	
Strauss	&	Morton,	2003).	Although	the	c‐factor	Riboflavin	was	previously	used	as	
a	pharmacotherapeutic	agent,	responsiveness	in	patients	was	shown	to	be	rare	
(Chalmers,	 Bain,	 &	 Zschocke,	 2006)	 and	 no	 firm	 evidence	was	 reported	 about	
improvement	 in	 the	 neurological	 outcome	 of	 patients	 upon	 its	 administration	
(Stefan	 Kölker,	 Garbade,	 et	 al.,	 2006).	 Even	 though	 the	 dietary	 treatment	 is	
effective,	 a	 relevant	 number	 of	 patients	who	were	 known	 to	 be	 ‘metabolically	
stable’,	 still	 suffer	 from	extra‐striatal	 (namely,	 frontotemporal	hypoplasia	 (Boy,	
Heringer,	 et	 al.,	 2017),	 white	 matter	 changes	 (Pierson	 et	 al.,	 2015),	
subependymal	mass	 lesions	 (Herskovitz	 et	 al.,	 2013)),	 extra	 cerebral	 and	 non‐
neurologic	 abnormalities	 (like	 peripheral	 polyneuropathy	 (Herskovitz	 et	 al.,	
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2013)	 and	 renal	 disease	 (S	 Kölker,	 Cazorla,	 et	 al.,	 2015;	 S	 Kölker,	
Valayannopoulos,	 et	 al.,	 2015)	 respectively),	 thus	 debating	 on	 our	 current	
understanding	 about	 the	 prediction	 and	 prevention	 of	 late	 GA‐I	 complications	
using	conventional	metabolic	treatment.	This	in	turn	questions	the	efficacy	of	the	
therapeutic	strategies	 followed	 in	treating	GA‐I,	 further	strengthening	the	need	
for	more	effective	and	novel	treatment	options	(Tuncel	et	al.,	2018).	
	
1.2.4.6.	Alternate	therapeutic	strategies	
	
Since	the	current	treatment	strategies	for	GA‐I	do	not	protect	patients	from	late‐
onset	 disorders,	 there	 is	 an	 urgent	 need	 to	 develop	 safe	 and	 state	 of	 the	 art	
treatment	 regimen	 to	 address	 the	 severe	 complications	 associated	 with	 GA‐I.	
Hence,	we	hypothesize	a	new	treatment	strategy	for	treating	GA‐I	based	on	the	
approach	 established	 and	 followed	 for	 treating	 the	 metabolic	 disorder	
Tyrosinaemia	type	I	(Lock	et	al.,	1998).	Tyrosinaemia	type	I	(MIM	#	27670)	is	an	
autosomal	 recessive	 disorder	 caused	 due	 to	 the	 deficiency	 of	 fumaryl	
acetoacetase	(FAH)	 that	catalyzes	 the	 final	step	 in	 the	degradation	of	Tyrosine.	
Defective	FAH	leads	to	accumulation	of	fumarylacetoacetate,	maleylacetoacetate	
and	succinylacetone.	Accumulation	of	these	metabolites	lead	to	liver	and	kidney	
damage	and	eventually	hepatocellular	carcinoma	(Kvittingen,	Bergan,	&	Berger,	
1993).	Interestingly,	as	a	treatment	option	for	Tyrosinaemia	type‐I,	Lindstedt	et	
al,	 have	 targeted	 4‐hydroxyphenylpyruvate	 dioxygenase	 an	 enzyme	 lying	 two	
metabolic	 steps	 ahead	 of	 fumaryl	 acetoactate	 hydrolase	 in	 Tryptophan	
catabolism	(Lindstedt,	Holme,	Lock,	Hjalmarson,	&	Strandvik,	1992)	by	using	a	
drug	 named	 2‐(2‐nitro‐4‐trifluoro‐	 methylbenzoyl)‐1,3‐cyclohexanedione	
(NTBC)	or	Nitisinone	(INN).	This	drug	was	branded	in	the	name	of	Orfadin	and	is	
a	potent	 inhibitor	of	4‐hydroxyphenylpyruvate	dioxygenase	 (Lock	et	al.,	1998).	
By	 targeting	 4‐hydroxyphenylpyruvate	 dioxygenase,	 they	 prevented	 the	
formation	of	maleylacetoacetate	and	fumaryl	acetoacetate.	This	treatment	option	
is	 still	 a	 gold	 standard	 treatment	 available	 for	 Tyrosinaemia	 type‐I	 patients	
preventing	liver	transplantation	and	other	side	effects.	Similarly,	the	strategy	of	
blocking	4‐hydroxyphenylpyruvate	dioxygenase	enzyme	using	Nitisinone	is	also	
studied	in	an	inherited	metabolic	disorder	called	Alkaptonuria,	in	which	patients	
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lack	 the	 capability	 of	 metabolizing	 Phenylalanine	 and	 Tyrosine	 (Ranganath,	
Jarvis,	&	Gallagher,	2013).		
	
In	 line	 with	 the	 above	 strategy	 followed	 for	 treating	 tyrosinaemia	 type‐I	 and	
alkaptonuria,	 we	 aim	 to	 find	 a	 pharmaceutical	 inhibitor	 for	 GA‐I	 patients	
targeting	enzymatic	steps	prior	to	GCDH.		
	
1.2.4.6.1.	Target	1,	DHTKD1	
	
DHTKD1	 is	 one	 of	 the	 two	 known	 isoforms	 of	 E1	 subunit	 of	 2‐oxoglutarate	
dehydrogenase	 complex	 (OGDHc)	 enzyme	 that	 catalyzes	 the	 conversion	 of	 2‐
oxoadipate	to	glutaryl‐CoA	(Danhauser	et	al.,	2012).	Defective	DHTKD1	activities	
results	 in	accumulation	of	metabolites	2‐oxoadipic	acid	and	2‐aminoadipic	acid	
which	are	considered	less	toxic	resulting	in	a	very	mild	clinical	phenotype	in	the	
affected	 patients.	 Since	 glutaryl‐CoA	 is	 the	 main	 substrate	 of	 GCDH	 and	 the	
precursor	 of	 toxic	 GA	 and	 3‐OH‐GA,	 pharmacological	 inhibition	 of	 DHTKD1	 in	
GA‐I	 affected	 individuals	 could	 be	 a	 new	 potential	 drug	 target	 preventing	 the	
accumulation	of	toxic	metabolites	(Danhauser	et	al.,	2012a).		
	
1.2.4.6.2.	Target	2,	AADAT		
	
Aminoadipate	 amino	 transferase	 (AADAT)	 (EC	 2.6.1.39)	 mediates	 the	
transamination	 of	 2‐aminoadipate	 to	 2‐oxoadipate	 (Nakatani	 et	 al.,	 1970)	 and	
lies	upstream	of	GCDH	and	DHTKD1	(Biagosch	et	al.,	2017).	AADAT	is	also	called	
as	 kynurenine	 aminotransferase	 II	 (KAT	 II),	 which	 is	 a	 pyridoxal	 phosphate‐
dependent	enzyme	and	is	well	reported	in	the	transamination	of	kynurenine	to	
kynurenic	 acid	 in	 tryptophan	 catabolism	 (Goh	 et	 al.,	 2002).	 Kynurenic	 acid	
(KYNA)	 is	 a	 neuroactive	 metabolite	 elevated	 in	 the	 brain	 of	 patients	 with	
psychiatric	and	neurological	disorders	(Linderholm	et	al.,	2016).	There	are	two	
known	 inhibitors	 of	 AADAT	 available	 that	 however	 have	 only	 been	 tested	
regarding	their	effect	on	Tryptophan	metabolism	but	not	on	Lysine	metabolism.	
Nematollahi	 et	 al,	 have	 observed	 that	NS‐1502	 is	 a	 reversible	 and	 competitive	
inhibitor	 of	 AADAT	 (Nematollahi,	 Sun,	 Jayawickrama,	 Hanrahan,	 &	 Church,	
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2016).	 Similarly,	 PF‐04859989	 a	 blood‐brain	 barrier	 penetrating	 AADAT	
inhibitor	was	shown	to	effectively	reduce	brain	KYNA	levels,	thereby	decreasing	
firing	 activity	 of	 midbrain	 dopamine	 neurons	 and,	 consequentially,	 having	 a	
potential	 to	 treat	 hyper	 dopaminergic	 conditions	 that	 are	 characteristic	 of	
schizophrenia	 and	 bipolar	 disorder	 (Linderholm	 et	 al.,	 2016).	 PF‐04859989	
forms	a	covalent	adduct	with	pyridoxal	phosphate	(PLP),	which	is	the	cofactor	of	
KAT	II,	in	its	active	site,	thus	inhibiting	its	activity	(Dounay	et	al.,	2012).	Till	date,	
no	disease‐causing	mutations	in	AADAT	have	been	identified	with	and	similarly,	
KAT‐II	 knockout	 mice	 were	 reported	 to	 remain	 asymptomatic	 (Potter	 et	 al.,	
2010;	Yu	et	al.,	2004).	
	
Figure	4:	Kynurenine	pathway	of	Tryptophan	metabolism	(Source:	Schwarz	2017)	
	
	
	
	
Figure	4:	KAT	II/Aminoadipate	aminotransferase	(AADAT)	(Hallen	et	al.,	2013)	
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1.3. Objectives	of	the	thesis	
	
GA‐I	disease	 treatment	 and	management	 involve	 reducing	 the	 toxic	metabolite	
accumulation	by	the	implementation	of	age‐dependent	dietary	lysine	restriction,	
supplementation	 of	 carnitine	 including	 the	 essential	 amino	 acids	 along	 with	
intermittent	emergency	treatment.	However,	the	metabolic	treatment	proved	of	
no	 help	 for	 patients	 who	 showed	 frequent	 deviations	 from	 the	 proposed	
treatment	 guidelines.	 Moreover,	 patients	 treated	 according	 to	 the	 current	
treatment	 recommendations	 are	 still	 prone	 to	 develop	 extra‐striatal,	 extra	
cerebral	 and	non‐neurologic	 abnormalities	 clearly	depicting	 the	need	 for	more	
effectual	 and	 novel	 therapeutic	 interventions	 to	 answer	 the	 long‐term	
complications	 of	 GA‐I	 disease.	 Hence,	 we	 intend	 to	 identify	 alternative	
therapeutic	 strategies	 in	 treating	 GA‐I	 disease.	 Thus,	 we	 hypothesize	 to	
pharmacologically	 inhibit	 the	 enzymatic	 steps	 prior	 to	 GCDH	 in	 the	 lysine	
catabolic	pathway,	eventually	preventing	the	toxic	metabolite	accumulation	and	
the	clinical	phenotype	of	GA‐I	patients.		
	
On	 the	 basis	 of	 our	 proposed	 hypothesis,	 in	 this	 thesis,	 we	 concentrated	 on	
investigating	the	following	steps.	
1) Pharmacological	 inhibition	 of	 DHTKD1	 in	 DHTKD1	 patient	 and	 control	
fibroblasts	using	 the	 available	 inhibitors	 and	biochemical	 assessment	 of	
GA	and	OA	levels	using	GCMS.	
2) Clinical	and	biochemical	characterization	of	the	generated	Dhtkd1‐/‐/Gcdh‐
/‐	mouse	model	 after	 giving	 standard	 diet	 (1.7%	 (w/w)	 or	 85mg)	 of	 L‐
lysine	 in	 food	and	high	 lysine	diet	 (4.7%	(w/w)	or	235mg	of	L‐lysine	 in	
food)	using	GCMS.	
3) Alternative	therapeutic	approach	involving	AADAT	by,	
A) Inhibition	of	AADAT	using	siRNA	and	further	proceeding	for	GA	
level	measurement	using	GCMS.	
B) Inhibition	 of	 AADAT	 in	 GA‐I	 patient	 and	 control	 fibroblasts	
using	the	inhibitor	PF‐04859989	and	quantitative	detection	of	
GA	levels	using	GCMS.	
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4) Generation	of	alternate	GA‐I	cell	culture	models	(GCDH	and	AADAT)	using	
CRISPR/Cas9	 technology	 and	 further	 analysis	 of	 GA	 levels	 in	 knockout	
cells	and	controls	using	GCMS.	
	
	
	
	
2.	MATERIALS	
AND	METHODS	
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2.1.	Materials	
	
2.1.1.	Chemicals	used	
	
Agarose		 	 	 	 	 	 	 	 Applichem	
40%	Acrylamide/Bis	Solution	 	 	 	 	 Bio	Rad	
APS,	Ammoniumpersulfate	(H8N2O8S2)	 	 	 	 Applichem	
Acetone	(C3H6O)	 	 	 	 	 	 	 Roth	
Acetic	acid	(C2H4O2)	 	 	 	 	 	 Carl	Roth	
Ampicillin	‐	Natriumsalz		 	 	 	 	 	 AppliChem	
Amphotericin	250	UG/ml	(Fungi	Zone)		 	 	 	 Life	technologies	
Bromophenol	blue	sodium	salt	(C19H9Br4NaO5S)	 	 Sigma‐Aldrich	
Bacteriological	agar	for	molecular	biology		 	 	 Sigma‐Aldrich	
BSA		 	 	 	 	 	 	 	 														Santa	Cruz				
																																																																																																																										Biotechnology	
β‐2‐Mercaptoethanol	(C2H6OS)	 	 	 Merck	
Bacillol	 		 	 	 	 	 	 	 Hartmann	AG	
Biozidal		 	 	 	 	 	 	 	 MIT‐	Diagnostics	
Bad	stabil	 	 	 	 	 	 	 	 Neo	lab	
Citric	acid	(C6H8O7)		 	 	 	 	 	 Roth	
Citric	acid	monohydrate	(C6H8O7	x	H2O)	 	 	 	 Sigma‐Aldrich	
DAPI,	10	mg		 	 	 	 	 	 	 	 Sigma‐Aldrich	
DIG	RNA	Labeling	Mix	 	 	 	 	 	 Sigma‐Aldrich	
Dimethyl	Sulfoxide	(DMSO),	cell	culture	reagent	 	 														Santa	Cruz			
																																																																																																																											Biotechnology	
DTT	(dithiothreitol)	 	 	 	 	 	 													Thermo	Scientific	
Dodecylsulfate·Na‐salt	in	Pellets	 	 	 	 	 SERVA	
dNTP	mix	10mM		 	 	 	 	 	 	 Thermo	fischer	
scientific	
DEPC,	diethylpyrocarbonate	(C6H10O5)	 	 	 	 Sigma‐Aldrich	
DNase	I	recombinant,	RNase‐free	from	bovine	pancreas	 	 Sigma‐Aldrich	
DMEM	high	w.	Glutmax‐1	 	 	 	 	 	 Life	Technologies	
EDTA	disodium‐ethylenediaminetetra‐acetate	 	 	 Sigma‐Aldrich	
Ethanol	(C2H6O)	99.8%	PA			 	 	 	 	 Roth	 	
Ethidium	bromide	(C21H20N3Br)	 	 	 	 	 Sigma‐Aldrich	
Fetal	calf	serum		 	 	 GIBCO	
FastAP	Thermosensitive	Alkaline	Phosphatase	(1	U/µL)		 Thermo	Fisher	
Scientific	
Gene	Ruler	1Kb	DNA	Ladder	 	 	 	 	 Thermo	Fisher	
Scientific	
Glycerol,	1,2,3	‐propanetriol	(C3H8O3)		 	 	 	 Sigma‐Aldrich	
Glucose	 	 	 Sigma‐Aldrich	
Glutaric	acid	 	 	 Sigma‐Aldrich	
Glutathione	sepharose	TM	4B	 	 	 	 	 GE	health	care	
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Hydrochloric	acid,	37%	(HCl)	 	 	 Sigma‐Aldrich	
Hepes,	N‐2‐hydroxyethylpiperazine‐N’‐2‐ethanesulfonic	acid		 Sigma‐Aldrich	
(C8H18N2O4S)	 	 	 	 	 	 	 Sigma‐Aldrich	
IPTG		 	 	 	 	 	 	 	 	 Bioline	
Isopropanol	70%		 	 	 	 	 	 	 Sigma‐Aldrich
	 	
Kanamycin	sulphate			 	 	 	 	 	 Sigma‐Aldrich	
Lipofectamine®	2000	Transfection	Reagent	 	 	 Thermo	Fisher	
Scientific	
Lysozyme	human	recombinant	 	 	 	 	 Sigma‐Aldrich	
L‐lysine	(monohydrochloride)	 	 	 	 	 Sigma‐Aldrich	
6X	Loading	dye	 	 	 	 	 	 	 Thermo	Fisher	
Scientific	
Magnesium	sulphate	anhydrous	 	 	 	 	 Sigma‐Aldrich	
MyTaq™	HS	Red	Mix		 	 	 	 	 	 Bioline	
Milchpulver	 	 	 	 	 	 	 	 Carl	Roth	
Methanol	(CH4O)	 	 	 	 	 	 	 Carl	Roth	
Mowiol®	4‐88	 	 	 Merck	
Magnesium	chloride	(MgCl2)		 	 	 	 	 Sigma‐Aldrich	
NotI‐HF	 	 	 	 	 	 	 	 New	England	
Biolabs	
NEB®	5‐alpha	Competent	E.	coli	(High	Efficiency)	 	 New	England	
Biolabs		
NBT/BCIP	Stock	Solution	 	 	 	 	 	 Sigma‐Aldrich	
β‐nicotinamide	 adenine	 dinucleotide	 	 	 	 Sigma‐Aldrich	
Nonidet	™	P‐40	 	 	 	 	 	 	 Sigma‐Aldrich	
2‐Oxoadipic	acid	 	 	 	 	 	 	 Sigma‐Aldrich	
Protector	RNAse	Inhibitor	2000	U	 	 	 	 	 Roche	
Protein	Assay	Reagent	A		 	 	 	 	 	 Bio‐Rad	
Protein	Assay	Reagent	B	 	 	 	 	 	 Bio‐Rad	
Protease	inhibitor	cocktail		 	 	 	 	 	 Sigma‐Aldrich	
Proteinase	K	 	 	 	 	 	 	 	 Carl	roth	
Penicillin	Streptomycin	(100	ml)	 	 	 	 	 Life	Technologies	
PMSF	 	 	 	 	 	 	 	 	 Sigma‐Aldrich	
Phusion	High‐Fidelity	DNA	Polymerase	 	 	 	 Thermo	Fisher	
Scientific	
Phosphate	buffered	saline	Dulbecco’s	w.o	Ca	&Mg	 	 Life	Technologies	
Potassium	chloride	(KCl)		 	 	 Sigma‐Aldrich	
Potassium	hydroxide	(KOH)		 	 	 Sigma‐Aldrich	
Puromycin		 	 	 Sigma‐Aldrich	
Ponceau	S	(C22H12N4Na4O13S4)	 	 	 Applichem,	
Darmstadt	
Protease‐Inhibitor	complete	mini	 	 	 	 	 Roche	
Diagnostics	
RNAse	inhibitor		 	 	 Sigma‐Aldrich	
Sodiumdeoxycholate			 	 	 	 	 	 Sigma‐Aldrich	
Sodium	chloride	 	 	 	 	 	 	 Roth	
SDS,	sodium	dodecyl	sulphate	(C12H25NaO4S)		 	 	 Sigma‐Aldrich	
SP6	RNA	Polymerase	 	 	 	 	 	 Sigma‐Aldrich	
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SensiFAST™	SYBR®	Hi‐ROX	Ki	 	 	 	 					Bioline	
SuperSignal™	West	Pico	Chemiluminescent	Substrate	1L					Thermo	Fisher		
																																																																																																																		Scientific	
sodium	azide	 	 					Sigma‐Aldrich	
sodium	cyanide	 																		Sigma‐Aldrich	
sheep	serum	 	 					Sigma‐Aldrich	
T7	RNA	Polymerase	 	 	 	 	 	 					Sigma‐Aldrich	
TRIzol®	Reagent	 	 	 	 	 	 					Life	Technologies	
Tween	20	(C58H114O26)	 	 	 	 	 					Carl	roth	
TRIS		 	 	 	 	 	 	 	 					Carl	Roth	
Triton™	X‐100	(Alkylphenylpolyethylenglykol)	 	 					Sigma‐Aldrich	
(C14H22(C2H4O)nO)	 	 	 	 	 					Sigma‐Aldrich	
Tris,	Hydrochloride	 	 	 	 	 	 					Santa	Cruz		
																																																																																																																		Biotechnology	
Trypton	 	 	 	 	 	 	 					Roth	
T4	Polynucleotide	Kinase	‐	500	units	 																																New	England								
																																																																																																																		Biolabs	(NEB)	
T4	DNA	Ligase	‐	100000	units	 	 	 																			New	England		
																																																																																																																		Biolabs	(NEB)	
Thiamine	pyrophosphate	(TPP)	 	 	 	 					Sigma‐Aldrich	
N,	N,	N	',	N'‐Tetramethylethylenediamine	(TEMED)	 					Sigma‐Aldrich	
Tryphan	blue		 	 	 	 	 	 					Sigma‐Aldrich	
Trypsin	0.25%	EDTA		 	 	 	 	 					Life	technologies	
Yeast	extract			 	 	 	 	 	 					Sigma‐Aldrich	
	
2.1.2.	Consumables	used	
	
Blotting	paper	580	x	600	mm	 	 					Neo	Lab	
Cryotubes	 	 					NeoLab	
Cell	scraper	25	cm	 	 					Sarstedt	
Centrifuge	tubes	(15	ml,	50	ml)	 	 	 	 					Sarstedt		
96	well	cell	culture	plates	 	 					Sarstedt		
6	well	cell	culture	plates		 	 					Neolab/Falcon	
24	well	cell	culture	plates		 	 	 	 	 					Sarstedt	
Eppendorf	tubes	(2	ml,	1.5	ml,	0.5	ml)	 	 					Starstedt	&	Neolab	
Gloves	 	 					VWR	
Microscope	slide	(24	x	50	mm)	 	 					Carl	Roth,	Karlsruhe 																																					
Microseal	'B'	Adhesive	Seals	 	 	 	 					Bio‐Rad	
Pasteur	pipettes	 	 					Stein	
Pipette	tips	(1‐10	μl,	10‐200	μl,	100‐1000	μl)	 	 					Sarstedt		
PCR	tubes	(0.2	ml,	8	strip)	 	 					Star	Lab	
Petri	plates	 	 					Sarstedt	
Sterile	disposable	pipettes	(2	ml,	5	ml,	10	ml,	25	ml)	 					Corning	Costar	
Sealing	film	Parafilm	 	 					Stein	
Skalpel		 	 					Pfm	medical	
T75	cell	culture	flasks	for	adherent	cells		 	 					Sarstedt	
T175	cell	culture	flasks		 	 					Sarstedt	
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T25	cell	culture	flasks	 	 					Sarstedt	
	
2.1.3.	List	of	primers	
All	the	primers	were	ordered	from	Life	technologies	
	
Name	of	the	primer	 Sequence	 application	
DHTKD1	Eco	RI	fwd	
	
ccggaattccagaccgagcggggcgtt
tacggctaccgg	 Cloning	
	DHTKD1	Not	I	rev	
	
aaggaaaaaactcgagtcaagcgaag
gtcttggcgagg	
Exon5	hum	gRNA	GCDH	fwd	
	
caccgatgcaccctatctatgccta	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
CRISPR	cloning	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Exon5	hum	gRNA	GCDH	Rev	
	
aaactaggcatagatagggtgcatc	
Exon1	hum	gRNA	GCDH	fwd	
	
caccgcctgcacgtccttcgcacg	
Exon1	hum	gRNA	GCDH	Rev	
	
aaaccgtgcgaaggacgtgcaggc	
GCDH	hum	gRNA1	F		
	
caccgtctcgtcggcggcgcagac	
GCDH	hum	gRNA1	R	 aaacgtctgcgccgccgacgagac	
	
GCDH	hum	gRNA2	F		
	
caccgcctgcacgtccttcgcacg	
	
GCDH	hum	gRNA2	R	 aaaccgtgcgaaggacgtgcaggc	
	
	
GCDH	hum	gRNA3	F		
	
caccctgacgagtatcacgtgatc	
	
GCDH	hum	gRNA3	R	 aaacgatcacgtgatactcgtcag	
	
	
hAADAT	sgRNA1	Fwd	 caccgaattacgcacggttcatca	
	
hAADAT	sgRNA1	Rev		 aaactgatgaaccgtgcgtaattc	
	
hAADAT	sgRNA2	Fwd		 caccgccaaggagatcatcgattt	
	
hAADAT	sgRNA2	Rev		
	
aaacaaatcgatgatctccttggc	
	
hAADAT	sgRNA3	Fwd		
	
caccgtgattacggcagtcttaaa	
	
hAADAT	sgRNA3	Rev		
	
aaactttaagactgccgtaatcac	
	
hAADAT	sgRNA4	Fwd		
	
caccgtactggaaactcattaacca	
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hAADAT	sgRNA4	Rev		
	
aaactggttaatgagtttccagtac	
	
hAADAT	sgRNA5	Fwd		
	
caccgtaagagacatactttccaga	
	
hAADAT	sgRNA5	Rev		
	
aaactctggaaagtatgtctcttac	
	
hAADAT	sgRNA6	Fwd		
	
caccgagatgaacctgcttattcag	
	
hAADAT	sgRNA6	Rev		
	
aaacctgaataagcaggttcatctc	
	
hAADAT	sgRNA7	Fwd		
	
caccgtcacatctggcagccaaca	
	
hAADAT	sgRNA7	Rev		 aaactgttggctgccagatgtgac	
	
Human	U6	seq	 actatcatatgcttaccgtaac	 Sequencing	
primers	
	T7	Reverse	primer	 aaaagcaccgactcggtgcc	
	
2.1.4.	List	of	antibodies	
	
Name	 Primary	(1°)/	
Secondary	(2°)	
Species	 type	 Manufacturer	
DHTKD1	N17		 1°	 donkey	 	 Santa	Cruz	
Biotechnology	
DHTKD1	(F‐11)	 1°	 	 	 Santa	Cruz	
Biotechnology	
KAT	II	(G‐4)	 1°	 goat	 	 Santa	Cruz	
Biotechnology	
Gamma	H2Ax	 1°	 	 	 	
Actin	(C4)	HRP	 1°	and	2°	 	 	 Santa	Cruz	
Biotechnology	
GCDH	 1°	 	 	 proteintech	
Anti‐rabbit	IgG	
HRP	
2°	 Donkey	 	 Santa	Cruz	
Biotechnology	
Anti‐mouse	IgG	
HRP	
2°	 Goat	 	 Santa	Cruz	
Biotechnology	
Anti‐goat	IgG	
HRP	
2°	 Donkey	 	 Santa	Cruz	
Biotechnology	
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2.1.5.	Inhibitors	used	
	
Name	 Target	 Source	
PF‐04859989	 AADAT/KAT	II	 Pfizer	
Acetyl	phosphonate	(AP)	
DHTKD1	
Obtained	
from	
Collaboration	
partners	in	
Munich	
Glutaryl	phosphonate	(GP)	
Diethyl	ester	of	glutaryl	phosphonate	
(DEGP)	
Triethyl	ester	of	glutaryl	phosphonate	
(TEGP)	
Tri	methyl	acetyl	phosphonate	(TMAP)	
	
2.1.6.	Commercially	available	kits	used	
	
Name	 Manufacturer	
ECL	Western	Blotting	System	 GE	Healthcare	
Nucleo	spin	plasmid	Mini/Midi	Prep	
Kit	
Machery	&	Nagel	(M&N)	
Nucleo	spin	gel	and	PCR	Clean‐up	Kit	 Machery	&	Nagel	(M&N)	
Maxima	first	strand	cDNA	synthesis	kit Thermo	Fischer	scientific	
TOPO	TA	Dual	Promoter	cloning	kit	 Thermo	Fischer	scientific	
	
2.1.7.	General	Buffers	used	
General	buffers	and	solutions	were	prepared	with	autoclaved	double‐distilled	
water.	For	all	RNA	work,	nuclease‐free	water	was	used.	Buffers	were	autoclaved	
at	121	°C	for	one	hour	or	sterile	filtered	through	a	0.22	µm	membrane	of	a	
vacuum‐driven	disposable	filter	unit.	If	not	listed	here,	buffer	compositions	are	
given	in	the	text.	
	
Name	 Components	added	 Remarks	
1)	 10X	 LB	
medium:	
Trypton	100	g	
NaCl	100	g	
Yeast	extract	50	g	
dd	H2O	to	1	liter	
pH	 was	 adjusted	 to	 7	
using	1	M	NaOH	
2)	PBS	(10X,	1L)	 NaCl	80	g	
KCl	2	g	
Na2HPO4	x	7H2O	26.8	g	
KH2PO4	2.4	g	
pH	was	adjusted	to	7.4	
3)	TAE	buffer	 Tris‐HCl	40	mM	
Acetic	acid	20	mM	
pH	was	adjusted	to	8.0	
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EDTA	2	mM	
Western	blotting	related	buffers	
1)	 RIPA	 buffer	 (10	
ml)	
Nacl	150	mM	
Triton	X	100	1%	
Sodium	deoxycholate	0.5%	
SDS	0.1%	
TRIS	50	mM	
Protease	inhibitor	mini‐	1	tablet	
pH	 was	 adjusted	 to	
8.0	
2)	 6X	 SDS	 loading	
dye	10	ml	
TRIS	pH	6.8	1	M‐	3.75	ml	
SDS‐	1.2	g	
Glycerol(100%)‐	6	ml	
Bromophenol	Blue‐	0.006	g	
DTT‐	0.462	g	
ddH20	to	10	ml	
	
3)	 SDS‐gel	 running	
buffer	
Tris‐HCl,	pH	8.3	0.25	M	
Glycine	1.92	M	
SDS	1	M	
	
4)	Ponceau	S	 Ponceau	S	0.2%	
Glacial	acetic	acid	1%	
	
5)TBST	(10X,	1L)	 Tris‐HCl,	pH	7.5	
NaCl	100	mM	
Tween	150	mM	
	
	
	
6)	Blotting	buffer	
(Transfer	buffer)	
Tris	base	25	mM	
Glycine	192	mM	
SDS	0.01	%	
Methanol	10	%	
	
	
7)	Lamelli	buffer	
(4X)	
(protein	gels)	
Tris‐HCl,	pH	6.8	0.28	M	
SDS	5.7	%	
EDTA	0.01	M	
Glycerol	100	%	
Bromophenol	blue	0.28	g/ml	
2‐Mercaptoethanol	0.06	ml/ml	
	
Protein	purification	related	buffers	
1)	Lysis	Buffer	
for	lysing	the	
bacterial	cell	pellet	
50	mM	Tris‐HCl	pH	7.5	
50‐200	mM	NaCl	
5	mM	DTT	
1	mM	PMSF	
	
2)	Binding	Buffer	 PBS,	PH	7.3	
(140	mM	NaCl	
2.7	mM	KCl	
10	mM	Na2HPO4		
1.8	mM	KH2PO4)	
pH	was	adjusted	to	7.3	
3)	Elution	Buffer	 50	mM	Tris‐HCl	
10	mM	reduced	glutathione	
pH	was	adjusted	to	7.3	
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2.1.8.	Instruments	used	
	
Name	 Manufacturer	
CFX96	 Touch™	 Real‐Time	 PCR	
Detection	system	
Bio‐RAD	
C1000	Touch™	Thermal	Cycler	 Bio‐RAD	
Light	Microscope	 Leica	GmbH,	Wetzlar	
Mini‐PROTEAN	Tetra	Cell	
Electrophoresis	apparatus	
Bio‐RAD	
Spectramax	340	PC	Plus	Microplate	
Reader	
Molecular	Devices,	Sunnyvale,	USA	
	
2.2.	Methods	
	
2.2.1.	Cloning	of	DHTKD1	into	pGEX4T1	vector	
	
2.2.1.1.	PCR	amplification	of	DHTKD1	
	
To	 clone	 DHTKD1	 gene,	 we	 have	 utilized	 the	 already	 available	 commercial	
plasmid	Lentiviral	vector	(Ex‐H4610‐LV21)	containing	DHTKD1	insert,	obtained	
from	 Genecopoeia.	 It	 was	 kindly	 provided	 by	 Dr.	 Holger	 Prokisch,	 Helmholtz	
Zentrum,	Munich.	 Primers	 specific	 for	 the	 5’	 and	 3’	 terminus	 of	 the	 construct,	
containing	 restriction	 enzyme	 overhangs	 were	 generated	 (Forward	 primer	
containing	EcoRI	overhang	and	NotI	overhang	in	the	reverse	primer)	and	used	to	
amplify	the	DNA	sequence.	A	non‐template	control	reaction	which	included	only	
ddH20	 without	 the	 plasmid	 was	 included	 to	 determine	 the	 specificity	 of	 the	
primers.	Automated	DNA	thermal	cycler	was	used	to	load	the	reaction	mixtures	
for	 further	amplification	of	 the	DNA.	Each	PCR	amplification	 contained	a	50	µl	
reaction	setup	as	in	the	table	below	(table	1a&1b).	
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Table	1a	&	1b:	PCR	reaction	set	up	and	amplification	conditions	used	for	cloning	DHTKD1	
	
After	the	completion	of	the	PCR	reaction,	 few	microliters	of	sample	was	 loaded	
on	 to	a	2%	agarose	gel	 to	check	 for	 the	required	size	of	 the	amplified	product.	
The	reaction	mix	was	 then	purified	using	 the	Nucleospin	gel	and	PCR	clean‐up	
kit	 (M&N).	 Briefly,	 the	 sample	 was	 mixed	 with	 2	 volumes	 of	 column	 binding	
buffer,	 loaded	on	 to	 the	matrix	containing	column	and	centrifuged	at	11,000×g	
for	 30	 sec	 at	 room	 temperature	 (RT).	 Flow	 through	 was	 discarded	 and	 the	
column	was	washed	with	washing	buffer,	centrifuged	at	11,000×g	for	30	sec	at	
RT	followed	by	dry	spinning	for	2	min	(at	11,000×g	RT).	Finally,	DNA	was	eluted	
into	a	clean	tube	using	35	µl	nuclease	free	water	which	was	directly	added	on	to	
the	column,	incubated	for	1	min	at	RT	and	then	centrifuged	at	11,000×g,	1	min.	
The	concentration	of	insert	(dsDNA)	was	determined	using	nanodrop	at	260	nm.	
	
2.2.1.2.	Restriction	digestion	of	vector	and	insert	
	
Both	the	vector	(pGEX4T1)	and	the	insert	(PCR	product)	were	digested	at	37	°C	
overnight	(O/N)	using	EcoRI	and	NotI	restriction	enzymes	separately	 in	 the	1X	
compatible	 buffer.	 The	 reaction	mixture	was	 set	 up	 according	 to	 table	 2a&2b.	
The	 vector	 and	 the	 insert	 were	 first	 digested	 with	 EcoRI	 enzyme	 in	 different	
tubes	followed	by	enzyme	heat	inactivation	@	80	°C	for	20	min	and	PCR	purified	
(as	per	2.2.1.1	Nucleospin	gel	and	PCR	clean‐up	kit	(M&N)).	The	digested	vector	
1a	Master	Mix	per	reaction	
5X	HF	Buffer	 10	µl	
10	mM	dNTP	Mix		 1	µl	
10	µM	F+R	Primers	 2	µl	
DHTKD1	insert	
containing	vector	
(100	ng)	
1	µl	
dd	H2O	 35	µl	
Phusion	Polymerase	 0.5	µl	
50	mM	Mgcl2	 0.5	µl	
Total	per	Reaction	 50	µl	
1b	PCR	conditions	
98	°C	 5	min	
98	°C	 30	sec	
65	°C	 45	sec	
72	°C	 3	min	
72	°C	 10	min	
12	°C	 pause	
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and	 insert	 were	 again	 used	 in	 the	 same	 reaction	 setup	 as	 above	 where	 Not	 I	
enzyme	is	used	instead	of	EcoRI.		
	
	
	
	
	
	
	
	
	
	
	
	
	
Table	2a&	2b:	Reaction	set	up	for	Restriction	digestion	
	
Restriction	enzyme	digested	 insert	 and	vector	were	analysed	by	 running	 them	
on	 2%	 agarose	 gel.	 Following	 the	 gel	 electrophoresis,	 the	 prominent	 (correct)	
size	band	was	excised	using	a	 sharp	disposable	 scalpel.	The	excised	DNA	band	
was	weighed	on	a	tarred	balance	and	processed	as	per	the	instruction	manual	of	
Nucleospin	gel	and	PCR	clean‐up	kit	(M&N).	Briefly,	the	gel	slice	was	melted	in	2	
volumes	(to	100	mg	of	gel	200	ul	of	buffer	was	added)	of	gel	solubilization	buffer	
and	 incubated	on	dry	bath	maintained	at	50	°C	 for	at	 least	10	min.	The	melted	
sample	was	then	loaded	onto	the	binding	column,	followed	by	centrifugation	at	
11,000×g	for	30	sec	at	RT.	After	binding	of	DNA,	the	flow	through	was	discarded	
and	 the	 column	was	washed	 twice	 using	 500	 ul	 of	wash	 buffer,	 centrifuged	 at	
11,000×g	for	30	sec	RT.	The	column	was	again	dry	spun	for	2	min	at	high	speed	
to	 remove	 the	 left	 over	 the	 buffer.	 Finally,	 DNA	was	 eluted	with	 nuclease‐free	
water	and	the	concentration	was	measured	using	nanodrop	at	260	nm	and	the	
quality	of	elution	was	determined	by	agarose	gel	electrophoresis.	
	
	
	
	
2a	EcoRI	digestion	
DNA	
(vector	or	
insert)	
Upto	30	
µl	
Cut	smart	
Buffer	
(10X)	
5	µl	
EcoRI	
(NEB)	
1	µl	
dd	H2O	 14	µl	
Total	
Reaction	
volume	
50	µl	
2b.NotI	digestion	
DNA	(vector	or	
insert)	
Upto	
	30	µl	
Cut	smart	
Buffer	(10X)	
5	µl	
NotI	(NEB)	 1	µl	
dd	H2O	 14µl	
Total	Reaction	
volume	
50	µl	
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2.2.1.3.	Ligation	of	vector	and	insert	
	
The	 purified	 vector	 and	 insert	 DNA	 samples	 obtained	 after	 gel	 elution	 were	
further	 used	 for	 ligation.	 The	 ligation	 reaction	 was	 carried	 out	 using	 T4	 DNA	
ligase	 as	 shown	 in	 table	 3.	 Different	molar	 ratios	 of	 vector:	 insert	 for	 ligation	
(1:3,	1:5,	1:6,	1:10)	were	used	along	with	a	negative	control	(only	vector	without	
insert).	 The	 insert	 molar	 ratios	 were	 calculated	 using	 the	 ligation	 calculator	
shown	below.	For	example,	a	ratio	of	3:1	can	be	calculated	as,	
݊݃	݋݂	ܸ݁ܿݐ݋ݎ	ݔ	ݏ݅ݖ݁	݋݂	ܫ݊ݏ݁ݎݐ	݅݊	ܾ݇
	ݏ݅ݖ݁	݋݂	ܸ݁ܿݐ݋ݎ	݅݊	ܾ݇ 	ݔ
3
1 ൌ ݊݃	݋݂	ܫ݊ݏ݁ݎݐ	
(vector	 in	ng‐	 50;	 Size	 of	DHTKD1	 insert=	2688	bp;	 Size	 of	 pGEX4T1	 vector=	
4969	bp).	
	
Components	 1:3	 1:5	 1:6	 1:10	 ‐ve	control	
10X	DNA	ligation	
buffer	
2	ul	 2	ul	 2	ul	 2	ul	 2	ul	
Vector	(digested)	 50	ng	 50	ng	 50	ng	 50	ng	 50	ng	
Insert	(Digested) 81.1	
ng	
135	ng 162.2	ng 270.5	
ng	
0.0	ul	
T4	DNA	Ligase	 1.0	ul	 1.0	ul	 1.0	ul	 1.0	ul	 1.0	ul	
ddH2O	added	
upto	
10	ul	 10	ul	 10	ul	 10	ul	 10	ul	
	
Table	3:	Ligation	reaction	set	up	with	different	ratios	of	pGEX4T1vector	and	DHTKD1	insert	
concentrations	
The	ligation	reaction	was	incubated	O/N	at	16	°C.	
	
2.2.1.4.	Transformation	and	positive	clone	confirmation	
	
Following	 the	next	day	after	 ligation,	 transformation	procedure	was	continued.	
Briefly,	 25	 µl	 of	 DH5α	 competent	 bacteria	were	mixed	with	 2	 µl	 of	 the	 above	
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ligation	reaction	mix	and	incubated	for	30	min	on	ice	followed	by	heat	shock	at	
42	 °C	 for	45	 sec	 and	 immediate	 cooling	 for	2	min	 on	 ice.	 To	 this	 900	µl	 of	 LB	
medium	 was	 added	 and	 incubated	 at	 37	 °C	 for	 1	 hr	 in	 a	 bacterial	 shaker	
incubator.	 The	 recovered	 bacteria	were	 then	 plated	 onto	 ampicillin‐containing	
LB	agar	plates	and	incubated	in	a	bacteriological	incubator	maintained	at	37	°C	
for	 16–18	 h.	 The	 well‐grown	 single	 colonies	 were	 selected	 for	 screening	 by	
inoculating	in	5.0	ml	of	LB	medium	containing	5	µl	of	ampicillin	(100	mg/ml)	and	
were	grown	individually	for	14‐16	h.	The	turbid	bacterial	culture	was	then	used	
for	 the	 preparation	 of	 plasmid	 DNA	 using	 NucleoSpin	 plasmid	 mini‐prep	 kit	
(Macherey‐Nagel).	 A	 selected	 number	 of	 clones	 were	 further	 confirmed	 using	
restriction	digestion	and	PCR	amplification	(colony	PCR)	using	specific	primers.	
The	 positive	 clones	were	 then	 sequence	 verified	 using	 vector‐specific	 primers	
from	 Thermo	 Fischer	 Scientific.	 The	 positive	 clones	 were	 further	 selected	 for	
protein	expression	and	purification.	
	
2.2.2.	 DHTKD1	 protein	 expression	 and	 purification	 using	
Glutathione	sepharose	beads	
	
2.2.2.1.	Transformation,	starter	culture	preparation	and	protein	
expression	
	
DHTKD1	 gene	 without	 the	 mitochondrial	 target	 sequence	 was	 cloned	 into	 a	
pGEX4t1	 vector	 as	 explained	 above	 (2.2.1).	 This	 vector	 was	 transformed	 into	
BL21DE3	 Lys	 bacteria,	 which	 can	 express	 the	 protein	 when	 induced.	 The	
bacteria	were	transformed	with	2	µl	of	plasmid	DNA	(80	ng/µl)	and	rest	of	the	
procedure	as	2.2.1.4.	The	turbid	bacterial	culture	grown	after	inoculating	a	single	
colony	was	 then	used	to	cultivate	 large	culture	 (500	ml	LB	medium	containing	
500	 µl	 of	 ampicillin	 (100	 mg/ml))	 in	 an	 Erlenmeyer	 flask.	 The	 culture	 was	
allowed	 to	 shake	 for	 2‐3	 h	 at	 37	 °C	 until	 the	 OD	@600	 reached	 0.6.	 Frequent	
measuring	of	OD	for	every	half	an	hour	was	done.	After	the	OD	has	reached	0.6,	2	
ml	of	culture	was	taken	and	stored,	which	was	used	as	a	un‐induced	control.	The	
culture	 was	 then	 induced	 for	 protein	 expression	 by	 adding	 0.3	 mM	 isopropyl	
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thiogalactoside	(IPTG)	and	set	for	shaking	at	37	°C	for	3½	to	4	h.	From	this,	2	ml	
of	culture	was	stored	to	be	used	as	an	induced	sample.	The	bacterial	culture	was	
pelleted	at	4000	rpm	for	15	min	at	4	°C	and	immediately	proceeded	for	the	next	
steps	of	purification.	A	part	of	pellet	 and	 supernatant	were	 stored	 for	western	
blot	 analysis.	 Optionally,	 the	 pellet	 could	 be	 stored	 at	 ‐80	 °C	 and	 used	 for	
purification	following	the	next	day.	To	the	pellet,	chilled	lysis	buffer	was	added,	
resuspended	 and	 cooled	 on	 ice	 for	 10	min	 (ratios	 of	 cell	wet	weight	 to	 buffer	
volume	of	1:1	to	1:4	were	used).	The	cell	suspension	was	then	sonicated	with	10	
short	bursts	of	10	sec	each	 followed	by	 intervals	of	30	sec	 for	cooling.	The	cell	
debris	 was	 removed	 by	 ultracentrifugation	 at	 4	 °C	 for	 30	 min	 at	 45,000	 rpm	
using	a	45Ti	rotor	(Beckman).	The	lysate	obtained	was	then	used	for	loading	on	
to	the	beads	and	1	ml	of	lysate	was	stored	for	SDS	analysis.	
	
2.2.2.2.	 Preparation	 of	 Glutathione	 sepharose	 beads	 and	
purification	of	protein	(protocol	from	GE	healthcare,	modified)	
	
The	volume	of	the	Glutathione	Sepharose	4B	beads	required	for	purification	was	
primarily	determined.	In	the	current	procedure,	5	ml	of	lysate	was	used	per	1	ml	
of	beads.	Beads	were	centrifuged	at	500×g	for	5	min	to	remove	the	supernatant	
followed	by	washing	with	5	ml	of	binding	buffer	and	centrifugation	at	500×g	for	
5	 min.	 The	 supernatant	 was	 carefully	 removed	 and	 the	 washing	 step	 was	
repeated	twice	to	make	sure	that	the	beads	are	clean.	To	the	washed	beads	cell	
lysate	was	added	and	incubated	for	at	least	30	min	at	RT	using	gentle	agitation	
such	 as	 end‐over‐end	 rotation.	 The	 supernatant	 (=flow	 through)	 obtained	 by	
centrifugation	at	500×g	for	5min	was	stored	to	measure	the	binding	efficiency	of	
the	lysate	via	SDS	PAGE.	The	beads	were	washed	by	adding	5	ml	binding	buffer	
to	 each	 1	ml	 slurry	 and	 inverting	 up	 and	 down	 for	 30	 sec.	 Centrifugation	was	
done	at	500×g	for	5min	and	the	supernatant	(=wash	1)	obtained	was	collected	
for	 SDS	PAGE	 analysis.	Wash	 steps	were	 repeated	 thrice	 and	 the	 supernatants	
(wash	2	and	wash	3)	were	collected	by	centrifugation.	Bound	protein	was	eluted	
by	adding	0.5	ml	of	elution	buffer	per	1	ml	slurry	of	Glutathione	sepharose	beads.	
The	mixture	was	gently	agitated	at	RT	for	10	min	followed	by	centrifugation	at	
500×g	for	5	min.	The	supernatant	obtained	was	the	eluted	protein.	Three	elution	
	44	
	
steps	 were	 performed	 separately	 to	 obtain	 the	 purified	 protein.	 The	 purified	
protein	was	flash	frozen	in	liquid	nitrogen	and	stored	at	‐80	°C.	
	
2.2.2.3.	Western	blotting	and	confirmation	of	purified	DHTKD1	
protein	
All	 the	 collected	 samples	 during	 the	 protein	 purification	 procedure	 were	 run	
through	SDS	PAGE	to	confirm	the	presence	of	DHTKD1	protein.	To	visualize	the	
protein	 expression,	 Coomassie	 staining	 and	 silver	 staining	 were	 done	 using	
standard	methods	according	to	Maniatis	and	Sambrook	et	al.	
	
2.2.3.	DHTKD1	enzyme	activity	assay	
	
DHTKD1	(EC	1.2.4.2)	pure	protein	used	for	the	assay	was	a	kind	gift	provided	by	
Dr.	 Wyatt	 Yue,	 Oxford	 University,	 UK.	 It	 was	 purified	 by	 nickel	 resin	 based	
affinity	 chromatography	 and	gel	 filtration	using	ACTA	purifier,	GE	Health	 care.	
The	activity	of	DHTKD1	(the	so‐called	E1	like	subunit	of	OGDHc)	was	assayed	in	
‐keto	 glutarate	 dehydrogenase	 complex	 buffer	 (buffer	 A)	 (table	 4)	 and	 was	
determined	as	a	reduction	in	2,6	dichlorophenol	indophenol	(DCPIP)	at	=	610–
750	 nm	 (Sauer	 et	 al.,	 2005).	 The	 activity	 was	 measured	 in	 buffer	 with	 and	
without	 2‐oxoadipate	 or	 with	 and	 without	 2‐oxoglutarate	 to	 check	 for	 the	
specificity	 of	 the	 substrate.	 The	 buffer	 contains	 dichlorophenolindophenol	
(DCPIP),	which	 is	 a	 colored	 dye	 that	 can	 be	 employed	 as	 a	 substrate	 in	 redox	
reactions.	DCPIP	is	blue	in	color	in	oxidized	conditions	and	becomes	colorless	in	
reduced	 conditions	 when	 measured	 at	 wavelength	 range	 610‐750	 nm	
(VanderJagt,	Garry,	&	Hunt,	1986).	
	
‐	keto	glutarate	dehydrogenase	complex	buffer	(buffer	A)	
Name	of	the	
reagent	
Stock	
concentration	
Final	
concentration	
used	
Remarks	
	
	
Potassium	
phosphate	
(KH2PO4)	
	
1	M	 35	mmol/liter	 5	ml	of	buffer	
was	prepared	
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EDTA	
	
0.5	M	 0.5	mmol/liter	 and	the	pH	was	
adjusted	to	7.4	MgSO4	 1	M	 0.5	mmol/liter	
Oxoadipate/alpha	
keto	glutarate	
100	mM	 2	mmol/liter	
TPP	 	 1mmol/	liter	(23	
mg	taken)	
2,6	
Dichlorophenol	
indophenol	(DCPIP)	
3	mM	 60	µM	DCPIP	
sodium	azide	
	
1	M	 5mM	
triton	X	100	
	
20%	 0.01%	
	
Table	4:	‐	keto	glutarate	dehydrogenase	complex	buffer	(buffer	A)	
	
2.2.4.	Determination	of	Km	and	Vmax	for	DHTKD1	
	
To	 determine	 the	 Km	 &	 Vmax	 for	 DHTKD1,	 different	 concentrations	 of	 the	
substrate	2‐oxoadipate	(0.1	mM,	0.05	mM,	0.1	mM,	0.25	mM,	0.5	mM,	0.75	mM,	1	
mM,	2	mM	and	no	substrate)	and	constant	amount	of	enzyme	were	analyzed	in	
buffer	A	without	Triton	X	100	(table	4),	in	a	96	well	micro	titer	plate	and	the	OD	
was	measured	at	=	610–750	nm.	The	OD	values	obtained	for	different	substrate	
concentrations	were	plotted	on	a	graph	and	Vmax	and	Km	were	calculated	using	
Hanes	Woolf	equation.	
ሾܵሿ
ܸ݋ ൌ
ሾܵሿ
ܸ݉ܽݔ ൅
݇݉
ܸ݉ܽݔ	
Vo=	 initial	 velocity;	 S=	 substrate	 concentration;	 Vmax	 =	 maximum	 velocity;	
1/Vmax=	Slope;	Y	intercept=	Km/Vmax	
	
2.2.4.1.	DHTKD1	inhibitor	studies	
	
In	 order	 to	 test	 the	 effect	 of	 inhibitor	 on	 the	 function	 of	 DHTKD1,	 we	 used	
1mmol/l	concentration	of	each	the	several	synthetic	analogues	of	2‐oxoglutarate	
namely,	 glutaryl	 phosphonate	 (GP),	 triethyl	 ester	 of	 glutaryl	 phosphonate	
(TEGP),	 trimethyl	 acetyl	 phosphonate	 (TMAP),	 acetyl	 Phosphonate	 (AP)	 and	
diethyl	ester	of	glutaryl	phosphonate	(DEGP)	and	incubated	DHTKD1	patient	and	
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control	fibroblasts	for	2.5h	and	24h	with	them.	Subsequently,	cells	pellets	were	
lysed	in	RIPA	buffer	and	GA	and	OA	levels	were	analyzed	using	GCMS.	
	
2.2.5.	Western	blotting	of	Dhtkd1	in	mouse	tissue	samples	
	
2.2.5.1.	Preparation	of	tissue	homogenates	
	
Liver	and	brain	tissues	of	Dhtkd1	and	Gcdh	single	(Dhtkd1‐/‐/Gcdh+/+;	Dhtkd1+/+/	
Gcdh‐/‐)	 and	 double	 KOs	 (Dhtkd1‐/‐/Gcdh‐/‐)	 along	 with	 wild‐type	
(Dhtkd1+/+/Gcdh+/+)	 mice	 were	 obtained	 from	 the	 collaboration	 partners	 in	
Helmholtz	 Zentrum,	Munich.	 The	 tissues	were	 chilled	 on	 ice	 in	 RC	 buffer	 (0.1	
ml/0.1	mg	 of	 tissue)	 (table	 5)	 and	were	 homogenized	with	 a	 Potter‐Elvehjem	
system	 (Fisher	 Scientific,	 Schwerte,	 Germany)	 using	 a	 size	 that	 allows	 the	
disruption	of	cell	membranes	but	not	organelles,	and	subcellular	fractions	were	
prepared.		
RC	buffer	composition	
Reagent	 Stock	
concentration	
Stock	
concentration	
Remarks	
sucrose	 1	M	 1	M	 pH	adjusted	to	
7.4	KCl	 1	M	 1	M	
MgCl2	 500	mM	 500	mM	
Tris‐HCl	 500	mM	 500	mM	
	
Table	5:	Composition	of	RC	Buffer	used	for	the	homogenization	of	tissues	
	
For	the	preparation	of	“mitochondrial‐enriched”	fractions,	 first	cell	debris	and	
nuclei	 were	 removed	 by	 centrifuging	 the	 homogenates	 at	 600×g,	 4	 °C	 for	 10	
min.	Next,	the	600×g	supernatant	obtained	was	centrifuged	for	10	min,	4	°C	at	
3,500×g	and	the	pellet	used	as	“mitochondria‐enriched”	fractions	(Kaminski	et	
al.,	2010).	
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2.2.5.2.	Determining	the	concentration	of	protein	
	
Protein	 concentration	 was	 determined	 using	 protein	 assay	 kit	 containing	
Reagent	 A	 and	 Reagent	 B	 from	 Bio‐Rad	which	 is	 similar	 to	 the	 colorimetric	
method	 for	 protein	 determination	 (Lowry,	 Rosebrough,	 Farr,	 &	 Randall,	
1951)described	by	Lowry.	BSA	solutions	of	different	concentrations	were	used	
as	a	standard.	BSA	and	samples	were	diluted	in	a	1%	SDS	solution	followed	by	
addition	 of	 25	 µl	 of	 reagent	 A	 and	 200	 µl	 of	 reagent	 B.	 After	 10	 min	 of	
incubation	 at	 RT,	 the	 absorbance	 was	 measured	 at	 750	 nm	 using	 a	
spectrophotometer,	 and	 the	 respective	 protein	 concentration	was	 calculated	
depending	on	the	BSA	standard	curve.	
	
2.2.5.3.	SDS‐PAGE,	immunoblotting	and	detection	by	enhanced	
chemiluminescence	
	
Mitochondrial‐enriched	 fractions	 (refer	 Section	 2.2.5.1)	 from	 livers	 of	
knockout	 and	 wild‐type	 mice	 were	 prepared	 (in	 RC	 buffer)	 and	 used	 for	
Western	blotting.	An	equal	amount	of	protein	was	 loaded	and	was	separated	
by	sodium	dodecyl	sulfate‐polyacrylamide	gel	electrophoresis	(SDS–PAGE)	and	
transferred	to	nitrocellulose	membranes	by	electroblotting.	After	blotting,	the	
membranes	 were	 incubated	 for	 1	 hr	 in	 blocking	 buffer	 (5%	 milk	 in	 TBST)	
followed	by	incubation	with	goat	polyclonal	antibody	generated	against	human	
DHTKD1	 (diluted	 in	 5%	milk	 in	 TBST;	 1:500)	 O/N	 at	 4	 °C	 with	 continuous	
shaking.	 Non‐specific	 binding	 was	 then	 removed	 by	 washing	 the	membrane	
(1x	 TBST,	 3	 times,	 10	 min	 each)	 followed	 by	 incubation	 with	 horseradish	
peroxidase‐conjugated	 secondary	 antibody	 (diluted	 in	 5%	 milk	 in	 TBST	
1:2000)	 at	 RT	 for	 1	 hr.	 Unbound	 antibody	 was	 cleared	 by	 washing	 the	
membrane	 (1X	 TBST,	 3	 times,	 10	 min	 each)	 and	 visualized	 by	 enhanced	
chemiluminescence	 according	 to	 the	 manufacturer's	 instructions	 (GE	
Healthcare,	Germany).	
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2.2.6.	Analysis	of	Glutaric	acid	(GA),	2‐oxoadipic	acid	(OA)	and	
2‐aminoadipic	acid	(AA)	quantitatively		
	
The	metabolites	 GA,	 2‐OA,	 and	 2‐AA	were	 quantitatively	measured	 in	 tissue	
homogenates	 from	 mice	 using	 GC‐MS	 with	 stable‐isotope	 dilution	 assay	 as	
described	 by	 (Sham	 et	 al;	 2012)	 with	 some	 modifications.	 Thousand	 micro	
liters	 of	 the	 suspension	 was	 used	 for	 liquid‐liquid	 extraction.	 In	 brief,	 as	
internal	 standards,	 10	 all	 each	 of	 1	 mmol/L	 stable	 isotope‐labeled	 d4‐
nitrophenol	 and	 d4‐GA	were	 added	 respectively.	 The	 samples	were	 acidified	
using	300	μL	of	5	M	HCl.	Following	this	solid	sodium	chloride	was	added	and	
extracted	 twice	 with	 5	 mL	 ethyl	 acetate.	 The	 obtained	 fractions	 were	 dried	
initially	 over	 sodium	 sulfate	 and	 followed	 by	 drying	 down	 at	 40	 °C	 under	
nitrogen	 stream.	 Samples	 were	 further	 derivatized	 using	 N‐methyl‐N‐
(trimethylsilyl)	heptafluorobutyramide	for	1	h	at	60	°C.	For	performing	GCMS	
analysis,	MSD	5975A,	the	quadrupole	mass	spectrometer	was	used	and	run	in	
the	 selective	 ion‐monitoring	 mode	 along	 with	 electron	 impact	 ionization.	 A	
capillary	 column	was	 used	 to	 achieve	 gas	 chromatographic	 separation	 using	
helium	as	a	carrier	gas.	One	micro	liter	of	the	sample	that	was	derivative	was	
injected	 in	split	 less	mode.	The	 temperature	parameters	used	 for	GC	were	as	
follows;	80	°C	for	2	min,	ramp	50	°C/min	to	150	°C,	ramp	10	°C/	min	to	300	°C,	
and	 hold	 for	 2	min	 at	 300	 °C.	 Interface	 temperature	was	 set	 to	 290	 °C	 and	
injector	 temperature	 to	 280	 °C.	 For	 quantification	 of	 the	 metabolites,	 the	
fragment	 ions	at	m/z	 261	 (GA),	m/z	 265	 (d4‐	GA)	and	m/z	 302	 (2‐oxoadipic	
acid)	 were	 analyzed.	 A	 dwell	 time	 of	 50	 ms	 was	 used.	 The	 obtained	 GCMS	
results	were	normalized	to	the	total	protein	content.	
	
2.2.7.	Measurement	of	Glutaryl	carnitine	levels		
	
Glutaryl	 carnitine	 (C5DC)	 levels	were	measured	 in	 the	 liver	 and	brain	 tissue	
homogenates	 (600×g	 supernatant)	 using	 ESI‐MS/MS	 as	 described	 previously	
(Sauer,	 Okun,	 Fricker,	 Mahringer,	 Müller,	 et	 al.,	 2006).	 Briefly,	 tissue	
homogenates	(100	µg)	were	placed	in	a	single	well	of	a	96‐	well	plate	and	100	
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μL	of	a	methanol	stock	solution	of	 internal	deuterated	standards	were	added	
and	 incubated	 for	 20	 min.	 Samples	 were	 centrifuged	 and	 the	 supernatant	
obtained	was	evaporated	until	dry,	reconstituted	in	60	μL	of	3	N	HCl/butanol,	
placed	 in	 sealed	 microtiter	 plates,	 and	 incubated	 at	 65	 °C	 for	 15	 min.	 The	
obtained	mixtures	were	 then	 dried	 and	 reconstituted	 in	 a	 100	 μL	 solvent	 of	
acetonitrile/water/formic	 acid	 (50:50:0.025	 v/v/v).	 A	 PE	 200	 auto	 sampler	
transferred	 20	 μL	 of	 each	 into	 the	 collision	 cell	 at	 a	 solvent	 flow	 rate	 of	 40	
μL/min	 using	 a	 PE	200	HPLC	pump.	 For	measuring	 acylcarnitines	 a	 positive	
precursor	 ion	 scan	 of	 m/z	 85	 (scan	 range	 m/z:	 225–502)	 was	 used	 and	
quantified	 against	 appropriate	 deuterated	 standards	 with	 concentrations	
expressed	as	μmol/L.	
	
2.2.8.	Culturing	of	fibroblasts,	HEK	293T	and	HeLa	cells	
	
Human	 Embryonic	 kidney	 cells	 (HEK	 293T),	 Human	 cervix	 epithelioid	
carcinoma	 cells	 (HeLa)	 and	 Normal	 human	 dermal	 fibroblast	 cells	 (NHDFC;	
patient	cells	and	controls)	were	cultured	in	T75	flasks	using	15	ml	Dulbeccos	
modified	 eagle	 medium	 (DMEM,	 500	 ml	 bottle)	 containing	 10%	 FCS,	 1%	
Penicillin‐Streptomycin	antibiotic	and	1%	Amphotericin	B	(250	UG/ml)	at	37	
°C	and	5%	CO2.	After	reaching	80‐90%	confluence,	cells	were	sub	cultured	in	a	
ratio	of	1:15	ml	of	DMEM.	
	
2.2.9.	AADAT	siRNA	treatment	
	
To	knockdown	AADAT	 gene	 in	 fibroblasts,	ONTargetPlus	 siRNA	pools	of	5nmol	
concentration	 from	 Dharmacon	 were	 ordered	 and	 resuspended	 in	 250µl	 of	
RNAse‐free	water	 to	obtain	 a	 final	 concentration	of	20µM,	 as	 recommended	 in	
the	protocol	provided	by	the	manufacturer.	Lipofectamine	RNAimax	was	used	as	
a	 transfection	 reagent	 and	 transfections	 were	 done	 according	 to	 the	
manufacturer’s	instructions.	Briefly,	cells	were	grown	in	6	well	plate,	until	70%	
confluence.	 Required	 concentration	 of	 siRNA	was	 resuspended	 in	 150	 µl	 Opti‐
MEM	in	a	1.5	ml	Eppendorf	tube.	In	another	tube,	5	µl	of	Lipofectamine	RNAimax	
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was	 dissolved	 in	 150	 µl	 Opti‐MEM.	 Contents	 of	 both	 tubes	 were	 mixed	 and	
incubated	 for	 5	 min	 at	 RT.	 The	 incubated	 transfection	 reaction	 was	 carefully	
added	 to	 cells	 dropwise.	 Forty‐eight	 hours	 after	 transfection	western	 blot	was	
performed	to	check	the	efficiency	of	knockdown.	
	
2.2.10.	CRISPR/Cas9	method	 for	 the	 generation	of	GCDH	 and	
AADAT	Knockouts		
	
2.2.10.1.	Designing	gRNAs	
	
For	 designing	 gRNAs,	 CCTop–CRISPR/Cas9	 target	 online	 predictor	 tool	
(Stemmer,	 Thumberger,	 Del	 Sol	 Keyer,	Wittbrodt,	 &	Mateo,	 2015)	 was	 used	
and	gRNAs	specific	to	the	human	GCDH	gene	and	AADAT	gene	were	generated	
in	different	exons	and	synthesized	from	Thermo	Fischer	scientific.	The	gRNAs	
were	designed	in	such	a	way	that	they	are	unique	with	no	off	targets	and	they	
are	 present	 immediately	 upstream	 of	 the	 proto	 spacer	 adjacent	 motive	
sequence	(PAM)	which	will	be	recognized	by	the	Cas9	protein	of	Streptococcus	
pyogenes.	 gRNAs	 were	 designed	 approximately	 20	 to	 23	 bp	 in	 length	 with	
overhangs	 containing	 BsmbI	 restriction	 sites.	 The	 gRNAs	 having	 leading	 G	
nucleotides	 at	 the	 5’	 end	 (single	 G	 for	 the	 T7	 promoter	 and	 two	 G’s	 for	 U6	
promoter)	 will	 be	 more	 efficient	 in	 inducing	 the	 double‐stranded	 breaks	
(DSBs).	So	additional	G	nucleotides	were	added	at	the	5’	end	of	the	gRNAs	in	
case	 of	 their	 absence.	 The	 gRNA	 oligos	were	 then	 directly	 used	 for	 the	 next	
steps	of	cloning.	
	
2.2.10.2.	Oligo	annealing	and	cloning	into	PX459	vector	(Ran	et	
al.,	2013)	(modified).	
	
PX459,	 a	mammalian	 expression	 vector	 having	 a	 human	 U6	 promoter,	 Cas9	
gene	and	a	puromycin	resistance	gene	was	used	to	clone	the	gRNAs.	Briefly,	1	
µg	of	plasmid	was	digested	using	BbsI	enzyme	 for	30	min	at	37	 °C	 (table	6).	
The	 cut	 vector	was	 then	gel	purified	 (as	 in	2.2.1.1)	using	Nucleospin	gel	 and	
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PCR	 clean‐up	 kit	 (M&N).	 Phosphorylation	 and	 annealing	 of	 gRNAs	was	 done	
followed	by	ligation	into	the	cut	PX459	vector	(table	7a&7a1)	at	RT	for	at	least	
1	 hr.	 The	 ligated	 reaction	 was	 then	 proceeded	 with	 transformation	 (refer	
2.2.1.4).	 Importantly,	 the	 ligation	 reaction	 and	 the	 transformation	 were	
included	 with	 proper	 controls,	 to	 get	 rid	 of	 false	 positives.	 The	 colonies	
obtained	were	selected	(10‐15	colonies)	and	mini	preparation	of	plasmid	was	
performed	by	 isolating	 the	 plasmid	 from	 the	O/N	 cultured	 colonies.	 Positive	
clones	were	 then	 selected	after	 confirmation	by	 sequencing	using	human	U6	
promoter	sequencing	primer.	
	
	
	
	
	
	
	
	
		
	
	
	
	
Table	7	a:	Phosphorylation	and	annealing	of	oligos;	7	a1:	Thermal	cycler	conditions	
	
	
Digestion	of	PX459	vector	
	Reagent	 Amount	
Vector(PX459)	 1	µg	
	 	
FastdigestBsmbI	
(Thermoscientific)	
1	µl	
Fast	AP	(Thermoscientific)	 1	µl	
10x	Fast	digest	Buffer	 2	µl	
Nuclease	free	H20	upto	 20	µl	
b.	Ligation	reaction	
Reagent	 amount	 Remarks	
Bsmb	 I	
digested	
plasmid		
50	ng	 The	
reaction	
was	 set	 up	
at	 RT	 for	 1	
hr	
Phosphorylat
ed	 and	
annealed	 oligo	
duplex	 (1:200	
diluted)	
1	µl	
10X	 T4	 DNA	
ligase	buffer	
1	µl	
T4	DNA	ligase	 0.5	µl	
Nuclease	 free	
water	upto	
10	µl	
b1.Thermal	cycler	
conditions	
37	°C‐	30	min	
95	 °C‐	 5	 min	 and	
then	ramp	down	to	
25	°C	at	5	°C/min	
	
	
Table	6:	Digestion	of	Px459	
vector	
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2.2.10.3.	 Determining	 the	 cytotoxicity	 of	 puromycin	 for	HEK	
and	HeLa	cells	
	
The	lowest	amount	of	puromycin	concentration	that	causes	cell	death	of	HEK	
and	HeLa	cells	varies	among	different	experimental	conditions	and	cell	types.	
To	 test	 this,	 approximately	25000	 cells	 (HEK	and	HeLa)	were	 seeded	 in	 two	
different	 96	 well	 plates	 containing	 100	 µl	 DMEM	 medium	 and	 were	 grown	
until	70‐80%	confluence.	Different	concentrations	of	puromycin,	0.5	µg/ml,	1	
µg/ml,	 1.5	 µg/ml,	 2	 µg/ml,	 2.5	 µg/ml,	 3	 µg/ml,	 4	 µg/ml	 until	 5	 µg/ml	were	
added	to	different	wells	of	both	HEK	and	HeLa	cells	from	the	stock	10	mg/ml.	
Untreated	cells	were	kept	as	controls.	The	medium	containing	puromycin	was	
changed	for	every	24	h	until	4	days	and	observed	for	highest	cell	death	at	the	
lowest	concentration.	For	HEK,	2	µg/ml	and	HeLa,	1	µg/ml	of	puromycin	was	
observed	to	be	the	lowest	concentration	that	could	effectively	kill	all	the	cells	
in	the	culture.		
	
2.2.10.4.	Transfection	of	PX459‐gRNA	constructs	into	HEK	and	
HeLa	cells	
	
HEK	 and	 HeLa	 cells	 were	 cultured	 in	 6‐well	 plates	 up	 to	 60%	 confluency.	
Transfections	 were	 done	 using	 Lipofectamine	 2000	 according	 to	
manufacturer’s	protocol.	Briefly,	1	µg	plasmid	was	resuspended	in	150	µl	Opti‐
MEM	 in	a	1.5	µl	Eppendorf	 tube.	 In	another	 tube,	5	µl	of	Lipofectamine	RNA	
2000	was	dissolved	 in	150	µl	Opti‐MEM.	Contents	of	both	 tubes	were	mixed	
and	 incubated	 for	 5min	 at	 RT.	 The	 incubated	 transfection	 reaction	 was	
carefully	 added	 to	 cells.	 Twenty	 four	 hours	 after	 the	 transfection,	 cells	were	
kept	under	antibiotic	selection	pressure.		
	
2.2.10.5.	Confirmation	of	Knockout	cells	by	western	blotting	
	
The	 transfected	 cells	which	 survived	 after	 puromycin	 selection	were	 further	
cultured	 in	 T75	 flasks	 and	 part	 of	 those	 were	 used	 to	 confirm	 the	 GCDH	
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Knockout	 and	AADAT	knockout.	 Cells	were	 lysed	 in	RIPA	buffer	 and	protein	
concentration	 was	 determined	 by	 Lowry	 method	 (refer	 2.2.5.2).	 Equal	
amounts	 of	 protein	 were	 loaded	 and	 the	 western	 blotting	 procedure	 was	
performed	as	in	2.2.5	by	using	GCDH	primary	antibody	(diluted	in	5%	milk	in	
TBST;	1:500)	and	anti‐rabbit	2°	antibody	(diluted	in	5%	milk	in	TBST;	1:2000).	
	
2.2.10.6.	 Generation	 of	 single	 cell	 clones	 of	 GCDH	 Knockout	
and	AADAT	knockout	cells	
Single	cell	clones	were	generated	using	serial	dilution	method.	Briefly,	100	µl	
cell	 culture	medium	was	 added	 to	 each	well	 of	 the	 96	well	 plate.	 To	 100	 µl	
medium	 in	 well	 number	 A1,	 another	 100	 µl	 medium	 containing	 4000	 cells	
were	added	and	mixed	well.	 From	 this	A1	well,	100	µl	was	 taken	and	mixed	
into	 well	 number	 A2	 and	 subsequently,	 serial	 dilution	 is	 done	 until	 well	 no	
A12.	Using	a	multi‐channel	pipette,	cells	from	the	top	wells	(A1	to	A12)	were	
serially	 diluted	 into	 bottom	 wells.	 Each	 well	 is	 checked	 for	 the	 presence	 of	
single	cells	and	marked.	Single	cells	were	allowed	to	grow	until	full	confluence	
and	eventually	upscaled	for	the	required	volume.	
	
2.2.11.	 Inhibitor	 treatment	 of	 patient	 fibroblasts	 and	
measurement	of	glutaricacid	(GA)	levels	using	GCMS	
	
GA‐I	 patient	 fibroblasts	 were	 used	 to	 test	 the	 effect	 of	 AADAT	 inhibitor.	 An	
equal	number	of	patient	fibroblasts	(5*10^6	Cells/	T75	flask)	were	seeded	and	
grown	until	confluence.	Cells	were	starved	overnight	 in	medium	without	FCS	
and	 on	 the	 following	 day,	 lysine	 load	 in	 DMEM	medium	 (5	mM	 lysine/5	ml	
medium)	 was	 given,	 along	 with	 different	 concentrations	 of	 inhibitor	 PF‐
04859989	(0.1	μM,	1	μM,	10	μM,	50	μM)	for	every	24	h	until	three	days.	After	
72	h,	cells	were	washed	in	PBS,	scraped	in	ddH20	(1	ml/T75	flask),	sonicated	
and	 centrifuged	 at	 13,000	 rpm	 for	 30	 min.	 Finally,	 the	 supernatant	 was	
collected	and	measured	for	GA	levels	by	GCMS	(refer	2.2.6)		
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2.2.12.	Establishing	enzyme	activity	assay	for	AADAT	in	patient	
fibroblasts	
	
GA‐I	patient	 fibroblasts	were	used	to	establish	AADAT	enzyme	activity	assay.	
Cells	were	 grown	 to	 confluence	 in	 10	 cm	 dishes.	 The	medium	was	 removed	
from	 cells,	 washed	 with	 PBS	 twice	 followed	 by	 trypsinization	 and	
centrifugation	for	10	min	at	3000	rpm.	The	supernatant	was	removed	and	cell	
pellets	 (1	ml	buffer/10^7	cells)	were	 lysed	 in	AADAT	assay	buffer	 (buffer	B)	
(table	8)	with	and	without	AADAT	 inhibitor	 (50	μM)	at	different	 time	points	
and	immediately	flash	frozen	in	liquid	nitrogen.	Samples	were	then	measured	
for	Oxoadipate	levels	by	GCMS	(refer	2.2.6).		
	
AADAT	assay	buffer	(buffer	B)	
Reagents	 Final	
concentration	
Remarks	
2‐aminoadipate	 1	mM	 pH	adjusted	to	9.5.	
The	buffer	was	made	
with	and	without	
AADAT	inhibitor	
(50	μM)	
2‐oxoglutarate	 1	mM	
NADP	 0.5	mM	
glutamate	
dehydrogenase	
10	μl	
RC	buffer	(refer	table	5)	
up	to	
	
	
10	ml	
	
Table	8:	AADAT	enzyme	activity	assay	buffer	
	
2.2.13.	Effect	of	PF‐04859989	inhibitor	on	HEK	and	HeLa	GCDH	
Knockout	cells	and	GA	detection	using	GCMS	
	
To	 test	 the	effect	of	 the	 inhibitor	on	HEK	and	HeLa	Knockout	cells,	 the	same	
method	used	for	fibroblasts	mentioned	above	in	2.2.11	section	was	followed.		
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2.2.14.	Detection	of	DNA	damage	in	fibroblasts	
	
2.2.14.1.	Seeding	of	patient	and	control	cells	
	
GA‐I	 patient	 and	 control	 fibroblasts	 were	 seeded	 (50,000	 cells/well)	
separately	in	a	24	well	plate	containing	12	mm	coverslips	in	each	well	which	
were	just	placed	before	addition	of	cells.	After	plating	the	cells,	the	coverslips	
were	left	undisturbed	in	the	cell	culture	incubator	at	37	°C,	5%	CO2	for	30	min	
so	that	they	get	attached	to	the	surface	of	the	coverslip.	1	ml	of	DMEM	medium	
was	added	to	the	coverslips	carefully.	After	4	h,	the	medium	was	removed	and	
continued	with	immunofluorescence	staining.	
	
2.2.14.2.	Immunofluorescence	staining	
	
All	the	incubation	steps,	before	primary	antibody	addition	was	carried	out	on	a	
rocking	 shaker	 at	 RT	 if	 unless	 otherwise	 stated.	 The	 medium	 was	 removed	
after	4	h	and	cells	(refer	2.2.14.1)	were	washed	gently	with	PBS	for	3	x	10	min.	
The	fixation	of	the	cells	was	done	using	4%	PFA	for	15	min	followed	by	washes	
with	PBS	for	2	x10	min.	To	permeabilize	the	cell	membranes,	2%	Triton‐X‐100	
in	PBST	was	added	for	15	min	to	each	well	and	cells	were	washed	with	PBS	for	
2	x	10	min.	Cells	were	 then	blocked	 in	blocking	buffer	containing	5%	BSA	 in	
PBS	 for	 30	 min.	 After	 blocking,	 100	 µl	 0f	 gamma	 H2Ax	 primary	 antibody	
(1°Ab)	prepared	 in	blocking	buffer	 (1:1000)	was	added	and	 incubated	 in	 the	
dark	 at	 4	 °C	O/N	with	no	 shaking.	On	 the	next	 day,	 1°	Ab	was	 removed	 and	
washes	with	 PBS	were	 done	 3	 x	 10	min.	 After	washing,	 100	 µl	 of	 Goat	 anti‐
mouse	IgG	Alexa‐488	secondary	antibody	prepared	in	blocking	buffer	(1:500)	
was	added	and	incubated	for	1	hr	at	RT.	2	x	10min	washes	with	PBS	were	done	
followed	by	DAPI	staining	(1:1000	in	PBS)	in	the	dark	for	15	min	at	RT.	DAPI	
was	removed	and	washed	with	PBS	2	x	10min.	Mounting	of	the	coverslips	on	
to	the	microscopic	slides	was	done	by	placing	1	drop	of	mounting	medium	on	
the	slide	and	carefully	placing	the	coverslips	containing	cells	(refer	2.2.14.1)	on	
to	the	mounting	medium	in	such	a	way	that	the	surface	containing	cells	were	
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placed	 downwards	 and	 without	 any	 air	 bubble	 formation.	 The	 slides	 were	
dried,	kept	away	from	exposure	to	light	and	finally	image	analysis	was	done.	
	
2.2.14.3.	Image	analysis	
	
Images	were	acquired	by	a	fluorescence	microscope	(Nikon)	using	60x	optics	or	
confocal	microscope	(Zeiss)	using	63x	objective.	 Image	analysis	was	performed	
using	Image	J	software	by	counting	the	number	of	Foci	in	the	nuclei	of	cells	and	
comparing	them	between	the	GA‐I	patient	and	control	cells.		
	
2.2.15.	Statistical	analysis	
	
We	performed	all	statistical	tests	in	Graph	pad	Prism	and	data	were	calculated	
and	presented	as	mean	±	S.D.	Student’s	T	test	or	ANOVA	was	used	to	reveal	
statistical	significance.	P	≤	0.05	was	considered	to	be	statistically	significant.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
3.	Results	
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3.1.	Can	targeting	DHTKD1	rescue	the	clinical	and	biochemical	
phenotype	of	GA‐I?	
	
In	order	to	 identify	novel	and	effective	therapeutic	 interventions	as	treatment	
strategies	 for	 GA‐I,	 based	 on	 our	 current	 knowledge	 from	 the	 literature,	 we	
tested	 if	 inhibition	of	DHTKD1	can	be	 therapeutically	effective	 in	rescuing	 the	
clinical	and	biochemical	phenotype	shown	in	GA‐I	disease.		
	
3.1.1.	Cloning,	expression	and	purification	of	DHTKD1protein	
	
We	initially	aimed	to	clone	and	purify	human	DHTKD1	protein	to	further	use	it	
in	the	pharmacological	testing	with	available	inhibitors.	In	order	to	achieve	this,	
we	 employed	 a	 pGEX‐4T1	 vector	 system	 (figure	 1A).	 It	 is	 a	 highly	 suitable	
heterologous	prokaryotic	expression	system,	 in	which	 the	proteins	of	 interest	
are	expressed	as	fusion	products	of	Glutathione‐S‐transferase	(GST).	This	helps	
in	 the	purification	using	affinity	column	based	chromatography.	DHTKD1	ORF	
without	 the	 mitochondrial	 targeting	 sequence	 present	 within	 the	 Lentiviral	
vector	 pReceiver‐Lv21	 (Ex‐H4610‐LV21)	 was	 PCR	 amplified	 using	 specific	
primers	and	gel	purified.	Both,	the	insert	and	the	vector	were	double	digested	
using	NotI	 and	 EcoRI	 restriction	 enzymes	 and	 gel	 purified.	 Subsequently,	 the	
insert	 and	 the	 vector	were	 ligated	using	 standard	molecular	biology	methods	
and	 transformed	 into	 chemically	 competent	 DH5α	 bacterial	 strain.	 Positive	
colonies	 were	 selected	 and	 cloning	 was	 confirmed	 by	 sequencing	 and	 PCR	
based	 amplification	 (colony	 PCR),	 which	 showed	 a	 band	 at	 around	 2600	 bp	
confirming	 the	 presence	 of	 DHTKD1	 (figure	 1B)	 insert.	 Single	 colonies	 were	
inoculated	 to	 grow	 further	 and	 pure	 plasmid	 containing	DHTKD1	 insert	 was	
isolated	 using	 midi	 plasmid	 purification	 kit.	 The	 purified	 plasmid	 was	 then	
transformed	 into	 BL21DE3	 Lys	 chemically	 competent	 bacterial	 strain,	 which	
have	 the	 ability	 to	 express	 the	 protein	 when	 induced	 using	
isopropylthiogalctoside	 (IPTG).	 DHTKD1	 protein	 was	 successfully	 purified	
using	glutathione	sepharose	beads	using	affinity	chromatography.	The	purified	
DHTKD1	protein	(103	KDa)	in	fused	form	with	GST	tag	(26	KDa)	was	observed	
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at	130	KDa	in	silver	staining	(figure	1C)	and	the	specificity	of	DHTKD1	protein	
was	further	confirmed	by	western	blot	(figure	1D).	The	obtained	pure	DHTKD1	
protein	was	flash	frozen	in	liquid	nitrogen	and	stored	at	‐80	°C	to	use	in	further	
biochemical	and	pharmacological	studies.	
	
 
	
Figure	1:	Cloning,	expression	and	purification	of	DHTKD1	protein:	A.	Schematic	representation	
of	pGEX‐4T‐	1	vector,	B.	Colony	PCR	showing	the	presence	of	DHTKD1	band	(2688	bp),	C.	Silver	
staining	 showing	DHTKD1	purified	protein	 along	with	GST	 fusion	 tag	 (130	KDa),	D.	Western	
blot	 showing	 DHTKD1	 purified	 protein	 (130	 KDa)	 (M‐	 marker,	 1.	 un	 induced	 cell	 pellet,	 2.	
induced	 cell	 pellet,	3.	 flow	 through,	4.	wash‐1,	5.	wash‐2,	6.	wash‐3,	7.	elute‐1,	8.	 elute‐2,	9.	
elute‐3).		
	
3.1.2.	Determining	the	substrate	specificity	and	enzyme	
kinetics	of	purified	DHTKD1	protein		
	
We	 aimed	 to	 test	 the	 affinity	 of	 DHTKD1	 towards	 its	 substrate	 2‐oxoadipate	
using	 the	 purified	 DHTKD1	 protein.	 Unexpectedly,	 we	 observed	 that	 the	
59	
	
purified	 DHTKD1	 protein	 (figure	 1D)	 was	 degraded	 despite	 careful	 and	
preventive	measures	employed	(figure	2	A).	However,	purified	DHTKD1	protein	
was	generously	provided	by	our	collaborator	Dr.Wyatt	Yue,	Oxford	University,	
UK.	 We	 obtained	 highly	 enriched	 DHTKD1	 protein	 that	 was	 purified	 using	
Nickel	 resin	 based	 affinity	 chromatography	 and	 gel	 filtration	 using	 an	 AKTA	
purifier,	GE	Healthcare.	The	pure	DHTKD1	protein	has	the	following	sequence	
(figure	 2B).	 The	 obtained	 DHTKD1	 protein	 was	 incubated	 with	 2‐oxoadipate	
and	 2‐oxoglutarate	 in	 separate	 reactions	 in	 buffer	 A,	 which	 contains	 the	
essential	 components	 that	 promote	 DHTKD1	 enzyme	 activity.	 2‐Oxoglutarate	
was	 used	 to	 check	 the	 substrate	 specificity	 of	 DHTKD1	 using	 the	 purified	
DHTKD1	 protein	 We	 observed	 enzyme	 activity	 with	 incubation	 with	 the	
substrate	2‐oxoadipate	but	not	with	2‐oxoglutarate	 (figure	3)	 suggesting	high	
affinity	of	DHTKD1	towards	2‐oxoadipate.	
	
Additionally,	we	aimed	to	assess	the	kinetic	parameters	of	DHTKD1,	providing	
the	necessary	Km	and	Vmax	values,	which	are	essential	 for	the	pharmacokinetic	
studies.	 The	 purified	 DHTKD1	 protein	 was	 incubated	 with	 different	
concentrations	(0.05	mM,	0.1	mM,	0.25	mM,	0.5mM,	0.75	mM,	1	mM,	2mM	and	
no	substrate)	of	substrate	2‐oxoadipate	in	buffer	A	and	subsequently	its	kinetic	
parameters	were	recorded	at	wavelength	range	610‐750	nm.	The	Km	and	Vmax	
values	for	DHTKD1	were	determined	using	Hanes‐	Woolf	equation	by	plotting	
(S)	on	X‐axis	against	(S)/V	on	Y	axis	(HALDANE,	1957;	Hanes,	1932).	The	Km	
obtained	 for	 DHTKD1	 was	 0.2	 mM	 and	 the	 Vmax	 was	 14.2	 µmol/min/mg	
(figure	4).		
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Figure	 2:	 A.	 Degraded	 Dhtkd1	 protein	 (7,	 8,	 9	 represents	 purified	 protein	 elutes	 1,	 2,	 3	
respectively	 in	degraded	 form)	B.	Protein	sequence	of	Dhtkd1	purified	protein	obtained	 from	
Dr.	Wyatt	Yue’s	laboratory.	
	
Figure	3:	Activity	of	pure	DHTKD1	protein	in	the	presence	or	absence	of	its	specific	substrate,	
2‐oxoadipate:	DHTKD1	enzyme	activity	was	observed	in	the	presence	of	substrate	2‐oxoadipate	
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(blue	 squares	 ‐	with	OA),	 but	 not	 in	 the	 absence	 of	 2‐oxoadipate	 (blue	 circles	 ‐	without	OA).	
Reference	line	(red).	
	
Figure	 4:	 Measurement	 of	 Km	 and	 Vmax	 for	 DHTKD1	 using	 Hanes‐Woolf	 plot:	 Different	
substrate	 concentrations	 (S)	 plotted	 on	X‐axis	 against	 the	 ratio	 of	 substrate	 concentration	 to	
initial	velocity	(S)/V	on	Y‐axis	yielded	Km	as	0.2	mM	and	Vmax	as	14.2	µmol/min/mg	for	DHTKD1	
protein.	
	
3.1.3.	Pharmacological	inhibition	of	DHTKD1		
	
In	 the	 next	 step,	 we	 tested	 the	 effect	 of	 specific	 synthetic	 analogues	 of	 2‐
oxoglutarate	 on	DHTKD1	 function	 in	vitro	 by	 incubating	 the	DHTKD1	 patient	
and	control	fibroblasts	(NHDFC)	with	phosphonate	analogues	namely,	glutaryl	
phosphonate	 (GP),	 triethyl	 ester	 of	 glutaryl	 phosphonate	 (TEGP),	 trimethyl	
acetyl	 phosphonate	 (TMAP),	 acetyl	 Phosphonate	 (AP)	 and	 diethyl	 ester	 of	
glutaryl	phosphonate	(DEGP).	Phosphonate	analogues	are	well	known	synthetic	
molecules,	reported	to	 inhibit	the	E1	subunit	of	OGDHc	enzyme	(V.	I.	Bunik	et	
al.,	2005).	
	
In	brief,	we	incubated	the	cells	with	1	mmol/l	concentration	each	of	the	above	
mentioned	phosphonate	analogues	at	two	different	time	points	(2.5	h	and	24	h)	
and	 tested	 their	 efficacy	 in	 blocking	 DHTKD1	 by	 measuring	 the	 GA	 and	 OA	
levels	 using	GCMS.	We	observed	 that	 the	 compounds	we	 tested	did	not	 show	
any	effect	on	the	GA	 levels	as	compared	to	the	basal	GA	 levels.	We	also	 found	
that	except	for	AP,	inhibition	with	other	compounds	did	not	show	any	rise	in	OA	
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levels	and	resembled	the	basal	OA	levels	(figure	5).	Blocking	with	AP	showed	an	
increase	in	OA	levels,	in	the	control	cells	compared	to	the	basal	OA	levels,	which	
confirms	 that	 AP	 is	 able	 to	 block	 DHTKD1	 function.	 Interestingly,	 DHTKD1	
patient	cells	also	displayed	increased	OA	levels	in	after	AP	treatment	for	24	h.	
This	 finding	 suggests	 that	 either	 residual	 activity	 of	 mutated	 DHTKD1	 or	 its	
isoforms	 (OGDH,	OGDHL)	partially	 compensating	 the	 loss	 of	DHTKD1	 activity	
are	blocked	by	AP.		
	
Figure	 5:	 Measurement	 of	 GA	 and	 OA	 levels	 in	 DHTKD1‐/‐	 patient	 and	 control	 fibroblasts:	
Different	substrate	analogues	of	2‐oxoglutarate	were	tested	on	DHTKD1‐/‐	patient	and	control	
fibroblasts	(medium	and	pellets).	Highlighted	shows	the	levels	of	GA	and	OA	after	AP	treatment.	
NHDF:	Normal	human	derived	fibroblasts,	taken	as	a	control.	Data	are	presented	as	n=1.	
	
3.1.4.	Murine	model	for	targeting	DHTKD1	
	
In	order	to	test	the	hypothesis	of	rescuing	GA‐I	phenotype	by	blocking	DHTKD1	
in	 vivo,	 we	 utilized	 mice	 with	 4	 different	 genotypes,	 i.e.,	 Dhtkd1	 Knockout	
(Dhtkd1‐/‐/	 Gcdh+/+),	 Gcdh	 Knockout	 (Dhtkd1+/+/	 Gcdh‐/‐),	 double	 Knockout	
(Dhtkd1‐/‐/	Gcdh‐/‐)	and	control	mice	(Dhtkd1+/+/	Gcdh+/+)	(table	A).	They	were	
treated	with	three	different	diets	 i.e;	standard	diet	which	contains	85mg	of	L‐
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lysine,	diet	with	high	lysine	in	chow	[contains	235mg	lysine	in	chow]	and	diet	
with	 lysine	 in	 both	 chow	 and	 water	 (376	 mg	 L‐lysine	 in	 total	 per	 day	 per	
mouse)	 (table	 A1)	 (Sauer	 et	 al.,	 2015);	 for	 GCMS	 studies,	 we	 used	 tissue	
homogenates	 from	 liver	 and	 brain	 in	 which	 the	 metabolites	 GA,	 OA,	 AA	 and	
C5DC	were	measured.	
	
Type	of	mice	 Genotype	 Knockout	status	
Dhtkd1	Knockout	mice	 Dhtkd1‐/‐/Gcdh+/+	 Dhtkd1	 gene	 is	
knocked	 out,	 Gcdh	
gene	is	normal.	
Gcdh	Knockout	mice	 Dhtkd1+/+/Gcdh‐/‐	 Gcdh	 gene	 is	 knocked	
out,	 Dhtkd1	 gene	 is	
normal.	
Double	Knockout	mice	 Dhtkd1‐/‐/Gcdh‐/‐	 Both	Dhtkd1	gene	and	
Gcdh	 gene	 are	
knocked	out.	
Control	mice	 Dhtkd1+/+/Gcdh+/+	 Both	 Dhtkd1	 gene	
and	 Gcdh	 gene	 are	
normal.	
	
Table	A:	Representation	of	different	mouse	models	along	with	their	genotypes	
	
Diet	type	 %	of	L‐lysine	
No	diet	or	standard	diet	 1.7%	(w/w)	or	85mg	of	L‐lysine	in	food	
4.7%	chow	diet	or	high	lysine	
diet	
4.7%	(w/w)	or	235mg	of	L‐lysine	in	food	
Chow	+	water	diet		 376	mg	L‐lysine	in	total	in	both	chow	and	
water	
	
Table	A1:	Representation	of	different	diets	used	(Sauer	et	al.,	2015)	
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Generation	of	Knockout	mice	(except	of	Gcdh‐/‐	mice),	maintenance,	behavioral	
and	 clinical	 characterization	were	 performed	 in	Munich	 by	 our	 collaboration	
partners	 (Group	 of	 Dr.	 Holger	 Prokisch,	 Helmholtz‐Zentrum),	 whereas	 the	
knockout	confirmation	by	western	blot	(figure	6),	biochemical	characterization,	
data	analysis	were	done	by	me.		
	
3.1.4.1.	 Generation	 of	 Dhtkd1	 Knockout	 (Dhtkd1‐/‐/	 Gcdh+/+)	
mice	
	
In	 brief,	 the	 generation	 of	 Dhtkd1‐/‐/Gcdh+/+	 mouse	 was	 done	 using	
Transcription	Activator	Like	Effector	Nucleases	(TALENs)	(wefers	et	al;	2013).	
Mutations,	which	resulted	in	loss	of	function	of	human	DHTKD1,	were	identified	
in	 exons	1,	 7	 and	13	 (Danhauser	 et	 al.,	 2012a).	 To	knock	out	Dhtkd1	in	mice,	
TALENs	 were	 designed	 that	 are	 specific	 for	 exon	 7	 and	 injected	 into	 mice.	
Genotyping	of	the	TALEN	injected	mice	via	Sanger	sequencing	showed	a	19	bp	
deletion	 in	exon	7	of	Dhtkd1,	which	predicted	 to	 cause	 frame	shift	mutations,	
thereby	leading	to	a	premature	stop	codon,	at	the	amino	acid	position	431	and	
giving	rise	to	a	truncated	protein.	The	generated	Dhtkd1‐/‐/Gcdh+/+	mice	which	
genetically	resembled	the	patient	mutation	p.Arg410*,	were	selected	for	further	
characterization	(Biagosch	et	al:	2017).		
	
Liver	tissues	from	the	Knockout	and	control	mice	were	collected	and	immuno‐
blotting	was	performed	using	Dhtkd1	specific	antibody.	Western	blot	analysis	
showed	the	presence	of	Dhtkd1	protein	in	samples	from	control	mice,	but	not	in	
Knockout	 samples,	 which	 confirmed	 the	 successful	 generation	 of	 Dhtkd1‐/‐
/Gcdh+/+	mice	(figure	6).	
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Figure	 6:	 Confirmation	 of	 Dhtkd1‐/‐/Gcdh+/+by	 Western	 blotting:	 Western	 blot	 showing	 the	
presence	of	103	Kda	Dhtkd1	protein	in	wildtype	sample,	but	not	 in	Dhtkd1‐/‐sample.	Actin	(42	
Kda)	was	used	as	a	loading	control.	
	
3.1.4.2.	Behavioral	and	biochemical	characterization	of	Dhtkd1‐
/‐/	Gcdh+/+	mice	
	
The	 generated	 Dhtkd1‐/‐/Gcdh+/+	 mice	 were	 characterized	 by	 assessing	
behavioral	abnormalities	using	neurobehavioral	experiments	like	grip	strength,	
inverted	 grid	 and	 balance	 beam	 analysis	 (Biagosch	 et	 al.,	 2017).	 Dhtkd1‐/‐
/Gcdh+/+	mice	 did	 not	 show	 any	 significant	 differences	 in	 its	 behavior	 and	
resembled	the	control	mice,	thereby	resembling	the	mild	phenotype	of	patients	
with	 DHTKD1	 mutations.	 Assuming	 that	 the	 knockout	 of	 Dhtkd1	 leads	 to	
accumulation	of	OA	and	AA	as	 seen	 in	patients	with	mutations	of	Dhtkd1,	 the	
Dhtkd1‐/‐/Gcdh+/+	mice	 were	 assessed	 biochemically	 via	 GCMS,	 by	 measuring	
the	GA,	OA	and	AA	levels	in	the	liver	and	brain	tissue	lysates.		
	
Surprisingly,	we	did	not	observe	any	significant	rise	in	OA	levels	in	the	liver	or	
brain	 samples	 of	 Dhtkd1‐/‐/Gcdh+/+	mice	 on	 standard	 diet	 or	 high	 lysine	 diet	
compared	 to	Dhtkd1+/+/Gcdh+/+	mice.	On	 the	other	hand,	 the	AA	 levels	 in	 liver	
tissue	lysates	were	significantly	increased	in	Dhtkd1‐/‐/Gcdh+/+	mice	to	148.8	±	
69.1	 fold	compared	 to	Dhtkd1+/+/Gcdh+/+	mice	on	standard	diet	 (P		0.05;	 two	
way	 ANOVA	 for	 multiple	 comparisons;	 Fisher’s	 LSD).	 A	 similar	 pattern	 was	
observed	in	the	Dhtkd1‐/‐/Gcdh+/+	mice	kept	on	high	lysine	diet,	which	showed	
significantly	 increased	 AA	 levels	 compared	 to	 Dhtkd1+/+/Gcdh+/+	mice	 in	 the	
liver	 tissue	 lysates	 (figure	9B)	 (10.33	±	0.21	 fold	 increase;	P		 0.05;	 two	way	
ANOVA	for	multiple	comparisons;	Fisher’s	LSD).	Brain	AA	levels	were	similar	in	
both	groups	(figure	9A).	As	expected,	we	did	not	observe	any	accumulation	of	
GA	 levels	 in	 the	Dhtkd1‐/‐/Gcdh+/+	mice	 in	 both	 brain	 and	 liver	 tissue	 lysates	
under	standard	diet,	high	lysine	diet	and	also	chow	+	water	diets	tested	(figure	
10	A&B).		
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3.1.4.3.	Knockout	of	Dhtkd1	was	not	able	to	rescue	the	clinical	
and	biochemical	phenotype	seen	in	Gcdh‐deficient	mice	
	
3.1.4.3.1.	Generation	and	characterization	of	double	Knockout	
(Dhtkd1‐/‐/Gcdh‐/‐)	mice	
	
The	Dhtkd1‐/‐/Gcdh‐/‐	mice	were	 generated	 by	 crossing	 the	well‐characterized	
Dhtkd1+/+/Gcdh‐/‐	mice	 with	 the	 above	 described	Dhtkd1‐/‐/Gcdh+/+	mice.	 At	 3	
months	 age,	 the	 generated	 Dhtkd1‐/‐/Gcdh‐/‐	 mice	 showed	 clinical	 phenotype	
under	 standard	 dietary	 conditions,	 similar	 to	 the	Dhtkd1+/+/Gcdh‐/‐	mice.	 For	
example,	we	observed	a	significant	reduction	in	the	locomotor	activity	in	both	
Dhtkd1‐/‐/Gcdh‐/‐	and	Dhtkd1+/+/	Gcdh‐/‐	mice,	as	compared	to	Dhtkd1‐/‐/Gcdh+/+	
mice,	 which	 was	 measured	 by	 counting	 the	 number	 of	 quardrants	 travelled	
with	in	an	arena	by	each	animal	in	30	sec	time	(Biagosch	et	al.,	2017).	We	also	
observed	a	more	pronounced	effect	 (significant	 reduction)	 in	 transfer	arousal	
of	 Dhtkd1‐/‐/Gcdh‐/‐	 mice	 than	 Dhtkd1+/+/Gcdh‐/‐	 mice	 when	 compared	 to	
Dhtkd1‐/‐/Gcdh+/+	mice,	 which	 was	 measured	 by	 placing	 the	 mouse	 into	 an	
arena	and	scoring	was	given	as	follows.	If	the	mouse	showed	freezing	behavior	
after	placing	into	the	arena	for	5	sec	or	more,	score	0	was	given.	If	the	mouse	
showed	a	brief	freezing,	score	1	was	given	and	score	2	was	given	if	the	mouse	
showed	immediate	movement	(Biagosch	et	al.,	2017).		
	
3.1.4.3.1.1.	 The	 clinical	 phenotype	 of	 Dhtkd1‐/‐/Gcdh‐/‐	 mice	
contradicts	our	current	hypothesis	
	
The	 generated	 Dhtkd1‐/‐/Gcdh‐/‐	 mice	 along	 with	 the	 Dhtkd1‐/‐/Gcdh+/+,	
Dhtkd1+/+/Gcdh‐/‐	and	Dhtkd1+/+/Gcdh+/+	mice	were	subjected	to	high	lysine	diet	
or	chow	+	water	diet	in	order	to	induce	a	clinical	phenotype	(Sauer	et	al.,	2015).	
We	 defined	 the	 clinical	 endpoints	 in	 our	 study	 as	 primarily	 weight	 loss,	
followed	by	seizures	and	death.	After	24	h	of	dietary	lysine	supply,	we	looked	
for	 the	 clinical	 phenotype	 if	 any	 and	 observed	 that	 one	Dhtkd1‐/‐	mice	 (n=7),	
four	Dhtkd1+/+/Gcdh‐/‐	mice	 (n=5)	and	none	of	 the	 control	mice	 (n=5)	 showed	
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weight	loss	of	>15%,	which	is	a	lethal	condition,	as	reported	before	(Sauer	et	al.,	
2015)	 (figure	 7).	 Surprisingly,	 all	 the	Dhtkd1‐/‐/Gcdh‐/‐	 mice	 (n=7)	 showed	 a	
critical	weight	loss	representing	the	same	clinical	characteristics	as	that	of	the	
Dhtkd1+/+/Gcdh‐/‐	mice	 (figure	7).	We	also	 tested	 for	 lethargic	behavior,	which	
was	estimated	by	keeping	the	mice	into	an	arena	with	four	quadrants	and	mice,	
which	 travelled	 less	 than	 two	 quardrants	 within	 30	 sec	 duration	 were	
considered	to	be	lethargic.	Four	Dhtkd1+/+/Gcdh‐/‐	mice	(n=5)	and	five	Dhtkd1‐/‐
/Gcdh‐/‐	 mice	 (n=6)	 showed	 more	 lethargic	 behavior,	 while	 only	 one	 of	 the	
wildtype	 (Dhtkd1+/+/Gcdh+/+)	 (n=7)	 and	 two	 of	 Dhtkd1‐/‐/Gcdh+/+	mice	 (n=7)	
showed	the	same	phenotype	(figure	7).		
	
This	 unexpected	 behavioral	 and	 clinical	 characteristics	 seen	 in	 the	 Dhtkd1‐/‐
/Gcdh‐/‐	 mice	 in	 turn	 questions	 our	 initial	 hypothesis	 of	 blocking	 DHTKD1	
function	to	rescue	the	clinical	phenotype	of	GA‐I.		
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Figure	7:	Clinical	and	behavioral	analysis	of	Dhtkd1−/−Gcdh	−/−	mice	on	different	diets:	A.	weight	
loss	measured	after	24	hrs	of	 lysine	treatment	B.	Lethargic	behavior	was	measured	by	keeping	
mice	into	an	arena	with	quardrants	and	locomotor	activity	was	observed	with	in	a	time	span	of	
30	sec	(no	diet;	high‐lysine	in	chow;	chow	and	water).	WT	=	Gcdh+/+/Dhtkd1+/+(n	=	8;6;7);	D:mut	
=	 Gcdh+/+/Dhtkd1−/−(n	 =	 5;5;7);	 G:mut	 =Gcdh−/−/Dhtkd1+/+(n	 =	 5;5;5);	 GD:mut	 =	
Gcdh−/−/Dhtkd1−/−(n	=	5;5;6).	*Fisher's	Exact	test:	P	<	0.05;	Source:	Biagosch	et	al	2017	
	
3.1.4.3.1.2.	The	biochemical	phenotypes	of	Dhtkd1‐/‐/Gcdh‐/‐	and	
Gcdh‐/‐	mice	do	not	differ	
	
Next	 we	 tested	 whether	 the	 same	 holds	 true	 biochemically,	 by	 measuring	
different	metabolites	(GA,	OA	and	AA)	in	the	liver	and	brain	homogenates	in	all	
the	four	different	genotypes	Dhtkd1‐/‐/Gcdh+/+,	Dhtkd1+/+/Gcdh‐/‐,	Dhtkd1‐/‐/Gcdh‐
/‐	and	Dhtkd1+/+/Gcdh+/+	upon	standard	diet,	high	 lysine	diet	and	chow	+	water	
diet,	using	GCMS.	Additionally,	we	also	measured	glutaryl	carnitine	(CD5),	which	
serves	 as	 a	 biological	marker	 for	 GA‐I	 detection	 in	 newborn	 screening	 (Sauer,	
Okun,	Fricker,	Mahringer,	Müller,	et	al.,	2006).	Biochemically,	we	expected	a	rise	
in	OA	and	AA	 levels	 in	Dhtkd1‐/‐/Gcdh‐/‐	mice	as	compared	 to	Dhtkd1+/+/Gcdh‐/‐	
and	Dhtkd1+/+/Gcdh+/+	mice.	With	respect	to	GA	levels,	we	expected	a	decrease	in	
Dhtkd1‐/‐/Gcdh‐/‐	mice	compared	to	Dhtkd1+/+/Gcdh‐/‐	mice.	We	first	started	with	
looking	 for	 differences	 in	 the	 OA	 levels.	 Overall,	 we	 did	 not	 observe	 any	
statistically	 significant	 changes	 of	 OA	 levels	 in	 Dhtkd1‐/‐/Gcdh+/+mice	 and	 the	
Dhtkd1‐/‐/Gcdh‐/‐	 mice	 compared	 to	 control	 mice	 in	 all	 the	 dietary	 regimen	
supplied.	(figure	8A&B).		
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Figure	8:	Graphs	 showing	OA	 levels	 in	 brain	 and	 liver:	Biochemical	 analyses	 of	 OA	 levels	 in	
brain	(A)	 and	 liver	 tissues	(B)	of	double	knockout	mice	 (Dhtkd1‐/‐/Gcdh‐/‐),	Dhtkd1	Knockout	
mice	(Dhtkd1‐/‐/Gcdh+/+),	Gcdh	Knockout	mice	(Dhtkd1+/+/Gcdh‐/‐)	as	compared	to	control	mice	
(Dhtkd1+/+/Gcdh+/+)	on	no	diet	or	high‐lysine	diet	or	chow	+	water	diet.	No	diet=	standard	diet	
(age	of	39.2	days	(sd	±	7.7));	chow	4.7%=high	lysine	in	chow	(age	of	39.7	days	(sd	±	3.5));	4.7%	
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chow+water=high	 lysine	 in	chow	and	water	(age	of	36.2	days	(sd	±	4.8));	n≥5	for	OA;	Data	 is	
presented	as	mean	and	error	bars	indicate	standard	deviation	(sd).	
	
With	regard	to	the	AA	levels	(n=4)	in	brain,	there	were	no	statistically	significant	
differences	 observed	 in	 all	 the	 genotypes	 and	 diets	 tested	 (figure	 9A).	 On	 the	
other	 hand	 in	 the	 liver	 samples	 of	 Dhtkd1‐/‐/Gcdh+/+	 mice,	 we	 observed	
significantly	 increased	 (P	 	 0.05;	 two	 way	 ANOVA	 for	 multiple	 comparisons;	
Fisher’s	LSD)	AA	levels	on	standard	diet	and	also	after	high	lysine	diet	compared	
to	 Dhtkd1+/+/Gcdh+/+	 mice	 (see	 3.1.4.2)	 (figure	 9B).	 As	 expected	 the	
Dhtkd1+/+/Gcdh‐/‐	mice	 did	 not	 show	 any	 rise	 in	 AA	 levels	 on	 standard	 diet	 as	
well	as	high	lysine	diet.	The	AA	levels	in	the	liver	tissue	lysates	of	Dhtkd1‐/‐/Gcdh‐
/‐	mice	on	high	 lysine	diet	 showed	a	 increase	 (5	±	0.5	 fold)	as	 compared	 to	 the	
Dhtkd1+/+/Gcdh+/+	mice	 P	 	 0.05;	 two	 way	 ANOVA	 for	 multiple	 comparisons;	
Fisher’s	LSD;	figure	9B).		
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Figure	9:	Graphs	 showing	AA	 levels	 in	 brain	 and	 liver:	Biochemical	 analyses	 of	 AA	 levels	 in	
brain	(A)	 and	 liver	 tissues	(B)	of	double	knockout	mice	 (Dhtkd1‐/‐/Gcdh‐/‐),	Dhtkd1	Knockout	
mice	(Dhtkd1‐/‐/Gcdh+/+),	Gcdh	Knockout	mice	(Dhtkd1+/+/Gcdh‐/‐)	as	compared	to	control	mice	
(Dhtkd1+/+/Gcdh+/+)	on	no	diet	or	high‐lysine	diet	or	chow	+	water	diet.	No	diet=standard	diet	
(age	of	39.2	days	(sd	±	7.7));	chow	4.7%=high	lysine	in	chow	(age	of	39.7	days	(sd	±	3.5));	4.7%	
chow+water=high	lysine	in	chow	and	water	(age	of	36.2	days	(sd	±	4.8));	n=3‐4	for	AA;	Data	is	
presented	as	mean	and	error	bars	indicate	standard	deviation	(sd).	(	represents	P		0.05;	two	
way	ANOVA	for	multiple	comparisons;	Fisher’s	LSD).	
	
In	 the	 next	 steps,	 we	 determined	 the	 GA	 levels	 in	 both	 brain	 and	 liver	 tissue	
lysates	 of	 the	 Dhtkd1+/+/Gcdh‐/‐	mice.	 As	 expected,	 in	 the	 brain	 tissue	 lysates,	
Dhtkd1+/+/Gcdh‐/‐	mice	 showed	 a	 significant	 accumulation	 (P	 	 0.05;	 two	 way	
ANOVA	 for	multiple	 comparisons;	 Fisher’s	 LSD)	 of	 GA	 levels	 on	 standard	 diet	
(60.23	±	9.25	fold	increase),	on	high	lysine	diet	(30.92	±	11.8	fold	increase)	and	
on	chow	+	water	diet	(33.43	±	8.95	fold	increase)	compared	to	Dhtkd1+/+/Gcdh+/+	
mice	(figure	10A).	In	the	liver	tissue	lysates,	Dhtkd1+/+/Gcdh‐/‐	mice	showed	the	
same	 pattern	 of	 significant	 GA	 accumulation	 as	 that	 seen	 in	 the	 brain	 tissue	
lysates	(P		0.05;	two	way	ANOVA	for	multiple	comparisons;	Fisher’s	LSD).	We	
observed	a	significant	increase	in	GA	levels	on	standard	diet	(46.17	±	12.05	fold	
increase),	 on	 high	 lysine	 diet	 (27.39	 ±	 15.96	 fold	 increase)	 and	 on	 chow	 plus	
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water	 diet	 (25.01	 ±	 16.75	 fold	 increase)	when	 compared	 to	Dhtkd1+/+/Gcdh+/+	
mice	 (figure	 10B).	 Also,	 when	 compared	 to	 the	 Dhtkd1‐/‐/Gcdh+/+	 mice,	
Dhtkd1+/+/Gcdh‐/‐	mice	 showed	 significantly	 increased	GA	 levels	 in	 brain	 tissue	
lysates	on	standard	diet	(41	±	6.3	fold	increase),	high	lysine	diet	(4.5	±	1.73	fold	
increase)	 and	 chow	 plus	 water	 diet	 (24.6	 ±	 6.6	 fold	 increase)	 (figure	 10A).	
Similarly,	 in	 the	 liver	 tissue	 lysates,	 the	Dhtkd1+/+/Gcdh‐/‐	mice	 as	 compared	 to	
the	Dhtkd1‐/‐/Gcdh+/+	mice	 showed	 a	 significant	 accumulation	 on	 standard	 diet	
(12.2	±	3.2	fold	 increase),	high	 lysine	diet	(5.75	±	3.35	fold	increase)	and	chow	
plus	water	diet	(9.2	±	6.15	fold	increase)	(P		0.05;	two	way	ANOVA	for	multiple	
comparisons;	Fisher’s	LSD)	(figure	10B).		
	
Surprisingly,	the	Dhtkd1‐/‐/Gcdh‐/‐	mice	also	showed	increased	GA	concentrations	
as	 compared	 to	 the	Dhtkd1+/+/Gcdh+/+	mice,	 similar	 to	 that	of	Dhtkd1+/+/Gcdh‐/‐	
mice.	In	brain	tissue	lysates,	we	observed	a	significant	accumulation	of	GA	levels	
(P		0.05;	two	way	ANOVA	for	multiple	comparisons;	Fisher’s	LSD)	on	standard	
diet	(50.57	±	10.2	fold	increase),	on	high	lysine	diet	(42	±	9.5	fold	increase)	and	
on	 chow	 plus	 water	 diet	 (38.5	 ±	 15.3	 fold	 increase)	 compared	 to	 the	
Dhtkd1+/+/Gcdh‐/‐	mice	(figure	10A).	Similarly,	the	liver	tissue	lysates	of	Dhtkd1‐/‐
/Gcdh‐/‐	mice	 also	 showed	 a	 significant	 accumulation	 of	 GA	 levels	 on	 standard	
diet	(35.2	±	8.27	fold	increase),	on	high	lysine	diet	(27.02	±	13.08	fold	increase)	
and	 on	 chow	 plus	 water	 diet	 (34.27	 ±	 16.9	 fold	 increase)	 compared	 to	 the	
Dhtkd1+/+/Gcdh+/+mice	(figure	10B).	These	results	contradicted	our	initial	idea	of	
exploiting	Dhtkd1	inhibition	as	novel	therapeutic	strategy	in	GA‐I.		
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Figure	10:	 Graphs	 showing	 GA	 levels	 in	 brain	 and	 liver:	Biochemical	 analyses	 of	 GA	 levels	 in	
brain	 (A)	 and	 liver	 tissues	 (B)	 of	 double	 knockout	mice	 (Dhtkd1‐/‐/Gcdh‐/‐),	 Dhtkd1	 Knockout	
mice	 (Dhtkd1‐/‐/Gcdh+/+),	 Gcdh	 Knockout	 mice	 (Dhtkd1+/+/Gcdh‐/‐)	 as	 compared	 to	 the	 control	
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mice	(Dhtkd1+/+/Gcdh+/+)	on	no	diet	or	high‐lysine	diet	or	chow	+	water	diet.	No	diet=standard	
diet	(age	of	39.2	days	(sd	±	7.7));	chow	4.7%=high	lysine	in	chow	(age	of	39.7	days	(sd	±	3.5));	
4.7%	chow+water=high	lysine	in	chow	and	water	(age	of	36.2	days	(sd	±	4.8));	n≥5	for	GA;	Data	
is	presented	as	mean	and	error	bars	indicate	standard	deviation	(sd)	(	represents	P		0.05;	two	
way	ANOVA	for	multiple	comparisons;	Fisher’s	LSD).	
	
Since	we	did	not	observe	a	reduction	 in	GA	 levels	 in	 the	Dhtkd1‐/‐/Gcdh‐/‐	mice,	
we	 further	 aimed	 to	 test,	 if	 this	 holds	 true	 with	 respect	 to	 glutaryl	 carnitine	
(C5DC)	 levels	(n	=	4).	We	did	not	observe	any	significant	differences	(P		0.05;	
two	way	 ANOVA	 for	multiple	 comparisons;	 Fisher’s	 LSD)	 in	 the	 CD5	 levels	 of	
Dhtkd1‐/‐/Gcdh+/+	 mice	 when	 compared	 to	 Dhtkd1+/+/Gcdh+/+	 mice	 under	
standard	 diet	 and	 high	 lysine	 diet	 conditions	 in	 both	 liver	 and	 brain	 tissue	
lysates	 (figure	 11	A&B).	When	we	 compared	 the	 CD5	 levels	 in	 liver	 and	 brain	
samples	of	Dhtkd1‐/‐/Gcdh+/+	mice	to	that	of	Dhtkd1+/+/Gcdh‐/‐	mice,	we	observed	
a	 significant	 rise	 in	 CD5	 levels	 of	 Dhtkd1+/+/Gcdh‐/‐	mice	 under	 standard	 diet	
(brain,	 5.6	±	 3.35	 fold	 increase;	 liver,	 23.2	±	2.4	 fold	 increase)	 and	high	 lysine	
diets	(brain,	8.34	±	5	fold	increase;	liver,	38.6	±	28.7	fold	increase).	In	the	brain	
tissue	 lysates	of	Dhtkd1+/+/Gcdh‐/‐mice,	we	observed	a	significant	up	regulation	
(P		0.05;	two	way	ANOVA	for	multiple	comparisons;	Fisher’s	LSD)	of	CD5	levels	
under	 high	 lysine	 diet	 (5.35	 ±	 3.21	 fold	 increase)	 as	 compared	 to	
Dhtkd1+/+/Gcdh+/+	 mice.	 In	 case	 of	 liver	 lysates,	 the	 Dhtkd1+/+/Gcdh‐/‐mice	
showed	a	significant	up	regulation	of	CD5	levels	 in	both	standard	diet	and	also	
under	 high	 lysine	 diet	 (17.45	 ±	 12.96	 fold	 increase)	 when	 compared	 to	 the	
Dhtkd1+/+/Gcdh+/+	mice	(figure	11	A&B).	
	
When	we	compared	the	CD5	levels	of	Dhtkd1+/+/Gcdh+/+	mice	to	that	of	Dhtkd1‐/‐
/Gcdh‐/‐	mice,	in	brain	and	liver	tissue	lysates,	we	found	a	significant	increase	(P	
	 0.05;	 two‐way	ANOVA	 for	multiple	 comparisons;	 Fisher’s	 LSD)	 in	 CD5	 levels	
upon	high	 lysine	diet	 (brain,	 6.03	±	 2.97	 fold	 increase;	 liver,	 12.76	±	 6.24	 fold	
increase),	 similar	 to	 the	 pattern	 observed	 for	 GA	 levels.	 We	 also	 observed	 an	
increase	in	CD5	levels	significantly	in	brain	lysates	of	Dhtkd1‐/‐/Gcdh‐/‐	mice	(9.4	
±	 4.6	 fold	 increase)	 under	 high	 lysine	 diet	 and	 in	 liver	 lysates	 under	 both	
standard	 diet	 (17.3	 ±	 8	 fold	 increase)	 and	 high	 lysine	 diets	 (28.3	 ±	 13.8	 fold	
increase)	as	 compared	 to	Dhtkd1‐/‐/Gcdh+/+	mice	 (figure	11	A&B).	 Similarly,	we	
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also	 observed	 a	 rise	 in	 CD5	 levels	 in	 both	Dhtkd1+/+/Gcdh‐/‐mice	 and	Dhtkd1‐/‐
/Gcdh‐/‐	mice	in	both	standard	diet	and	high	lysine	diet	in	both	the	brain	and	liver	
tissue	samples,	replicating	the	pattern	seen	for	GA	levels	(figure	11	A&B).	
	
The	 increase	 in	 GA	 levels	 in	Dhtkd1‐/‐/Gcdh‐/‐	mice	 similar	 to	Dhtkd1+/+/Gcdh‐/‐	
mice	shows	that	 the	Knockout	of	Dhtkd1	 in	Gcdh	knockout	mice	did	not	rescue	
the	biochemical	phenotype	of	GA‐I.	The	increase	in	CD5	levels	in	Dhtkd1‐/‐/Gcdh‐
/‐	mice	 compared	 to	 Dhtkd1+/+/Gcdh	 +/+	mice	 or	Dhtkd1‐/‐/Gcdh+/+	mice	 further	
strengthens	the	idea	that	Dhtkd1	may	not	be	an	effective	therapeutic	strategy	to	
treat	GA‐1	disorder	either	clinically	or	biochemically.	
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Figure	 11:	 Graphs	 showing	 CD5	 levels	 in	 brain	 and	 liver:	 Biochemical	 analyses	 of	 glutaryl	
carnitine	 (CD5)	 levels	 in	 brain	 (A)	 and	 liver	 tissues	 (B)	 of	 double	 knockout	 mice	 (Dhtkd1‐/‐
/Gcdh‐/‐),	Dhtkd1	Knockout	mice	 (Dhtkd1‐/‐/Gcdh+/+),	Gcdh	Knockout	mice	 (Dhtkd1+/+/Gcdh‐/‐)	
as	compared	to	control	mice	(Dhtkd1+/+/Gcdh+/+)	on	no	diet	or	high‐lysine	diet	or	chow	+	water	
diet.	No	diet=standard	diet	(age	of	39.2	days	(sd	±	7.7));	chow	4.7%=high	lysine	in	chow	(age	of	
39.7	days	(sd	±	3.5));	4.7%	chow+water=high	lysine	in	chow	and	water	(age	of	36.2	days	(sd	±	
4.8));	n=3‐4	for	CD5;	Data	is	presented	as	mean	and	error	bars	indicate	standard	deviation	(sd)	
(	represents	P		0.05;	two‐way	ANOVA	for	multiple	comparisions;	Fisher’s	LSD).	
	
3.2.	AADAT	as	an	alternative	target	for	treating	GA‐1	patients?	
	
Our	results	clearly	indicated	that	DHTKD1	is	not	a	suitable	drug	target	in	GA‐I.	
In	the	next	steps	we	employed	a	similar	strategy	as	that	followed	for	DHTKD1,	
targeting	AADAT.	To	achieve	this,	we	performed	siRNA	mediated	knock	down	
of	 AADAT	 on	 patient	 fibroblasts,	 tested	 the	 effect	 of	 AADAT	 inhibitor	 PF‐
04859989	on	patient	 and	 control	 fibroblasts	 and	 later	moved	on	 to	 knocking	
out	AADAT	in	GCDH	Knockout	cell	models	by	employing	CRISPR/Cas9	method.	
	
3.2.1.	siRNA	mediated	knockdown	of	AADAT 
First,	we	performed	 siRNA‐mediated	AADAT	knockdown	experiments	 in	GA‐I	
patient	fibroblast.	siRNA	transfections	were	done	using	electroporation	or	lipid	
mediated	 methods.	 Fibroblasts	 did	 not	 survive	 electroporation	 mediated	
transfection,	 however,	 we	 were	 successful	 in	 transfecting	 the	 fibroblasts,	 by	
employing	 lipofectamine	RNAi	max	method.	Different	concentrations	of	siRNA	
(5	nM,	10	nM,	25	nM,	50	nM)	(figure	12)	were	transfected	into	fibroblasts,	cell	
lysates	 were	 made	 72	 h	 after	 transfection	 and	 analyzed	 by	 western	 blot.	
Surprisingly,	 we	 did	 not	 observe	 any	 reduction	 in	 AADAT	 levels	 after	 siRNA	
knockdown	 at	 all	 concentrations	 tested	 (figure	 12)	 compared	 to	 the	 mock	
control	and	the	non‐targeting	control.		
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Figure	12:	siRNA	mediated	knock	down	of	AADAT:	Western	blot	showing	knock	down	
efficiency	of	AADAT	after	transfection	with	AADAT	siRNA	(5	nM,	10	nM,	25	nM,	50	nM)	in	
comparison	to	the	non‐targeting	control	(NTC)	and	mock	control.	Actin	was	used	as	a	loading	
control.	 
	
3.2.2.	Inhibition	of	AADAT	by	PF‐04859989	in	vitro	
	
In	 the	next	steps,	we	aimed	 to	 test	 the	activity	of	AADAT	 in	 the	presence	and	
absence	 of	 PF‐04859989	 (50	 µM),	 a	 known	 and	 specific	 to	 AADAT/KAT‐II	
inhibitor.	To	perform	this,	we	took	the	cell	lysates	from	GA‐I	patient	fibroblasts	
and	incubated	them	with	and	without	PF‐04859989	for	different	time	points	(0	
h,	 0.5	 h,	 1	 h)	 in	 AADAT	 activity	 assay	 buffer	 and	 2‐oxoadipate	 levels	 were	
measured	by	GCMS.	We	observed	a	 significant	 reduction	 in	AADAT	activity	 in	
the	presence	of	inhibitor,	when	compared	to	the	controls	at	all	the	time	points	
tested	(at	0	h,	0.32		0.07	fold	reduction;	at	0.5	h,	0.27		0.01	fold	reduction;	at	
1h,	0.27		0.05	fold	reduction	compared	to	their	respective	controls;	P		0.05;	
statistical	test;	students	T	test)	(figure13).		
	
	
	
	
	
AADAT 
Actin 
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Figure	13:	Analysis	of	2‐oxoadipate	levels	in	the	presence	and	absence	of	inhibitor	at	different	
time	points:	Data	was	normalized	to	control	0	h	sample	values	and	error	bars	indicate	standard	
deviation	(sd)		represents	P		0.05;	statistical	test:	students	T	test.	
	
3.2.3.	 Effect	 of	 lysine	 stress	 induction	 on	 GA	 levels	 of	 GA‐I	
patient	and	control	fibroblasts		
	
In	the	next	steps	we	wanted	to	establish	a	cell	culture	model	to	further	test,	 if	
PF‐04859989	 prevents	 GA	 production.	 To	 this	 end	 we	 applied	 GA‐I	 patient‐
derived	 fibroblasts.	 These	 cells	 produce	 only	 small	 amounts	 of	 GA	due	 to	 the	
fact	 that	 fibroblasts	 display	 a	 rather	 slow	metabolism	 and,	 in	 addition,	 their	
lysine	metabolism	 is	 virtually	 inactive	 under	 nutrient	 conditions	 of	 standard	
media.	Therefore	we	tested	if	we	could	enhance	the	biochemical	phenotype	of	
patient‐derived	fibroblasts.	Similar	to	mice	experiments,	we	exposed	these	cells	
to	high	lysine	stress.	In	brief,	we	first	starved	the	patient	and	control	fibroblasts	
overnight	and	put	them	under	lysine	(5	mM)	stress	for	next	3	consecutive	days,	
by	changing	the	old	medium	and	replacing	with	lysine	containing	medium	each	
day.	 Finally,	 the	 cells	 were	 lysed	 and	 GA	 levels	 using	 were	 quantitatively	
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detected	 using	 GCMS.	 We	 saw	 a	 significant	 rise	 in	 GA	 levels	 in	 both	 tested	
patient	fibroblasts	cell	lines	(Patient	1,	8268.3	±	1235.4	fold	increase;	patient	2,	
3.68	±	 0.76	 fold	 increase	 compared	 to	 their	 respective	without	 lysine	 treated	
samples;	 P	 	 0.05;	 one‐way	 ANOVA	 for	 both;	 Fisher’s	 LSD)	 compared	 to	 the	
lysine	untreated	samples.	As	expected,	GA	 levels	 in	 the	control	cells	remained	
same	before	and	after	lysine	treatment	(figure	14).		
		
Figure	14:	Measurement	of	GA	levels	in	patient	and	control	fibroblasts:	GA	levels	in	patient	and	
control	 fibroblasts	 with	 lysine	 and	 without	 lysine	 treatment.	 N=3	 independent	 experiments,	
Data	 is	 presented	 as	mean	 and	 error	 bars	 indicate	 standard	 deviation	 (SD)		 represents	P		
0.05;	one‐way	ANOVA	for	multiple	comparisons;	Fisher’s	LSD	test.	
3.2.4.	 Effect	 of	 AADAT	 inhibitor	 on	 GA	 levels	 of	 patient	 and	
control	fibroblasts	
After	observing	a	rise	in	GA	accumulation	after	lysine	treatment	in	GA‐I	patient	
fibroblasts	(figure	14),	we	aimed	to	inhibit	the	same	(GA	accumulation)	in	both	
GA‐I	 patient	 there	 is	 no	 increase	 in	 controls	 by	 targeting	 AADAT	 using	 PF‐
0485998.	We	starved	the	cells	overnight	and	the	following	day	kept	them	under	
lysine	 (5	mM)	stress	 together	with	different	 concentrations	of	 inhibitor	along	
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with	 lysine	 (lys+1	 μM,	 lys+10	 μM,	 lys+50	 μM)	or	 incubating	 them	 only	 with	
inhibitor	without	additional	lysine	in	the	medium	(only	1	μM,	only	10	μM,	only	
50	μM)	for	the	next	3	consecutive	days,	by	adding	lysine	and	inhibitor	each	day.	
Cells	 were	 then	 lysed	 and	 GA	 accumulation	 was	 observed	 using	 GCMS.	
Unexpectedly,	we	saw	a	very	poor	and	non‐significant	rise	in	GA	levels	in	both	
the	 patient	 (1&2)	 fibroblasts	 (figure	 15)	 after	 lysine	 treatment.	 This	 poor	
metabolic	response	to	the	applied	inhibitor,	which	is	in	contrast	to	our	previous	
study,	 was	 reproduced	 in	 four	 independent	 experiments	 (n=4).	 Overall,	 the	
instability	of	the	biochemical	phenotype	of	GA‐I	patient	fibroblasts	questioned	
the	suitability	of	this	cell	system	for	further	inhibitor	studies.	
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Figure	15:	GA	levels	in	patient	and	control	fibroblasts	following	inhibitor	treatment;	GA	levels	
after	treating	with	only	lysine	(only	lysine),	lysine	+	inhibitor	(lys+1	μM,	lys+10	μM,	lys+50	μM)	
and	only	inhibitor	(only	1	μM,	only	10	μM,	only	50	μM).	Figures	also	show	untreated	samples;	A.	
patient	1;	B.	patient	2;	C.	control	1;	D.	control	2	Data	was	normalized	to	the	untreated	sample	
(n=4	independent	experiments).	
3.3.	Generation	of	alternative	GA‐I	cell	culture	models	
	
3.3.1.	CRISPR/Cas9‐mediated	generation	of	knockout	cells	
	
In	order	to	successfully	simulate	the	biochemical	effect	of	loss	of	GCDH	activity,	
we	aimed	to	switch	to	a	more	suitable	cell	model.	To	this	end	we	employed	HEK	
and	HeLa	cells,	which	are	fast	growing	and	easy	to	transfect	cells.	We	aimed	to	
generate	 GCDH	 Knockout,	 AADAT	 Knockout	 and	 double	 Knockouts	 (GCDH‐/‐
/AADAT‐/‐)	in	HEK	 and	HeLa	 cells	 by	 utilizing	 CRISPR/Cas9	methodology.	We	
used	PX459	plasmid	containing	Cas9	gene	and	puromycin	antibiotic	resistance	
gene	(figure	16A)	to	clone	gRNAs	against	GCDH	or	AADAT.	HEK	and	HeLa	cells	
were	 successfully	 transfected	 with	 CRISPR/cas9	 plasmids	 containing	 gene	
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specific	 gRNAs	 against	 GCDH	 or	 AADAT.	 After	 twenty	 four	 hours	 after	
transfection,	 transfected	 cells	were	kept	under	Puromycin	 antibiotic	 pressure	
continuously	for	four	days	until	all	the	cells	died	in	mock	(transfection	reagent	
was	used	as	mock)	transfected	conditions.	The	cells	survived	under	Puromycin	
antibiotic	pressure	were	further	subjected	to	Western	blot	analysis.	Absence	of	
GCDH	or	AADAT	expression	in	knockout	samples	in	comparison	to	the	controls,	
confirmed	 the	 generation	 of	 knockouts	 (figure	 16B,	 C,	D).	 The	Knockout	 cells	
were	 further	 screened	 for	 single	 cell	 clonal	 selection	 (figure	 16E).	 The	 single	
cell	clones	for	GCDH	Knockout	were	observed	to	be	indeed	true	Knockouts,	as	
seen	by	the	absence	of	GCDH	protein	via	immunoblotting.	From	these	single	cell	
clones,	HeLa	9(4)	(figure	16	E)	and	HEK	6	were	used	for	further	experiments.	
However,	 for	 AADAT,	 despite	 absence	 of	 the	 band	 for	 AADAT	 protein	 in	
western	blot	analysis	(figure	16C),	the	single	cell	clones	showed	AADAT	protein	
and	hence	were	not	used	for	further	analysis.		
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Figure	 16:	 Generation	 of	 HEK	 and	 HeLa	 GCDH	 and	 AADAT	 knockout	 cells	 A:	 Schematic	
representation	 of	 PX459	 plasmid	 containing	 Cas9	 gene	 and	 Puromycin	 antibiotic	 resistance	
gene	B:	The	upper	panel	shows	GCDH	expression	only	in	controls	but	not	in	the	knockouts	and	
the	 lower	 panel	 represents	 actin	 as	 the	 loading	 control.	 HEK6,	 HeLa6;	 HEK9,	 HeLa9‐	 GCDH	
knockouts;	HEK	ctrl,	HeLa	ctrl‐	controls.	C:	The	upper	panel	shows	AADAT	expression	only	in	
HeLa	ctrl,	HeLa	ctrl	5	&	6.	In	HeLa	4	&	11	no	expression	of	AADAT	is	seen,	showing	the	presence	
of	knockout.	The	lower	panel	represents	actin	as	the	loading	control.	D:	The	upper	panel	shows	
AADAT	 expression	 in	 all	 samples,	 but	 AADAT	 expression	 is	 slightly	 reduced	 in	 HEK	 6,	 3&4	
showing	 the	 presence	 of	 putative	 double	 Knockout.	 The	 lower	 panel	 represents	 actin	 as	 the	
loading	control	(numbering	for	all	the	blots	is	done	for	internal	reference).	E.	Single	cell	clones	
generated	 from	HeLa	6	and	HeLa9	GCDH	Knockouts	 (see	B).	The	upper	panel	 showing	GCDH	
knockout,	seen	clearly	in	HeLa	6	(1),	HeLa	6	(2),	HeLa	9	(4).	The	lower	panel	represents	actin	as	
loading	control.	
3.3.2.	Analysis	of	GA	levels	in	GCDH	Knockout	and	control	cells	
after	inhibitor	treatment	
	
To	check	 the	effect	of	PF‐0485998	on	GA	production	 levels	 in	GCDH	Knockout,	
GCDH	 Knockout	 cells	 and	 control	 cells	 were	 treated	 with	 and	 without	 lysine,	
along	 with	 different	 concentrations	 of	 AADAT	 inhibitor.	 As	 expected	 in	 the	
control	HEK	and	HeLa	cells,	we	did	not	observe	any	significant	differences	in	GA	
production	after	 lysine	 treatment	 in	comparison	to	untreated	cells	(Figure	17A	
&C;	 P	 ≥	 0.05;	 one	 way	 ANOVA	 for	 multiple	 comparisons;	 Fisher’s	 LSD).	 Upon	
lysine	 treatment,	we	 observed	 that	 GCDH	Knockout	 showed	 an	 increase	 in	GA	
accumulation,	in	both	HEK	(21.99		6.4	fold	increase;	P		0.05;	one	way	ANOVA	
for	multiple	 comparisons;	 Fisher’s	LSD,	Figure	17C)	 and	HeLa	 cells	 (1.2		 0.98	
fold	increase;	P	≥	0.05;	one	way	ANOVA	for	multiple	comparisons;	Fisher’s	LSD,	
Figure	 17D),	 when	 compared	 to	 their	 respective	 lysine	 untreated	 controls.	 In	
HEK	cells	with	GCDH	knockout,	we	observed	a	significant	reduction	in	GA	levels	
when	treated	with	 lysine	plus	50	µM	concentration	of	AADAT	inhibitor	(0.59		
0.06	fold	decrease;	P		0.05;	one	way	ANOVA	for	multiple	comparisons;	Fisher’s	
LSD,	 Figure	 17C)	 compared	 with	 only	 lysine	 treated	 cells.	 In	 HeLa	 GCDH	
Knockouts,	we	observed	a	profound	reduction	in	GA	levels	upon	lysine	treatment	
after	 addition	 of	 even	 only	 1	 µM	 inhibitor	 (0.39		 0.1	 fold	 decrease;	 one	way	
ANOVA	 for	multiple	 comparisons;	 Fisher’s	 LSD,	 Figure	 17D)	 concentrations	 of	
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inhibitor	compared	with	lysine	alone	treated	cells.	These	results	clearly	indicate	
that	 inhibition	of	AADAT	with	PF‐0485998	 concentration‐dependently	 reduces	
the	GA	levels	in	GCH	Knockout	conditions.	
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Figure	17:	Graphs	showing	the	effect	of	AADAT	inhibitor	on	GA	levels	in	HEK	and	HeLa	KO	cells	
and	controls.	Data	was	normalized	to	 the	untreated	sample.	A,	B,	C,	D	represents	GA	 levels	 in	
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HEK	 (control),	 HEK	GCDH‐/‐(HEK	 GCDH	 knockout),	 HeLa	 (control),	 HeLa	GCDH‐/‐(HeLa	 GCDH	
knockout)	 respectively	 at	 different	 concentrations	 of	 inhibitor	with	 lysine	 (lys+0.1	 μM,	 lys+1	
μM,	lys+10	μM,	lys+50	μM)	and	only	inhibitor	(only	0.1	μM,	only	1	μM,	l	only	10	μM,	only	50	μM)	
used.	Figures	also	show	untreated	and	only	lysine	(only	lys)	treated	samples.	N=3	independent	
experiments,	 (	 represents	P		 0.05;	 one‐way	ANOVA	 for	multiple	 comparisons;	Fisher’s	LSD	
test	(for	HEK	GCDH	knockout),	Tukey’s	multiple	comparision	test	(for	HeLa	GCDH	knockout).	
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4.	Discussion	
	
GA‐I	 is	 an	 autosomal	 recessive	 cerebral	 organic	 aciduria	 caused	 by	 defective	
GCDH,	 a	 key	 enzyme	 in	 the	 catabolic	 pathways	 of	 lysine,	 OH‐lysine	 and	
tryptophan.	 This	 disease	 is	 complicated	 by	 acute	 or	 insidious‐onset	 striatal	
damage	 precipitated	 by	 episodes	 that	 are	 likely	 to	 induce	 catabolism	 and	
occurring	as	a	 result	of	 the	accumulation	of	 the	 toxic	metabolites	GA,	3‐OH	GA	
and	glutaryl‐CoA	(Stefan	Kölker	et	al.,	2011).	After	early	diagnosis	via	newborn	
screening	 (NBS),	 neonatal	 start	 and	 adherence	 to	 the	 recommended	 dietary	
treatment	prevents	striatal	 lesions	 in	 the	majority	of	patients	(Boy,	Mengler,	et	
al.,	2018).	However,	several	recent	clinical	follow‐up	studies	raise	concern	about	
the	efficacy	of	the	current	dietary	treatment	and	questions	whether	this	dietary	
treatment	leads	to	a	life	long	disease‐free	state	in	all	the	affected	individuals.	The	
answer	 seems	 to	 be	 ambiguous,	 since	many	 patients	who	 are	 diagnosed	 early	
and	 received	 proper	 metabolic	 and	 emergency	 maintenance	 treatment	 still	
suffer	 from	extra‐striatal,	 extra‐cerebral	 and	non‐neurologic	 abnormalities	 like	
changes	in	white	matter	(Tuncel	et	al.,	2018),	sub‐ependymal	mass	lesions	(Boy,	
Heringer,	 et	 al.,	 2017;	 Harting	 et	 al.,	 2015),	 peripheral	 polyneuropathy	
(Herskovitz	et	al.,	2013a)	and	chronic	renal	failure	(S	Kölker,	Valayannopoulos,	
et	al.,	2015)	suggesting	that	the	disease	course	extends	to	other	organs	as	well.	
This	 in	 turn	 clearly	 highlights	 the	 fact	 that	 there	 is	 an	 immediate	 need	 for	
employing	novel	therapeutic	interventions,	for	a	disease‐free	long‐term	outcome	
in	GA‐I	patients.		
	
Our	current	study	aims	to	explore	several	novel	ways	to	treat	patients	with	GA‐I.	
For	the	first	time,	we	tested	inhibition	of	enzymatic	steps	upstream	to	GCDH	step	
(DHTKD1	 and	 AADAT)	 to	 prevent	 toxic	 metabolite	 accumulation	 in	 and	
eventually	improving	the	life	at	later	stages	of	GA‐I	patients.	
	
4.1.	 Inhibiting	of	DHTKD1	 function	does	not	rescue	 the	clinical	
and	biochemical	phenotype	of	Gcdh‐/‐	mice	
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DHTKD1,	 also	 called	 human	 thiamin	 diphosphate	 (ThDP)‐dependent	 2‐
oxoadipate	dehydrogenase	(E1a)	(Nemeria	et	al.,	2018),	is	an	E1‐like	subunit	of	
the	 2‐oxoglutarate	 dehydrogenase	 complex	 (OGDHc).	 It	 has	 been	 shown	 to	
catalyze	 the	 oxidative	 decarboxylation	 of	 2‐oxoadipate	 (OA)	 to	 glutaryl‐CoA	 in	
the	 final	 degradative	 pathway	 of	 L‐lysine,	 OH	 lysine	 and	 L‐tryptophan	
(Danhauser	 et	 al.,	 2012a).	 DHTKD1	 is	 also	 reported	 to	 have	 a	 role	 in	 the	
mitochondrial	 ATP	 production	 and	 functional	 integrity	 as	 shown	 by	 Xu	 and	
coworkers	 (W.	 Xu	 et	 al.,	 2013).	 As	 a	 first	 therapeutic	 target,	 we	 focused	 on	
blocking	 DHTKD1.	 We	 started	 our	 approach	 simultaneously	 in	 vitro	 using	
DHTKD1	patient‐derived	dermal	fibroblasts	and	in	vivo	using	relevant	Knockout	
mouse	models.		
	
In	vitro,	 using	 control	 and	 DHTKD1	 patient‐derived	 fibroblasts,	 we	 tested	 the	
effect	of	several	phosphonate	analogs	of	2‐oxoglutarate	on	DHTKD1	activity	and	
observed	 that	 AP	was	 able	 to	 influence	 the	 enzymatic	 function	 of	DHTKD1,	 as	
seen	 by	 the	 increased	 OA	 levels	 in	 control	 fibroblasts.	 We	 also	 found	 some	
surprising	 observations,	 namely,	 increased	 OA	 levels	 in	 AP‐treated	 DHTKD1	
patient‐derived	fibroblasts.	OA	levels	are	higher	in	DHTKD1	patient	cells	due	to	
loss	of	function	mutations	in	DHTKD1	(Danhauser	et	al.,	2012a).,	however,	here	
we	 found	 that	 the	OA	 levels	 in	 the	DHTKD1	patient‐derived	 fibroblasts	 treated	
with	 AP	 even	 further	 increased,	 whereas	 other	 tested	 compounds	 (GP,	 TEGP,	
TMAP,	DEGP)	did	not	show	an	effect.	This	observation	 is	best	explained	by	co‐
expression	of	other	enzymes	(isoforms	of	DHTKD1‐like	OGDHc,	OGDHL	as	shown	
in	(Goncalves,	Bunik,	&	Brand,	2016;	W.	Xu	et	al.,	2013)),	partially	compensating	
the	loss	of	DHTKD1	function	in	the	lysine	degradation	pathway.	Thus,	AP	might	
have	blocked	these	enzymes,	in	turn	leading	to	a	rise	in	OA	levels.	
	
To	 test	 our	 hypothesis	 in	vivo,	we	 generated	Dhtkd1‐/‐	mice	 using	 TALENS	 and	
crossed	 these	 mice	 with	 the	 well‐characterized	 Gcdh‐/‐	 mice,	 to	 generate	 the	
Dhtkd1‐/‐	/Gcdh‐/‐	mice.	We	 tested	 the	clinical	and	biochemical	characteristics	of	
the	 newly	 generated	 knockout	 mice	 and	 compared	 them	with	 the	 Gcdh‐/‐	 and	
Dhtkd1+/+/	 Gcdh+/+	 mice.	 Dhtkd1‐/‐	 mice	 resembled	 the	 patients	 with	 2‐
aminoadipic	 2‐oxoadipic	 aciduria	 and	 were	 presented	 with	 a	 mild	 or	
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asymptomatic	clinical	phenotype	and	biochemically	showed	increased	AA	levels	
but	 not	 GA	 levels	 (Biagosch	 et	 al.,	 2017).	 In	 Gcdh‐/‐	 mice,	 toxic	 metabolite	
production	and	severe	neurologic	phenotype	as	that	of	the	affected	GA	I	patients	
can	be	induced	by	giving	a	high	lysine	diet	(Sauer	et	al.,	2015).	Mice	with	all	the	
four	 different	 genotypes	 (Dhtkd1‐/‐,	 Gcdh‐/‐,	 Dhtkd1‐/‐	 /Gcdh‐/‐	 and	 Dhtkd1+/+/	
Gcdh+/+)	 were	 fed	 with	 a	 high	 lysine	 diet	 (4.7%	 lysine	 in	 chow)	 and	 we	 then	
checked	for	phenotypic	changes.	For	evaluation	of	the	therapeutic	efficacy	of	our	
treatment,	 weight	 loss,	 seizures	 and	 finally	 death	 were	 considered	 as	 critical	
clinical	 parameters	 and	 GA	 accumulation	 in	 brain	 and	 liver	 tissues	 were	
considered	as	the	biochemical	parameters.		
	
According	 to	 our	 hypothesis,	 because	 of	 the	 knockout	 of	 Dhtkd1,	 the	 toxic	
metabolite	 accumulation	 should	 be	 subsided	 in	 Dhtkd1‐/‐	 /Gcdh‐/‐	mice.	 As	 a	
result,	no	apparent	clinical	changes	should	occur.	To	our	surprise,	we	saw	that	
the	Dhtkd1‐/‐	/Gcdh‐/‐	mice	 exhibited	 a	 drastic	weight	 loss	 of	 >	 15%	 as	well	 as	
showed	 lethargic	 behavior	 upon	 the	 start	 of	 the	 high	 lysine	 diet,	 thereby	
clinically	 resembling	 Gcdh‐/‐	 mice.	 Biochemically,	 Dhtkd1‐/‐	 and	 the	 Dhtkd1‐/‐	
/Gcdh‐/‐	mice	 should	 resemble	DHTKD1	 patients	 and	 show	 accumulation	 of	 OA	
and	AA	with	increased	dietary	lysine,	but	no	GA	production.	As	expected,	in	both	
Dhtkd1‐/‐	and	the	Dhtkd1‐/‐	/Gcdh‐/‐	mice,	with	respect	to	the	OA	levels,	we	saw	a	
slight	 increase	 in	 liver	 samples.	 Also,	we	 observed	 an	 increase	 in	AA	 levels,	 in	
brain	 and	 liver	 samples	 under	 control	 diet,	 in	 both	Dhtkd1‐/‐	 and	 the	Dhtkd1‐/‐	
/Gcdh‐/‐	mice	and	this	was	markedly	increased	upon	high	lysine	diet.	With	regard	
to	 the	GA	 levels,	we	 found	 that	 the	Dhtkd1‐/‐	mice	behaved	as	expected	and	no	
increase	in	GA	levels	were	seen,	but	the	Dhtkd1‐/‐	/Gcdh‐/‐	mice,	similar	to	Gcdh‐/‐	
mice	showed	an	increase	in	GA	levels	on	control	diet	which	rose	profoundly	with	
dietary	 lysine	 supply,	 in	 both	 brain	 and	 liver	 samples,	 contradicting	 our	
hypothesis.	We	also	measured	the	levels	of	glutaryl	carnitine,	which	is	a	valuable	
marker	 for	 neonatal	 and	 high‐risk	 screening	 (S.	 Kölker	 et	 al.,	 2007),	 and	 is	
usually	 found	accumulated	 in	body	 fluids	 (plasma,	CSF,	urine)	of	GA‐I	patients.	
Formation	 of	 glutaryl	 carnitine	 is	 a	 physiological	 detoxifying	 mechanism	 to	
prevent	 accumulation	of	 glutaryl	 –CoA	 (Stefan	Kölker	 et	 al.,	 2011;	 Sauer	 et	 al.,	
2011;	 Seccombe,	 James,	 &	 Booth,	 1986).	 Our	 data	 showed	 similar	 levels	 of	
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glutaryl	 carnitine	 in	 both	 Gcdh‐/‐and	 Dhtkd1‐/‐	 /Gcdh‐/‐	 mice,	 indicating	 that	
glutaryl	 CoA	 is	 the	 precursor	 of	 GA	 in	 both	 the	 model.	 Summarizing,	 genetic	
knockout	 of	 Dhtkd1	 does	 not	 rescue	 the	 clinical	 or	 biochemical	 phenotype	
observed	 in	 Gcdh‐/‐	 mice,	 further	 raising	 questions	 about	 our	 current	
understanding	of	lysine	degradation.		
	
Based	on	our	in	vitro	and	in	vivo	derived	results,	we	assume	that	loss	of	DHTKD1	
activity	was	compensated	by	other	proteins	which	facilitate	the	conversion	of	2‐
OA	 into	 glutaryl‐CoA.	 Different	 studies	 from	 the	 literature	 report	 on	 the	
existence	of	isoforms	of	DHTKD1	namely,	2‐oxoglutarate	dehydrogenase	(OGDH,	
E1o;	EC1.2.4.2)	and	OGDH‐like	protein	(OGDHL,	EC	1.2.4)	(V.	Bunik	&	Degtyarev,	
2008).	 OGDH	 is	 the	 E1o	 subunit	 of	 OGDHc,	 which	 additionally	 includes	
dihydrolipoyl	 succinyl	 transferase	 (DLST,	 E2;	 EC	 2.3.1.61)	 and	 dihydrolipoyl	
dehydrogenase	(DLDH,	E3;	EC1.8.1.4)	as	the	E2	and	E3	subunits	respectively	and	
together	 catalyzes	 the	 oxidative	 decarboxylation	 of	 2‐oxoglutarate	 (α‐
ketoglutarate;	OG)	to	succinyl‐CoA.	The	protein	product	of	DHTKD1	and	OGDHL	
gene	 are	 subunits	 of	 an	 alternative	 OGDHc	 with	 affinities	 for	 different	 but	
structurally	 similar	 substrates	 like	 2‐oxoadipate,	 2‐oxo‐4‐hydroxyglutarate,	
products	of	 carboligase	 reaction	between	2‐oxodicarboxylate	and	acetaldehyde	
or	 glyoxalate	 (V.	 Bunik	 &	 Degtyarev,	 2008;	 V.	 Bunik,	 Kaehne,	 Degtyarev,	
Shcherbakova,	 &	 Reiser,	 2008).	 Also,	 recent	 findings	 from	 Nemeria	 and	
colleagues	 showed	 that	 OGDH	 accepts	 both	 OG	 and	 OA	 as	 specific	 substrates,	
although	 with	 a	 3	 times	 lower	 affinity	 for	 OA	 (Nemeria	 et	 al.,	 2017).	 Little	 is	
known	about	OGDHL.	It	was	shown	to	be	mainly	expressed	in	the	brain	and	favor	
OG	 as	 substrate	 (V.	 Bunik	 et	 al.,	 2008).	 Overall	 OGDH	 or	 OGDHl	 could	
compensate	for	the	loss	of	DHTKD1	activity.	
	
Another	source	of	glutaryl‐CoA	generation	might	be	succinyl‐CoA:glutarate‐CoA	
transferase	(SUGCT)	or	C7Orf10,	which	adds	CoA	from	Succinyl‐CoA	to	glutarate,	
thus	forming	glutaryl‐CoA	(Sherman	et	al.,	2008).	However,	GA	obtained	in	this	
step	 comes	 from	 an	 yet	 unknown	metabolic	 pathway	 or,	more	 likely	 from	 gut	
microbiome	(Backes	et	al.,	2002;	Baric	et	al.,	1999a;	Tomé	&	Bos,	2007)	and	can	
therefore	 only	 account	 for	 GA	 accumulation	 in	 intracerebral	 tissue	 due	 to	 the	
92	
	
extremely	low	permeability	of	the	BBB	for	this	metabolite.	In	summary,	because	
of	the	functional	similarity	of	DHTKD1	to	other	proteins	(OGDH,	OGDHL),	these	
findings	exclude	DHTKD1	as	a	target	protein	for	pharmacological	GA‐I	treatment.	
Moreover,	 DHTKD1	mutations	 have	 been	 suggested	 to	 play	 a	 role	 in	 Charcot‐
Marie‐Tooth	 (CMT)	 disease,	 one	 of	 the	 most	 common	 subgroups	 of	 inherited	
peripheral	neuropathies	(Baets,	Jonghe,	&	Timmerman,	2014).	.	Individuals	with	
CMT	are	 characterized	by	 gradually	 advancing	distal	 neuropathy	 of	 hands	 and	
legs.	CMT	is	divided	into	two	subtypes,	i.e.	CMT1,	where	myelin	derived	from	glia	
is	affected	and	CMT2,	where	the	nerve	axon	is	affected.	A	nonsense	mutation	in	
DHTKD1	in	exon	8	(c.1455T>G	(p.Tyr485*)	was	reported	to	be	associated	with	
CMT2	 leading	 to	 inadequate	 energy	 production	 and	malfunction	 of	 peripheral	
nerves	in	a	Chinese	family	of	affected	individuals	Xu	et	al	2012).	The	implications	
of	this	study	remained	unclear,	since	CMT	and	2	amino	2‐oxoadipdic	aciduria	are	
clinically	 distinct	 disorders	 and	 several	 reports	 have	 confirmed	 mutations	 in	
DHTKD1	in	patients	with	the	latter	disease.	However,	Xu	et	al.	have	shown	in	a	
recent	study	that	old	DHTKD1‐deficient	mice	develop	symptoms	of	CMT2	(W.	Y.	
Xu	 et	 al.,	 2018).	 This	 study	 provides	 another	 argument	 against	 inhibiting	
DHTKD1	as	therapeutic	strategy.		
	
4.2.	Development	of	an	alternative	therapeutic	strategy	
	
Next,	 we	 targeted	 aminoadipate	 aminotransferase	 (AADAT),	 which	 is	 two	
enzymatic	steps	ahead	of	GCDH	in	the	lysine	degradation	pathway.		
	
Besides	 its	 role	 in	 lysine	 metabolism,	 AADAT	 catalyzes	 the	 conversion	 of	
kynurenine	to	KYNA	in	tryptophan	catabolism.	KYNA	is	a	neuroactive	metabolite	
which	 was	 shown	 to	 be	 an	 antagonist	 of	 glutamate	 receptors,	 α‐7	 nicotinic	
acetylcholine	 receptor	 and	 also	 N‐methyl‐D‐aspartate	 (NMDA)	 receptor,	 and,	
thereby	is	a	neuro‐modulatory	metabolite	(Schwarcz	&	Stone,	2017).	KYNA	was	
found	to	accumulate	in	several	neurocognitive	disorders	like	cerebral	ischemia,	
epilepsy,	 Alzheimer’s,	 Parkinson’s,	 Huntington’s	 disease	 (Vamos,	 Pardutz,	
Klivenyi,	 Toldi,	 &	 Vecsei,	 2009).	 Interestingly,	 blocking	 KYNA	 generation	 by	
pharmacologically	 targeting	AADAT	 in	different	animal	models	 (rats,	primates)	
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has	been	tested	as	a	novel	treatment	option	for	neurological,	neurodegenerative	
disorders	and	psychiatric	diseases	such	as	depression	and	schizophrenia	(Koshy	
Cherian	et	al.,	2014).	This	approach	was	shown	to	be	effective	 in	rats	and	non‐
human	 primates	 with	 neurological	 disease	 symptoms	 similar	 to	 psychiatric	
disorders	like	schizophrenia	(Dounay,	Tuttle,	&	Verhoest,	2015).	Importantly,	no	
disease‐causing	mutations	in	AADAT	are	known	suggesting	that	a	loss	of	AADAT	
activity	 is	 well	 tolerated	 being	 in	 line	 with	 the	 positive	 effect	 of	 the	
aforementioned	 inhibitor	 on	 neurotransmission.	 Aadat	 knockout	 (KAT	 II‐/‐)	 in	
mice	 was	 shown	 to	 effectively	 reduce	 the	 formation	 of	 endogenous	 KYNA	
resulting	 in	 enhanced	 cognitive	 behavior	 (Potter	 et	 al.,	 2010).	 Henceforth,	 we	
first	 tested	whether	 PF04859989,	which	 is	 a	 potent,	 irreversible	 and	 selective	
inhibitor	of	kynurenine	deamination	via	AADAT,	will	also	block	the	deamination	
of	 2‐aminoadipate.	 Indeed,	 we	 could	 show	 that	 PF04859989	 concentration‐
dependently	inhibits	the	enzymatic	production	of	OA.	Next,	we	proceeded	to	test	
our	hypothesis,	i.e.,	that	inhibition	of	AADAT	prevents	GA	accumulation,	in	a	cell	
culture	 model.	 To	 test	 this,	 we	 first	 used	 GA‐I	 patient‐derived	 fibroblasts.	
However,	GA	accumulation	 in	 these	 cells,	being	a	prerequisite	 for	drug	 testing,	
was	not	stable	and	reproducible.	A	likely	explanation	for	this	observation	is	the	
low	 metabolic	 activity	 of	 fibroblasts	 that	 results	 in	 GA	 levels	 close	 to	 the	
detection	limit	of	our	method.	
	
To	 circumvent	 this	 problem,	we	 genetically	modified	HEK	 and	HeLa	 cells,	 that	
are	established	as	simple	and	reliable	cell	models	in	the	scientific	community	to	
further	 delineate	 the	 effect	 of	 AADAT	 blockade	 in	 GA‐I	 disease.	 We	 used	
CRISPR/Cas9	methodology	and	successfully	generated	GCDH	knockouts	in	both	
HEK	 and	 HeLa	 cell	 lines.	 They	 mimicked	 the	 biochemical	 GA‐I	 phenotype	 as	
shown	 by	 the	 increased	 basal	 GA	 levels	 that	 could	 be	 enhanced	 by	 additional	
lysine	treatment.	In	the	next	steps,	we	used	these	generated	GCDH	knockout	cell	
lines	 to	 test	 the	 effect	 of	 different	 concentrations	 of	 PF04859989,	 with	 or	
without	 lysine	 treatment	 on	 GA	 accumulation.	 Strikingly,	 we	 found	 a	 strong	
reduction	in	GA	levels	at	an	inhibitor	concentration	of	50	µM	for	HEK	and	at	10	
µM	 for	 HeLa	 GCDH	 knockout	 cells.	 For	 HeLa	 cells,	 GA	 production	 was	 almost	
abolished.	 Thus	 we	 were	 able	 to	 show	 that	 AADAT	 inhibition	 indeed	 can	
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successfully	reduce	toxic	metabolite	production.	To	compare	the	efficacy	of	 the	
tested	inhibitor	with	a	complete	loss	of	AADAT,	we	went	on	further	to	knock	out	
AADAT	 in	 GCDH	deficient	HEK	 and	 HeLa	 cells.	 We	 were	 successful	 in	 cloning	
AADAT	CRISPR	constructs	and	performing	 transfections	of	 these	plasmids	 into	
HEK	and	HeLa	control	and	GCDH	Knockout	cells.	Western	blot	analysis	indicated	
knockout	of	AADAT	in	HEK	and	HeLa	after	transfection,	but	no	single	cell	clones	
could	be	established.	Unfortunately,	we	also	observed	that	GCDH	knockout	cells	
did	not	survive	additional	AADAT	Knockout.	Further	experiments	are	to	be	done,	
to	identify	the	optimal	conditions	needed	for	the	generation	of	a	single	(AADAT‐/‐
)	and	double	knockouts	(GCDH‐/‐/AADAT‐/‐)	in	HEK	and	HeLa	cells.		
	
4.3.	Outlook	1.	Novel	mechanism	of	chronic	GA‐induced	toxicity		
	
A	yet	poorly	understood	finding	in	GA‐I	patients	with	chronic	disease	course	in	
adolescence	 and	 adulthood	 are	 sub‐ependymal	mass	 lesions	 (Herskovitz	 et	 al.,	
2013b;	 Korman	 et	 al.,	 2007).	 The	 prognostic	 value	 and	 origin	 of	 these	 sub‐
ependymal	 cell	 masses	 remain	 elusive,	 yet	 it	 may	 indicate	 starting	
tumorigenesis.	 Recent	 studies	 revealed	 that	 accumulating	 succinate	 and	
fumarate	 levels	 in	Krebs‐cycle‐deficient	hereditary	cancer	syndromes	block	the	
homologous	 recombination	 (HR)	 DNA‐repair	 pathway	 resulting	 in	 increased	
number	of	DNA	double‐strand	breaks	(DSBs)	(Sulkowski	et	al.,	2018).	Due	to	the	
structural	 similarity	 of	 these	 metabolites	 to	 the	 toxic	 metabolite	 GA,	 we	
questioned	 whether	 increased	 levels	 of	 GA	 would	 act	 as	 an	 endogenous	 DNA	
damaging	agent,	resulting	 in	DNA	DSBs	 formation,	 further	 leading	to	activation	
of	 DNA	 repair	 pathways.	 Un	 repaired	 DSBs	 are	 considered	 harmful	 and	 are	
enough	to	trigger	cell	cycle	arrest	and	cell	death,	further	leading	to	chromosomal	
redisposition	 in	 turn	 resulting	 in	 activation	 of	 oncogenes	 causing	 malignancy	
(Panier	&	Boulton,	 2014).	 To	 see	 if	 GA	 is	 resulting	 in	DNA	DSBs,	which	might	
further	power	the	malignant	transformation,	we	looked	for	DNA	damage	foci	in	
GA‐I	 patient	 and	 control	 fibroblasts.	 DNA	 damage	 foci	 are	 chromosomal	
modifications	 resulting	 from	 DNA	 damage	 response	 proteins	 like	 RAD51	
recombinase	 (RAD51),	 p53	 binding	 protein	 (53BP1),	 gamma‐	 histone	 variant	
H2AX	(H2AX)	 that	are	recruited	 to	 the	regions	with	chromosomal	DNA	DSBs,	
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(Rothkamm	et	al.,	2015).	Additionally,	and	as	a	response	to	DNA	damage,	kinases	
like	 DNA‐dependent	 protein	 kinase	 (DNA‐PK),	 ataxia	 telangiectasia	 mutated	
(ATM)	and	ATM‐Rad3‐related	(ATR)	are	activated	at	the	site	of	DNA	damage	and	
inturn	 phosphorylates	 the	 histone	 variant	 H2AX,	 resulting	 in	 the	 formation	 of	
H2Ax.	 The	 formed	H2Ax	 binds	with	 other	 DNA	 damage	 signalling	 elements	
like	53BP1	and	Mediator	of	DNA	damage	checkpoint	protein	1	(MDC1)	(Panier	&	
Boulton,	 2014).	 Since,	 this	 process	 of	 DNA	 damage	 response	 involving	 several	
thousands	of	histone‐related	modifications	and	signalling	reactions,	is	restricted	
to	a	particular	region	of	the	chromosome	involving	DNA	damage,	this	region	can	
be	 detected	 under	 a	 microscope	 following	 immunostaining	 against	 H2Ax	 as	
distinct	 spots,	 called	 together	 as	 DNA	 damage	 foci.	 This	 sort	 of	 nuclear	
reprogramming	 is	often	associated	with	diseases	 like	 cancer	 (Rothkamm	et	al.,	
2015).		
	
By	 performing	 immunofluorescence	 (IF)	 analysis	 on	 patient	 and	 control	
fibroblasts	 using	 gammaH2Ax	 antibody	 (marker	 for	 DSBs),	 we	 detected	
increased	levels	of	DNA	damage	in	patient	cells	compared	to	control	cells	(figure	
19),	as	observed	by	the	significantly	increased	number	of	foci,	(GA‐I	patient	cells,	
10.5	 	 0.8;	 control	 cells,	 3.8	 	 1.3;	 P	 ≤	 0.005,	 Student’s	 T‐test).	 Such	 an	
observation	 probably	 suggests	 the	 underlying	 DNA	 damage	 due	 to	 the	
accumulation	 of	 the	 toxic	 metabolite	 GA.	 However,	 in	 GA‐I,	 we	 need	 to	
investigate	further,	if	at	all	there	is	a	link	between	the	increased	number	of	foci	
and	complications	associated	with	it,	especially	in	the	later	stages	of	the	disease.	
This	 finding	 eventually	 gives	 new	 insights	 into	 the	 understanding	 of	 the	
mechanism	behind	GA‐I	disease	toxicity,	which	might	in	turn	help	patients	live	a	
long‐term	disease‐free	state.	
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Figure	19:	Immunofluorescence	staining	of	control	cells	(upper	panel)	and	patient	cells	
(lower	 panel)	 using	 gamma	 H2Ax	 antibody,	 shows	 the	 foci	 (green)	 inside	 the	 DAPI	
stained	cells.	Quantification	of	 the	 foci	showed	the	significantly	higher	number	 in	GA‐I	
patient	cells	compared	to	controls	(n=3).	**	mark	represents	P	≤	0.005,	Student’s	T‐test.	
	
4.4.	Outlook	2,	Role	of	DHTKD1	in	Diabetes	
	
Interestingly,	Dhtkd1	was	shown	to	be	up‐regulated	in	diabetes	condition	by	Wu	
and	 colleagues	 via	 multilayered	 transcriptome,	 metabolome	 and	 targeted	
proteomics	in	BXD	genetic	reference	mouse	lines	on	two	different	diets	(Y.	Wu	et	
al.,	2014).	Also,	reports	from	different	groups	suggest	that	Dhtkd1	might	play	a	
role	in	the	regulation	of	glucose	levels	and	insulin	sensitivity	via	AA	in	humans	as	
well	as	in	mice,	thus	influencing	the	development	of	diabetes	(Wang	et	al.,	2013;	
Y.	 Wu	 et	 al.,	 2014;	 Zhao,	 Rio,	 Barrere‐Cain,	 &	 Yang,	 2015).	 To	 test	 this,	 we	
performed	 immunoblot	 analysis	 on	 the	 liver	 and	 kidney	 tissue	 samples	 of	
streptozotocin	(STZ)‐induced	diabetic	mice	and	control	mice	(SHAM)	to	check	if	
there	 is	 an	upregulation	 of	Dhtkd1	 under	 diabetes	 condition.	 Interestingly,	we	
observed	a	significant	rise	(figure	18)	in	Dhtkd1	levels	in	the	liver	samples	of	STZ	
mice	when	compared	to	SHAM	mice	(control	mice),	implying	an	overexpression	
of	 Dhtkd1	 in	 the	 liver	 tissue	 under	 diabetes	 condition.	 From	 this	 study,	 we	
confirm	 that	 the	 role	 of	 DHTKD1	 in	 diabetes	 can	 be	 further	 analyzed	 and	
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extrapolated	 in	 different	 areas	 of	 diabetic	 research	 like	 contributing	 to	 better	
diagnosis	and	treatment	of	diabetes	or	most	likely,	its	prevention.	This	will	be	an	
interesting	 focus	 of	 future	 studies	 and	may	 even	 be	 a	 possible	 application	 for	
DHTKD1	inhibition.		
	
Figure	 18:	 Expression	 of	 DHTKD1	 in	 diabetes:	 Western	 blot	 showing	 expression	 of	
DHTKD1	is	liver	and	kidneys	of	Sham	and	STZ	mouse.	Graphs	show	the	quantification	of	
Western	 blot,	 DHTKD1	 values	 normalized	 to	 Actin.	 (n=3),	 bars	 indicate	 standard	
deviation	(sd)	*	mark	represents	P	≤	0.05,	Student’s	T‐test.	
	
	
	
	
	
5.	CONCLUSIONS	
 
 98 
 
5. Conclusions 
 
1) From  the  in  vitro  and  in  vivo  experiments  performed  and  the  results  obtained,  we 
conclude that DHTKD1 is not a suitable target for GA‐I treatment due to its multiple isoforms, 
which can replace its metabolic function. Also, proper delineation of lysine degradation pathway 
is essential to clearly understand the source of GA production and accumulation. .  
 
2)  From the in vitro experiments we performed using PF‐04859989 in HEK and HeLa GCDH 
knockout cells, we can reasonably conclude that AADAT can be targeted as a novel therapeutic 
strategy in GA‐I. Furthermore, mouse in vivo studies are still to be done to add an additional 
layer of confidence. 
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